2-Aminoimidazole derivatives as PRMT5 inhibitors

MTA-cooperative PRMT5 inhibitors, represented by compounds of Formula I, address the challenge of PRMT5 activity in MTAP-deficient cells by inhibiting PRMT5 in the presence of MTA, effectively treating MTAP-associated cancers by reducing methylation activity and inhibiting cell proliferation.

JP2024542145APending Publication Date: 2024-11-13MIRATI THERAPEUTICS INC
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2024526929
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-06-29
Filing Date
2022-11-04
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

There is a need for new inhibitors that can effectively target protein arginine N-methyltransferase 5 (PRMT5) in the presence of elevated methylthioadenosine (MTA) concentrations, particularly in MTAP-deficient cells, as these cells are dependent on PRMT5 activity due to the loss of MTAP activity, which is common in various cancers.

Method used

Development of MTA-cooperative PRMT5 inhibitors, represented by specific compounds of Formula I, which can inhibit PRMT5 activity in the presence of bound MTA, thereby regulating its function in cells, including MTAP-deficient cells.

Benefits of technology

These inhibitors provide therapeutic benefits by reducing PRMT5 methylation activity, making them effective in treating a wide range of cancers, including MTAP-associated cancers, by inhibiting cell proliferation and sensitizing cells to PRMT5 depletion.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542145000001
    Figure 2024542145000001
  • Figure 2024542145000002
    Figure 2024542145000002
  • Figure 2024542145000003
    Figure 2024542145000003
Patent Text Reader

Abstract

Disclosed herein are 2-aminoimidazole derivatives. These compounds inhibit protein arginine N-methyltransferase 5 (PRMT5) activity. In addition to these compounds, disclosed herein are pharmaceutical compositions containing these compounds and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority from U.S. Provisional Application No. 63 / 276,479, filed November 5, 2021, and U.S. Provisional Application No. 63 / 356,861, filed June 29, 2022, the disclosures of each of which are incorporated by reference in their entireties herein.

[0002] The present invention relates to compounds that are MTA-associated inhibitors of protein arginine N-methyltransferase 5 (PRMT5). In particular, the invention relates to compounds, pharmaceutical compositions containing these compounds, and methods of their use. [Background technology]

[0003] Protein arginine N-methyltransferase (PRMT5) is a type II arginine methyltransferase that catalyzes the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to the ω-nitrogen of the guanidino functional group of protein L-arginine residues (ω-monomethylation) and the transfer of a second methyl group to the other ω-nitrogen to obtain symmetric dimethylarginine (sDMA). PRMT5 forms a complex with MEP50 (methylosomal protein 50), which is required for substrate recognition and orientation, and is also required for PRMT5-catalyzed histone 2A and histone 4 methyltransferase activity (see, e.g., Ho et al., (2013) PLOS ONE 8(8):10.1371 / annotation / e6b5348e-9052-44ab-8f06-90d01dc88fc2).

[0004] Homozygous deletions of p16 / CDKN2a are common in cancer, and these mutations are commonly associated with co-deletions of adjacent genes, including the gene encoding methylthioadenosine phosphorylase (MTAP). It is estimated that approximately 15% of all human cancers have homozygous deletions of the MTAP gene (see, e.g., Firestone & Schramm (2017) J. Am. Chem Soc. 139(39):13754-13760. doi:10.1021 / jacs.7b05803. Epub 2017 Sep 20).

[0005] Cells lacking MTAP activity have elevated levels of the MTAP substrate, methylthioadenosine (MTA), a potent inhibitor of PRMT5. Inhibiting PRMT5 activity reduces methylation activity and increases the sensitivity of cell proliferation to PRMT5 depletion or loss of activity. Thus, loss of MTAP activity reduces the methylation activity of PRMT5 and renders cells selectively dependent on PRMT5 activity. Summary of the Invention

[0006] There is a need to develop new MTA-cooperative PRMT5 inhibitors that can inhibit PRMT5 activity in the presence of elevated MTA concentrations, especially in MTAP-deficient cells.

[0007] The present inventors have recognized that MTA-cooperative inhibition of PRMT5 activity in MTAP-deficient cancers provides therapeutic benefit against a wide range of cancers. The compounds of the present invention provide this therapeutic benefit as MTA-cooperative inhibitors of PRMT5 to negatively regulate the activity of MTA-bound PRMT5 in cells, particularly MTAP-deficient cells, or to treat various forms of MTAP-associated cancers.

[0008] In one aspect of the invention, there is provided a compound of formula I, [ka] During the ceremony, X is CR 2 or N, Y is CR 3 or N, R 1 is -C1-C2 alkyl or -CH2-phenyl; R 2 is hydrogen, cyano, -C1-C2 haloalkyl, or halogen; R 3 is hydrogen, halogen, or -LR 30 and -L is absent or -(CH2) 0-2 -NH-(CH2) 0-2 -, -N(CH3)-(CH2) 0-2 -, -N(C(O)CH3)-(CH2) 0-2 -, (-CH2-) 1-2 , -C(halo)2-, -C(CH3)H-, -O-, -S-, -C(O)-, -NH-(CH2) 0-1 -CH(CH3)-(CH2) 0-1 -, -NH-C(O)-(CH2) 0-1 - and -NH-CH(phenyl)-(CH2) 0-1 - selected from the group consisting of R 30 is phenyl, isoxazole, oxazole, pyrrolidinone, morpholine, imidazopyridine, piperidinone, pyridinone, naphthalene, pyrazine, pyrazolidinone, -N(C1-C2 alkyl)2, thiazole, thiadiazole, pyrimidine, imidazole optionally substituted with naphthyl, which naphthyl is further optionally substituted with one or more substituents selected from cyano, halogen, and -C(O)NH2, pyrrolidine optionally fused to cyclopropane, pyrazole optionally substituted with -CH2-CH2-pyrrolidinone or naphthalene, pyridine optionally fused to cyclohexane, triazole optionally fused to a ring forming pyrrolidine or morpholine, or tetrahydrofuran optionally spiro-bonded to cyclobutane; Each R 30is optionally substituted or optionally further substituted with one or more substituents independently selected from: -C1-C3 alkyl, -C1-C2 haloalkyl, halogen, hydroxy, -C(O)NH2, -C1-C2 alkoxy, phenyl, cyano-phenyl, and cyano; R 4 is hydrogen, -C1-C2 alkyl, -CH2-O-CH3, or halogen; R 5 but, hydrogen, -LR 50 where L is defined as above, R50, -CH(OH)-CH3, pyridine, pyrazine, isoxazole, pyridazine, pyrimidine, pyrazole, pyrrolidine or morpholine optionally fused to a ring forming a triazole, tetrahydro-thiopyran-dioxide, thiazole, furan, isoquinoline, naphthalene, pyrrolidine, phenyl where L is not absent, imidazole optionally fused to piperidine, tetrahydrofuran optionally substituted with imidazole, tetrahydropyran optionally spiro-linked to cyclobutane, or cyclobutane fused to tetrahydropyran; Each R 50 is optionally substituted or optionally further substituted with one or more substituents independently selected from halogen, hydroxy, -C1-C4 alkyl, -C1-C4 alkoxy, -C1-C4 haloalkyl, cyano, and phenyl; 50 , -(C0-C3)alkyl-(CO)N(R 10 )(R 11 ) in which R 10 is pyridyl(C1-C6 alkyl), wherein the pyridyl is optionally substituted with halogen (preferably bromo) or trifluoromethyl; R 11is pyridyl (C1-C6 alkyl), pyrimidinyl (C1-C6 alkyl), naphthyl optionally substituted at the 1, 3, or 4 positions (position 2 being the point of attachment to N) with one, two, or three, independently, of cyano, C1-C3 alkyl, cyclopropylmethyl, cyclopropyl, halogen, or C1-C2 alkoxy, or 5,6,7,8-tetrahydroquinoxalinyl; 10 )(R 11 ),or -(C0-C3)alkyl-NH-C(O)(C1-C2alkyl)(R 12 ) in which R 12 is hydrogen, C1-C2 alkyl, or naphthyl optionally substituted with one or more independently selected from cyano, chloro, fluoro, cyclopropyloxy, cyclopropylmethyl, or C1-C2 alkyl; 12 ) and R 3 , R 4 , and R 5 (i) hydrogen, (ii) C alkyl, (iii) R 2 is not cyano; (iv) halogen; (v) cyano; or (vi) R 5 and Y is nitrogen or R 2 is cyano, and R 1 is C alkyl and Y is nitrogen, then R 1 is not a C1 alkyl group, or a pharma- ceutically acceptable salt thereof is provided.

[0009] In another aspect of the invention, there is provided compounds and salts of formula I, wherein ring A is [ka] is selected from.

[0010] In another aspect of the present invention, intermediates useful in the preparation of compounds of formula I are provided.

[0011] In another aspect of the present invention, there is provided a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present invention, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0012] Yet another aspect of the invention is a method for inhibiting PRMT5 activity in a cell, the method comprising contacting the cell with a compound of formula I. In one embodiment, the contacting is performed in vitro. In one embodiment, the contacting is performed in vivo.

[0013] Also provided herein is a method of inhibiting proliferation of a cell in vitro or in vivo, the method comprising contacting the cell with an effective amount of a compound of formula I, as defined herein, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition thereof. In one embodiment, the cell is an MTAP-deficient cell.

[0014] Also provided is a method for treating cancer in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound or pharmaceutical composition of the invention, or a pharma- ceutically acceptable salt thereof.

[0015] Also provided herein is a method of treating cancer in a patient in need of such treatment, the method comprising: (a) determining that the cancer is associated with an MTAP double deletion (e.g., an MTAP-associated cancer); and (b) administering to the patient a therapeutically effective amount of a compound of formula I, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition thereof. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] The present invention relates to MTA-associated PRMT5 inhibitors. In particular, the present invention relates to compounds that inhibit PRMT5 activity in the presence of bound MTA, pharmaceutical compositions comprising a therapeutically effective amount of the compounds, and methods of use thereof.

[0017] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. All patents, patent applications, and publications mentioned herein are incorporated by reference to the extent that they are consistent with this disclosure. Unless otherwise expressly defined, terms and scopes have the definitions generally defined.

[0018] For the sake of brevity, chemical moieties are defined and referred to primarily as monovalent chemical moieties (e.g., alkyl, aryl, etc.) throughout. Nevertheless, such terms may also be used to convey corresponding multivalent moieties under appropriate structural circumstances clear to one of skill in the art. For example, while an "alkyl" moiety generally refers to a monovalent radical (e.g., CH3-CH2-), under certain circumstances, a divalent linking moiety may be an "alkyl", in which case one of skill in the art would understand that the alkyl is the divalent radical equivalent to the term "alkylene" (e.g., -CH2-CH2-). (Similarly, in situations where a divalent moiety is required and described as "aryl", one of skill in the art would understand that the term "aryl" refers to the corresponding divalent moiety, arylene). It is understood that all atoms have their normal valence for bond formation (i.e., 4 for carbon, 3 for N, 2 for O, and 2, 4, or 6 for S, depending on the oxidation state of S).

[0019] As used herein, "PRMT5" refers to the mammalian protein arginine N-methyltransferase 5 (PRMT5) enzyme.

[0020] As used herein, "PRMT5 inhibitor" or "MTA-associated PRMT5 inhibitor" refers to the compounds of the present invention represented by formula (I) as described herein. These compounds can negatively regulate or inhibit all or part of the enzymatic activity of PRMT5 in the presence of bound MTA in vitro or in vivo, or in cells expressing elevated levels of MTA.

[0021] As used herein, "MTAP" refers to the mammalian methylthioadenosine phosphorylase (MTAP) enzyme.

[0022] As used herein, "MTAP-associated disease or disorder" refers to a disease or disorder associated with, mediated by, or having a loss of MTAP activity that results in sensitization of the disorder to selective inhibition of PRMT5 activity. A non-limiting example of an MTAP-associated disease or disorder is an MTAP-associated cancer.

[0023] The term "amino" refers to --NH.sub.2.

[0024] The term "acetyl" refers to -C(O)CH3.

[0025] As used herein, the term "acyl" refers to an alkylcarbonyl or arylcarbonyl substituent, where the alkyl and aryl moieties are as defined herein.

[0026] The term "alkyl" as used herein refers to saturated straight and branched chain aliphatic groups having 1 to 12 carbon atoms. Thus, "alkyl" includes C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, ​​C47, C48, C49, C50, C51, C52, C53, C54, C55, C56, C57, C58, C59, C60, C61, C62, C63, C64, C65, C66, C67, C68, C69, C70, C71, C72, C73, C74, C75, C76, C77, C78, ​​C79, C80, C81, C82, C83, C84, C85, C86, C87, C88, C89, C91, C92, C93, C94, C95, C96, C97, C98, C99, C99, C91, C92, C93, C94, C95, C96, C97, C98, C99, C99, C101, C102, C103, C104, C105, C106, C107, C108, C109, C1 10 , C 11 , and C 12 Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl.

[0027] As used herein, the term "alkenyl" refers to an unsaturated straight or branched chain aliphatic group having one or more carbon-carbon double bonds and having 2 to 12 carbon atoms. Thus, "alkenyl" includes C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, ​​C47, C48, C49, C50, C51, C52, C53, C54, C55, C56, C57, C58, C59, C60, C61, C62, C63, C64, C65, C66, C77, C78, ​​C79, C82, C83, C84, C85, C86, C87, C88, C89, C91, C92, C93, C94, C95, C96, C97, C98, C99, C99, C91, C92, C93, C94, C95, C96, C97, C98, C99, C99, C101, C102, C103, C104, C105, C106, C107, C108, C109, C111, C112, C113, C114, C115, C115, C116 10 , C 11 , and C 12Examples of alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, and hexenyl.

[0028] The term "alkynyl" as used herein refers to an unsaturated straight or branched chain aliphatic group containing one or more carbon-carbon triple bonds having 2 to 12 carbon atoms. Thus, "alkynyl" includes C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, ​​C47, C48, C49, C50, C51, C52, C53, C 10 , C 11 , and C 12 Examples of alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, and hexynyl.

[0029] An "alkylene", "alkenylene", or "alkynylene" group is an alkyl, alkenyl, or alkynyl group, as defined herein above, that is located between and functions to link two other chemical groups. Examples of alkylene groups include, but are not limited to, methylene, ethylene, propylene, and butylene. Representative alkenylene groups include, but are not limited to, ethenylene, propenylene, and butenylene. Representative alkynylene groups include, but are not limited to, ethynylene, propynylene, and butynylene.

[0030] The term "alkoxy" refers to -OC1-C6 alkyl.

[0031] The term "cycloalkyl" as used herein refers to saturated and partially unsaturated cyclic hydrocarbon groups having 3 to 12 carbons. Thus, "cycloalkyl" includes C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C210, C220, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, ​​C47, C48, C49, C50, C51, C52, C53, C54, C55, C56, C57, C 10 , C 11 , and C 12 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.

[0032] The term "heteroalkyl" is as defined herein above, and one or more of the carbon atoms in the chain are independently O, S, or NR x and R x is hydrogen or C1-C3 alkyl. Examples of heteroalkyl groups include methoxymethyl, methoxyethyl, and methoxypropyl.

[0033] An "aryl" group is a C6-C aryl group containing one to three aromatic rings. 14 It is an aromatic moiety. Therefore, "aryl" includes C6, C 10 , C 13 , and C 14 Cyclic hydrocarbon groups include: Representative aryl groups are C6-C 10 It is an aryl group. Particular aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, and fluorenyl. "Aryl" groups also include fused polycyclic (e.g., bicyclic) ring systems in which one or more of the fused rings are non-aromatic, provided that at least one ring is aromatic, such as indenyl.

[0034] An "aralkyl" or "arylalkyl" group comprises an aryl group covalently bonded to an alkyl group, which in turn is bonded to another group via the alkyl moiety. Representative aralkyl groups include, but are not limited to, -(C1-C6)alkyl (C6-C8)alkyl, -(C1 ... 10 ) aryl. For example, arC1-C3 alkyl is an aryl group covalently linked to a C1-C3 alkyl.

[0035] A "heterocyclyl" or "heterocyclic" group is a mono- or bicyclic (fused or spiro) ring structure having three to twelve atoms (3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 atoms), e.g., four to eight atoms, in which one or more ring atoms are independently selected from -C(O)-, N, NR 4, O, or S, with the remainder of the ring atoms being quaternary or carbonyl carbons. Examples of heterocyclic groups include, but are not limited to, epoxy, oxiranyl, oxetanyl, azetidinyl, aziridinyl, THFyl, tetrahydropyranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, piperazinyl, imidazolidinyl, thiazolidinyl, thiatanyl, dithianyl, trithianyl, azathianyl, oxathianyl, dioxolanyl, oxazolidinyl, oxazolidinonyl, decahydroquinolinyl, piperidonyl, 4-piperidonyl, thiomorpholinyl, dimethyl-morpholinyl, and morpholinyl. Specifically excluded from the scope of this term are compounds having adjacent ring O and / or S atoms.

[0036] As used herein, "L-heterocyclyl" refers to a heterocyclyl group covalently attached to another group via a linker (eg, an alkylene linker).

[0037] As used herein, the term "heteroaryl" refers to a group having 5 to 14 ring atoms, preferably 5, 6, 10, 13, or 14 ring atoms, with 6, 10, or 14 pi electrons shared in a cyclic array, and having, in addition to carbon atoms, 1 to 3 heteroatoms, each independently N, O, or S. "Heteroaryl" also includes fused polycyclic (e.g., bicyclic) ring systems in which one or more of the fused rings is non-aromatic, provided that at least one ring is aromatic and at least one ring contains an N, O, or S ring atom.

[0038] Examples of heteroaryl groups include acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzo[d]oxazol-2(3H)-one, 2H-benzo[b][1,4]oxazin-3(4H)-one, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, furanyl, and furanyl. Lazanyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazo aryl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclinyl, These include thiazolyl, thiazinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienoxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, and xanthenyl.

[0039] An "L-heteroaryl" group includes a heteroaryl group covalently attached to another group via a linker (eg, an alkylene linker).

[0040] An "arylene," "heteroarylene," or "heterocyclylene" group is a divalent aryl, heteroaryl, or heterocyclyl group, respectively, as defined herein above, that is positioned between and serves to connect two other chemical groups.

[0041] As used herein, when a moiety (e.g., cycloalkyl, aryl, heteroaryl, heterocyclyl, urea, etc.) is described as "optionally substituted" without explicitly reciting substituents, it means that the group optionally has 1 to 4, preferably 1 to 3, and more preferably 1 or 2 non-hydrogen substituents.

[0042] The term "halogen" or "halo" as used herein refers to chlorine, bromine, fluorine, or iodine.

[0043] The term "haloalkyl" refers to an alkyl chain in which one or more hydrogens have been replaced by halogen. Exemplary haloalkyls are trifluoromethyl, difluoromethyl, fluorochloromethyl, chloromethyl, and fluoromethyl.

[0044] The term "hydroxyalkyl" refers to -alkylene-OH.

[0045] As used herein, an "effective amount" of a compound is an amount sufficient to negatively regulate or inhibit the activity of the PRMT5 enzyme.

[0046] As used herein, a "therapeutically effective amount" of a compound is an amount sufficient to alleviate or in any way reduce a symptom, or to halt or reverse the progression of a condition, or to negatively regulate or inhibit the activity of PRMT5. Such an amount may be administered as a single dosage or may be administered according to a regimen, thereby being effective.

[0047] As used herein, treatment refers to any manner in which the symptoms or pathology of a condition, disorder, or disease are alleviated or beneficially altered in a patient.

[0048] As used herein, alleviation of symptoms of a particular disorder by administration of a particular compound or pharmaceutical composition refers to any relief, whether permanent or temporary, persistent or transient, that can result from or be associated with administration of the composition.

[0049] compound In one aspect of the invention, there is provided a compound of formula I, [ka] During the ceremony, X is CR 2 or N, Y is CR 3 or N, R 1 is -C1-C2 alkyl or -CH2-phenyl; R 2 is hydrogen, cyano, -C1-C2 haloalkyl, or halogen; R 3 is hydrogen, halogen, or -LR 30 and -L is absent or -(CH2) 0-2 -NH-(CH2) 0-2 -, -N(CH3)-(CH2) 0-2 -, -N(C(O)CH3)-(CH2) 0-2 -, (-CH2-) 1-2, -C(halo)2-, -C(CH3)H-, -O-, -S-, -C(O)-, -NH-(CH2) 0-1 -CH(CH3)-(CH2) 0-1 -, -NH-C(O)-(CH2) 0-1 - and -NH-CH(phenyl)-(CH2) 0-1 - selected from the group consisting of R 30 is phenyl, isoxazole, oxazole, pyrrolidinone, morpholine, imidazopyridine, piperidinone, pyridinone, naphthalene, pyrazine, pyrazolidinone, -N(C1-C2 alkyl)2, thiazole, thiadiazole, pyrimidine, imidazole optionally substituted with naphthyl, which naphthyl is further optionally substituted with one or more substituents selected from cyano, halogen, and -C(O)NH2, pyrrolidine optionally fused to cyclopropane, pyrazole optionally substituted with -CH2-CH2-pyrrolidinone or naphthalene, pyridine optionally fused to cyclohexane, triazole optionally fused to a ring forming pyrrolidine or morpholine, or tetrahydrofuran optionally spiro-bonded to cyclobutane; Each R 30 is optionally substituted or optionally further substituted with one or more substituents independently selected from: -C1-C3 alkyl, -C1-C2 haloalkyl, halogen, hydroxy, -C(O)NH2, -C1-C2 alkoxy, phenyl, cyano-phenyl, and cyano; R 4 is hydrogen, -C1-C2 alkyl, -CH2-O-CH3, or halogen; R 5 but, hydrogen, -LR 50 where L is defined as above and R 50 but, -CH(OH)-CH3, pyridine, pyrazine, isoxazole, pyridazine, pyrimidine, pyrazole, pyrrolidine or morpholine optionally fused to a ring forming a triazole, tetrahydro-thiopyran-dioxide, thiazole, furan, isoquinoline, naphthalene, pyrrolidine, phenyl where L is not absent, imidazole optionally fused to piperidine, tetrahydrofuran optionally substituted with imidazole, tetrahydropyran optionally spiro-linked to cyclobutane, or cyclobutane fused to tetrahydropyran; Each R 50 is optionally substituted or optionally further substituted with one or more substituents independently selected from halogen, hydroxy, -C1-C4 alkyl, -C1-C4 alkoxy, -C1-C4 haloalkyl, cyano, and phenyl; 50 , -(C0-C3)alkyl-(CO)N(R 10 )(R 11 ) in which R 10 is pyridyl(C1-C6 alkyl), wherein the pyridyl is optionally substituted with halogen (preferably bromo) or trifluoromethyl; R 11 is pyridyl (C1-C6 alkyl), pyrimidinyl (C1-C6 alkyl), naphthyl optionally substituted at the 1, 3, or 4 positions (position 2 being the point of attachment to N) with one, two, or three, independently, of cyano, C1-C3 alkyl, cyclopropylmethyl, cyclopropyl, halogen, or C1-C2 alkoxy, or 5,6,7,8-tetrahydroquinoxalinyl; 10 )(R 11 ),or -(C0-C3)alkyl-NH-C(O)(C1-C2alkyl)(R 12 ) in which R 12is hydrogen, C1-C2 alkyl, or naphthyl optionally substituted with one or more independently selected from cyano, chloro, fluoro, cyclopropyloxy, cyclopropylmethyl, or C1-C2 alkyl; 12 ) and R 3 , R 4 , and R 5 (i) hydrogen, (ii) C alkyl, (iii) R 2 is not cyano; (iv) halogen; (v) cyano; or (vi) R 5 and Y is nitrogen or R 2 is cyano, and R 1 is C alkyl and Y is nitrogen, then R 1 is not a C1 alkyl group, or a pharma- ceutically acceptable salt thereof is provided.

[0050] In certain embodiments of formula I, R 3 (if present), R 4 , and R 5 at least one of is not hydrogen, C1 alkyl, or C1 alkoxy; R 3 (if present), R 4 , and R 5 When each is hydrogen, R 2 is not cyano or halogen, R 1 is C1 alkyl, and R 2 (if present), R 3 (if present), and R 4 When each is hydrogen, R 5 is not an unsubstituted phenyl, Y is nitrogen or R 2 If is cyano, R 1 is not a C1 alkyl, When Y is nitrogen, R 1 is not a C1 alkyl.

[0051] In another aspect of the invention, there is provided compounds and salts of formula I, wherein ring A is [ka] is selected from.

[0052] In one embodiment, a compound or salt of formula I is provided, wherein A is [ka] It is.

[0053] In another aspect of the invention, there is provided compounds and salts of formula I, wherein ring A is [ka] It is.

[0054] In another aspect of the invention, there is provided compounds and salts of formula I, wherein ring A is [ka] and R 1 is not a C1 alkyl.

[0055] In one aspect of the invention, there is provided a compound of formula IA, [ka] During the ceremony, R 1 is -C1-C2 alkyl or -CH2-phenyl; R 2 is hydrogen, cyano, -C1-C2 haloalkyl, or halogen; R 3is optionally substituted with hydrogen, halogen, -L-phenyl, -L-isoxazole, -L-oxazole, -L-pyrrolidinone, -L-morpholine, -L-imidazopyridine, -L-piperidinone, -L-pyridinone, -L-naphthalene, -L-pyrazine, -L-pyrazolidinone, -LN(C1-C2 alkyl)2, -L-thiazole, -L-thiadiazole, -L-pyrimidine, naphthyl, where the naphthyl is optionally substituted with cyano, halogen, and -C(O) NH), -L-pyrrolidine optionally fused to cyclopropane, -L-pyrazole optionally substituted with -CH-CH-pyrrolidinone or naphthalene, -L-pyridine optionally fused to cyclohexane, -L-triazole optionally fused to a ring forming pyrrolidine or morpholine, and -L-tetrahydrofuran optionally spiro-bonded to cyclobutane; 3 is optionally substituted or optionally further substituted with one or more substituents independently selected from: -C1-C3 alkyl, -C1-C2 haloalkyl, halogen, hydroxy, -C(O)NH2, -C1-C2 alkoxy, phenyl, cyano-phenyl, and cyano; R 4 is hydrogen, -C1-C2 alkyl, -CH2-O-CH3, or halogen; R 5 is hydrogen, -L-CH(OH)-CH3, -L-pyridine, -L-pyrazine, -L-isoxazole, -L-pyridazine, -L-pyrimidine, -L-pyrazole, -L-triazole optionally fused to a ring forming a pyrrolidine or morpholine, -L-tetrahydro-thiopyran-dioxide, -L-thiazole, -L-furan, -L-isoquinoline, -L-naphthalene, -L-pyrrolidine, -L-phenyl (wherein L is not absent), -L-imidazole optionally fused to piperidine, -L-tetrahydrofuran optionally substituted with imidazole, -L-tetrahydropyran optionally spiro-linked to cyclobutane, and -L-cyclobutane fused to tetrahydropyran; R 5is optionally substituted or optionally further substituted with one or more substituents independently selected from halogen, hydroxy, -C1-C4 alkyl, -C1-C4 alkoxy, -C1-C4 haloalkyl, cyano, and phenyl; -L is absent or -(CH2) 0-2 -NH-(CH2) 0-2 -, -N(CH3)-(CH2) 0-2 -, -N(C(O)CH3)-(CH2) 0-2 -, (-CH2-) 1-2 , -C(halo)2-, -C(CH3)H-, -O-, -S-, -C(O)-, -NH-(CH2) 0-1 -CH(CH3)-(CH2) 0-1 -, -NH-C(O)-(CH2) 0-1 - and -NH-CH(phenyl)-(CH2) 0-1 - selected from the group consisting of R 3 , R 4 , and R 5 (i) hydrogen, (ii) C alkyl, (iii) R 2 is not cyano; (iv) halogen; (v) cyano; or (vi) R 5 or R 2 is cyano, and R 1 is C1 alkyl, or a pharma- ceutically acceptable salt thereof is provided.

[0056] In one embodiment, a compound of formula I or IA is provided, wherein L is absent.

[0057] In one embodiment, a compound of formula I or IA is provided, wherein L is -NH-.

[0058] In one embodiment, a compound of formula I or IA is provided, wherein L is -(CH2)0-2-NH-(CH2)0-2.

[0059] In one embodiment, a compound of formula I or IA is provided, wherein R 3 includes heteroaryl. In this embodiment, for example, R 3 is -L-isoxazole, -L-oxazole, -L-imidazopyridine, -L-pyrazine, -L-pyrazolidinone, -L-thiazole, -L-thiadiazole, -L-pyrimidine, -L-imidazole optionally substituted with naphthyl, which naphthyl is further optionally substituted with one or more substituents selected from cyano, halogen, and -C(O)NH2, -L-pyrazole optionally substituted with -CH2-CH2-pyrrolidinone or naphthalene, -L-pyridine optionally fused to cyclohexane, or -L-triazole optionally fused to a ring forming pyrrolidine or morpholine; R 3 is optionally substituted or optionally further substituted.

[0060] In one embodiment, a compound of formula I or IA is provided, wherein R 3 In this embodiment, for example, R 3 is -L-pyrrolidinone, -L-morpholine, -L-piperidinone, -L-pyridinone, -L-pyrrolidine optionally fused to cyclopropane, or -L-tetrahydrofuran optionally spiro-linked to cyclobutane; R 3 is optionally substituted or optionally further substituted.

[0061] In one embodiment, a compound of formula I or IA is provided, wherein R 5 includes heteroaryl. In this embodiment, for example, R 5 is -L-pyridine, -L-pyrazine, -L-isoxazole, -L-pyridazine, -L-pyrimidine, -L-pyrazole, -L-triazole optionally fused to a ring forming a pyrrolidine or morpholine, -L-thiazole, -L-furan, -L-isoquinoline, or -L-imidazole optionally fused to piperidine; R 5is optionally substituted or optionally further substituted.

[0062] In one embodiment, a compound of formula I or IA is provided, wherein R 5 In this embodiment, for example, R 5 is -L-tetrahydro-thiopyran-dioxide, -L-pyrrolidine, -L-tetrahydrofuran optionally substituted with imidazole, -L-tetrahydropyran optionally spiro-linked to cyclobutane; R 5 is optionally substituted or optionally further substituted.

[0063] In one embodiment, a compound of formula I or IA is provided, wherein R 3 or R 5 In this embodiment, for example, (a)R 3 is -L-isoxazole, -L-oxazole, -L-imidazopyridine, -L-pyrazine, -L-pyrazolidinone, -L-thiazole, -L-thiadiazole, -L-pyrimidine, -L-imidazole optionally substituted with naphthyl, which naphthyl is further optionally substituted with one or more substituents selected from cyano, halogen, and -C(O)NH2, -L-pyrazole optionally substituted with -CH2-CH2-pyrrolidinone or naphthalene, -L-pyridine optionally fused to cyclohexane, or -L-triazole optionally fused to a ring forming pyrrolidine or morpholine; R 3 is optionally substituted or optionally further substituted; R 5 is hydrogen, -L-CH(OH)-CH3, -L-tetrahydro-thiopyran-dioxide, -L-naphthalene, -L-pyrrolidine, -L-phenyl (L is not absent), -L-tetrahydrofuran optionally substituted with imidazole, -L-tetrahydropyran optionally spiro-bonded to cyclobutane, or -L-cyclobutane fused to tetrahydropyran; R 5is optionally substituted or optionally further substituted, or (b)R 3 is hydrogen, halogen, -L-phenyl, -L-pyrrolidinone, -L-morpholine, -L-piperidinone, -L-pyridinone, -L-naphthalene, -LN(C1-C2 alkyl)2, -L-pyrrolidine optionally fused to cyclopropane, or -L-tetrahydrofuran optionally spiro-linked to cyclobutane; R 3 is optionally substituted or optionally further substituted with one or more substituents; R 5 is -L-pyridine, -L-pyrazine, -L-isoxazole, -L-pyridazine, -L-pyrimidine, -L-pyrazole, -L-triazole optionally fused to a ring forming a pyrrolidine or morpholine, -L-thiazole, -L-furan, -L-isoquinoline, or -L-imidazole optionally fused to piperidine; R 5 is optionally substituted or optionally further substituted.

[0064] In one embodiment, a compound of formula I or IA is provided, wherein R 3 or R 5 In this embodiment, for example, (a)R 3 is -L-pyrrolidinone, -L-morpholine, -L-piperidinone, -L-pyridinone, -L-pyrrolidine optionally fused to cyclopropane, or -L-tetrahydrofuran optionally spiro-linked to cyclobutane; R 3 is optionally substituted or optionally further substituted; R 5is hydrogen, -L-CH(OH)-CH3, -L-pyridine, -L-pyrazine, -L-isoxazole, -L-pyridazine, -L-pyrimidine, -L-pyrazole, -L-triazole optionally fused to a ring forming a pyrrolidine or morpholine, -L-thiazole, -L-furan, -L-isoquinoline, -L-naphthalene, -L-phenyl (L is not absent), -L-imidazole optionally fused to piperidine, or -L-cyclobutane fused to tetrahydropyran; R 5 is optionally substituted or optionally further substituted with one or more substituents independently selected from halogen, hydroxy, -C1-C4 alkyl, -C1-C4 alkoxy, -C1-C4 haloalkyl, cyano, and phenyl; (b)R 3 is hydrogen, halogen, -L-phenyl, -L-isoxazole, -L-oxazole, -L-imidazopyridine, -L-naphthalene, -L-pyrazine, -L-pyrazolidinone, -LN(C1-C2 alkyl)2, -L-thiazole, -L-thiadiazole, -L-pyrimidine, -L-imidazole optionally substituted with naphthyl, which naphthyl is further optionally substituted with one or more substituents selected from cyano, halogen, and -C(O)NH2, -L-pyrazole optionally substituted with -CH2-CH2-pyrrolidinone or naphthalene, -L-pyridine optionally fused to cyclohexane, or -L-triazole optionally fused to a ring forming pyrrolidine or morpholine; R 3 is optionally substituted or optionally further substituted; R 5 is -L-tetrahydro-thiopyran-dioxide, -L-pyrrolidine, -L-tetrahydrofuran optionally substituted with imidazole, -L-tetrahydropyran optionally spiro-linked to cyclobutane; R 5 is optionally substituted or optionally further substituted.

[0065] In one embodiment, R 5is triazolylmethylamino substituted on the triazole with fluoromethyl, difluoromethyl or trifluoromethyl.

[0066] In one embodiment, R 5 is triazolylmethylamino substituted on the triazole with methyl and fluoromethyl, difluoromethyl or trifluoromethyl.

[0067] In one embodiment, R 5 is ((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methyl)amino.

[0068] In one embodiment, R 5 is triazolylmethylamino substituted on the triazole with C1-C6 alkyl, preferably methyl or ethyl.

[0069] In one embodiment, R 5 is ((4-ethyl-4H-1,2,4-triazol-3-yl)methyl)amino.

[0070] In one embodiment, R 5 is -(C1-C2 alkyl)-NH-C(O)(C1-C2 alkyl)(R 12 ) in which R 12 is C1-C2 alkyl, or naphthyl optionally substituted independently with one or more cyano, chloro, fluoro, cyclopropyloxy, cyclopropylmethyl, or C1-C2 alkyl.

[0071] In one embodiment, R 5 is -(C1-C2 alkyl)-NH-C(O)(C1-C2 alkyl)(R 12 ) in which R 12 is naphthyl substituted with one or two independently selected cyano, chloro, fluoro, cyclopropyloxy, cyclopropylmethyl, or C1-C2 alkyl.

[0072] In one embodiment, R5 is -(C1-C2 alkyl)-NH-C(O)(C1-C2 alkyl)(R 12 ) in which R 12 is naphthyl substituted with cyano.

[0073] In one embodiment, R 5 is (N-(1-cyanonaphthalen-2-yl)acetamido)methyl.

[0074] In one embodiment, the compound of formula I is [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] or a pharma- ceutically acceptable salt of one of the above compounds.

[0075] Pharmaceutical Compositions The compounds of formula I can be formulated into pharmaceutical compositions.

[0076] In another embodiment, the present invention provides a pharmaceutical composition comprising the PRMT5 inhibitor according to the present invention and a pharma- ceutical acceptable carrier, excipient, or diluent.The compounds of the present invention can be formulated by any method known in the art and prepared for administration by any route, including but not limited to parenteral, oral, sublingual, transdermal, topical, intranasal, intratracheal, or intrarectal.In certain embodiments, the compounds of the present invention are administered intravenously in hospital.In certain other embodiments, administration can be preferably by oral route.

[0077] The characteristics of the carrier will depend on the route of administration. As used herein, the term "pharmaceutical acceptable" refers to a non-toxic material that is compatible with a biological system, such as a cell, cell culture, tissue, or organism, and does not interfere with the effectiveness of the biological activity of the active ingredient(s). Thus, in addition to the inhibitor, the composition according to the invention may contain diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The preparation of pharmaceutical acceptable formulations is described, for example, in Remington's Pharmaceutical Sciences, 18 th Edition, ed. A. Gennaro, Mack Publishing Co., Easton, Pa., 1990.

[0078] As used herein, the term "pharmaceutically acceptable salt" refers to a salt that retains the desired biological activity of the above-identified compound and exhibits minimal or no undesired toxic effects.Examples of such salts include, but are not limited to, the acid addition salts formed with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, etc.), and the acids formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, and polygalacturonic acid. The compounds may also be administered as pharma- ceutically acceptable quaternary salts known to those of skill in the art, including, in particular, quaternary ammonium salts of the formula -NR+Z-, where R is hydrogen, alkyl, or benzyl, and Z is a counterion, including chloride, bromide, iodide, --O-alkyl, toluenesulfonate, methylsulfonate, sulfonate, phosphate, or carboxylate (e.g., benzoate, succinate, acetate, glycolate, maleate, malate, citrate, tartrate, ascorbate, benzoate, cinnamoate, mandelloate, benzylloate, and diphenylacetate).

[0079] The active compound is contained in a pharma- ceutically acceptable carrier or diluent in an amount sufficient to deliver a therapeutically effective amount to the patient without causing serious toxic effects to the patient being treated. For all the above conditions, the dose of the active compound ranges from about 0.01 to 300 mg / kg per day, preferably 0.1 to 100 mg / kg per day, and more usually from 0.5 to about 25 mg per kilogram of recipient body weight per day. Typical topical dosages range from 0.01 to 3% weight / weight in a suitable carrier. The effective dosage range of the pharma- ceutically acceptable derivatives can be calculated based on the weight of the parent compound to be delivered. If the derivative is active in itself, the effective dosage can be estimated as above using the weight of the derivative, or by other means known to those skilled in the art.

[0080] Pharmaceutical compositions containing the compounds of the invention can be used in the methods described herein.

[0081] How to use In yet another aspect, the invention provides a method for inhibiting PRMT5 activity in a cell, the method comprising contacting a cell in which inhibition of PRMT5 activity is desired with an effective amount of a compound of formula I, a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition containing the compound or a pharma- ceutically acceptable salt thereof. In one embodiment, the cell is an MTAP-deficient cell.

[0082] The compositions and methods provided herein are considered to be particularly useful for inhibiting PRMT5 activity in cells in vivo. In one embodiment, cells in which inhibition of PRMT5 activity is desired are contacted in vivo with a therapeutically effective amount of a compound of formula I, or a pharma- ceutically acceptable salt thereof, to negatively regulate PRMT5 activity. In other embodiments, a pharmaceutical composition containing a therapeutically effective amount of a pharma- ceutically acceptable salt or compound of formula I may be used. In one embodiment, the cells are MTAP-deficient cells. In one embodiment, negatively regulating PRMT5 activity occurs in the presence of bound MTA.

[0083] By negatively regulating the activity of PRMT5, particularly in the case of cells lacking MTAP activity, the method is designed to inhibit PRMT5 activity and block cell proliferation. Cells can be contacted with a single dose or multiple doses according to a specific treatment regimen to affect the desired negative regulation of PRMT5. The degree of PRMT5 inhibition can be monitored in vitro for the enzyme in the presence and absence of MTA and in cells using well-known methods, including the method described in Example B below, to assess the efficacy and dosage of treatment.

[0084] In another aspect, a method of treating cancer is provided comprising administering to a patient having cancer a therapeutically effective amount of a compound of formula I, a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or a pharma- ceutically acceptable salt thereof. In one embodiment, the cancer is an MTAP-associated cancer.

[0085] The compositions and methods provided herein may be used for the treatment of a wide variety of cancers, including, for example, tumors such as prostate cancer, breast cancer, brain cancer, skin cancer, cervical cancer, testicular cancer, etc. More specifically, cancers that may be treated by the compositions and methods of the present invention include, but are not limited to, tumor types such as astrocytoma, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, hepatocellular carcinoma, laryngeal cancer, lung cancer, oral cancer, ovarian cancer, prostate cancer, and thyroid cancer, as well as sarcoma. More specifically, these compounds can be used to treat: cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma, and teratoma; lung: primary bronchial carcinoma (squamous cell, small undifferentiated cell, large undifferentiated cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondrotic hamartoma, mesothelioma; gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor, vipoma), small intestine (adenocarcinoma, lymphoma, carcinoid tumor, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large intestine (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma). tumor, leiomyoma); genitourinary tract: kidney (adenocarcinoma, Wilms' tumor (nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, malignant teratoma, choriocarcinoma, sarcoma, interstitial cell tumor, fibroma, fibroadenoma, adenomatoid tumor, lipoma); liver: hepatocellular carcinoma, bile duct cancer , hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma;biliary tract: gallbladder cancer, ampulla of Vater cancer, bile duct cancer;bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor of bone chordoma, osteochondroma (osteochondral exostosis), benign chondroma, chondroblastoma, chondromyxoid fibroma, osteoid osteoma, and giant cell tumor;Nervous system: skull (osteoma, hemangioma, granuloma, xanthomas, osteitis deformans), meninges (meningioma, malignant meningioma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal neurofibroma, meningioma, glioma, sarcoma); gynecology: uterus (endometrial cancer), cervix (cervical cancer, preneoplastic cervical dysplasia), ovary (ovarian cancer (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa theca cell tumor, Sertoli-Leydig cell tumor, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, carcinoma in situ, adenocarcinoma, fibrosarcoma, malignant melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tube (carcinoma); hematology: blood (myeloid leukemia (acute and chronic), acute lymphocytic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, myelodysplastic syndromes), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma); skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, lenticular dysplastic nevus, lipoma, hemangioma, dermatofibroma, keloid, psoriasis; and adrenal gland: neuroblastoma. In certain embodiments, the cancer is diffuse large B-cell lymphoma (DLBCL).

[0086] In one embodiment, the cancer is an MTAP-associated cancer selected from hepatocellular carcinoma, breast cancer, skin cancer, bladder cancer, liver cancer, pancreatic cancer, and head and neck cancer.

[0087] The concentration and route of administration to the patient will vary depending on the cancer being treated. The compounds, their pharma- ceutically acceptable salts, and pharmaceutical compositions containing such compounds and salts may also be co-administered with other anti-neoplastic compounds, e.g., chemotherapeutic agents, or used as pre- or post-operative adjuvants in combination with other treatments, such as radiation or surgical intervention.

[0088] Reaction Schemes, Intermediates, and Examples The compounds of the invention may be prepared using commercially available reagents and intermediates in the synthetic methods and reaction schemes described herein, or may be prepared using other reagents and conventional methods well known to those of skill in the art.

[0089] Intermediate A [ka] 4-Bromo-1-methyl-1H-1,3-benzodiazol-2-amine (20 g, 88.5 mol, 1 eq.) and acetic anhydride (9.93 g, 0.097 mol, 1.1 eq.) were combined in CHCl3 / MeCN (1:1 v / v, 500 mL) at room temperature. The mixture was stirred at 50° C. for 16 h, cooled to room temperature, and concentrated in vacuo. The residue was treated with saturated sodium bicarbonate solution (200 mL) and the product was extracted with ethyl acetate (250 mL×3). The combined organic layers were washed with brine (300 mL), dried over sodium sulfate, filtered, and evaporated under reduced pressure to give N-(4-bromo-1-methyl-1H-1,3-benzodiazol-2-yl)acetamide, intermediate A (23.5 g, 87.68 mol, 99% yield) as a brown solid. LCMS [ESI, M+1] + :268.0 / 270.0. 1 H NMR(400MHz,DMSO-d6) δ 10.81(s,1H),7.53(dd,J=8.0,0.9Hz,1H),7.42(dd,J=7.8,0.9Hz,1H),7.22-7.06(m,1H),3.61(s,3H),2.16(s,3H).

[0090] Intermediate B [ka] Intermediate B was synthesized from 5-bromo-1-methyl-1H-1,3-benzodiazol-2-amine following the same procedure as for intermediate A to give N-(5-bromo-1-methyl-1H-1,3-benzodiazol-2-yl)acetamide, intermediate B, as a brown solid. LCMS [ESI, M+1] + :268.2 / 270.2. 1H NMR(400MHz,DMSO-d6) δ 10.69(s,1H),7.73(d,J=1.9Hz,1H),7.49(d,J=8.7Hz,1H),7.37(dd,J=8.4,1.9Hz,1H),3.59(s,3H),2.15(s,3H).

[0091] Intermediate C [ka] To a solution of 4-bromo-1-methyl-1H-benzo[d]imidazol-2-amine (2.00 g, 8.85 mmol, 1.00 equiv) in toluene (100 mL) and dimethylformamide (20.0 mL) was added 4-methylbenzenesulfonic acid hydrate (101 mg, 531 μmol, 0.06 equiv) and hexane-2,5-dione (5.05 g, 44.2 mmol, 5.19 mL, 5.00 equiv). The mixture was stirred at 145° C. for 48 h before being concentrated. The residue was diluted with water (200 mL) and extracted with ethyl acetate (50.0 mL×3). The organic layer was washed with brine (100 mL), dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (5-20% ethyl acetate in petroleum ether) to give 4-bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)-1-methyl-1H-benzo[d]imidazole, intermediate C (1.60 g, 5.26 mmol, 60% yield) as a pale yellow solid. LCMS [ESI, M+1] + =306.0. 1 H NMR (400MHz, CDCl3) δ=7.59(d,J=7.6Hz,1H),7.39(d,J=8.0Hz,1H),7.32-7.28(m,1H),5.97(s,2H),3.52(s,3H),2.09(s,6H).

[0092] Intermediate D and E and E-1 [ka] Step 1: To a solution of 3-fluoro-2-nitro-aniline (2.00 g, 12.8 mmol, 1.00 equiv) in N,N-dimethylformamide (30.0 mL) was added N-chlorosuccinimide (1.71 g, 12.8 mmol, 1.00 equiv) in N,N-dimethylformamide (20.0 mL) at 0 °C. The mixture was stirred at 0 °C for 0.5 h, then warmed to 10 °C and stirred for 16 h. The mixture was poured into water (200 mL) and extracted with ethyl acetate (50.0 mL x 3). The combined organic layers were washed with water (50.0 mL) and brine (50.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography (15-30% ethyl acetate in petroleum ether). The product was further purified by preparative HPLC (methanol / water (0.05% formic acid) 0-40%) to give two fractions that were concentrated in vacuo to remove acetonitrile. The resulting aqueous mixture was extracted with ethyl acetate (20.0 mL x 3). The combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo to give 4-chloro-3-fluoro-2-nitro-aniline (500 mg, 2.62 mmol, 21% yield) as a yellow solid. GCMS [ESI,M] + :189.9. 1 H NMR (400 MHz, CDCl3) δ = 7.30-7.11 (m, 1H), 6.50 (dd, J = 2.0, 9.2 Hz, 1H), 5.55 (br s, 2H); FNMR (400 MHz, CDCl3) δ = -117.65 (s, 1F) and 6-chloro-3-fluoro-2-nitroaniline (400 mg, 2.10 mmol, 16.4% yield) as an orange solid.

[0093] 1 H NMR(400MHz,CDCl3) δ=7.41(dd,J=4.8,8.8Hz,1H),6.50(dd,J=8.8,10.8Hz,1H),6.06(br s,2H);FNMR(400MHz,CDCl3) δ=-117.10(s,1F);

[0094] Step 2: To a solution of 4-chloro-3-fluoro-2-nitro-aniline (500 mg, 2.62 mmol, 1.00 equiv) in acetonitrile (10.0 mL), copper(II) bromide (879 mg, 3.94 mmol, 184 μL, 1.50 equiv) was added, followed by dropwise addition of tert-butylnitrile (468 μL, 3.94 mmol, 1.50 equiv) at 10° C. under nitrogen atmosphere. The mixture was stirred at 10° C. for 16 h. The mixture was poured into water (30.0 mL) and extracted with ethyl acetate (15.0 mL×3). The combined organic layers were washed with water (15.0 mL x 3), brine (15.0 mL x 2), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give 1-bromo-4-chloro-3-fluoro-2-nitrobenzene (500 mg, 1.97 mmol, 75% yield) as an orange solid. GCMS [ESI,M] + :254.8.

[0095] Step 3: To a solution of 1-bromo-4-chloro-3-fluoro-2-nitrobenzene (400 mg, 1.57 mmol, 1.00 equiv) in tetrahydrofuran (1.00 mL) was added methylamine (2 M in tetrahydrofuran, 3.14 mL, 4.00 equiv) at 10° C. The mixture was stirred at 60° C. for 16 h. The mixture was poured into saturated sodium bicarbonate solution (15.0 mL) and extracted with ethyl acetate (10.0 mL×3). The combined organic layers were washed with water (10.0 mL×2) and brine (10.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give 3-bromo-6-chloro-N-methyl-2-nitroaniline (400 mg, 1.45 mmol, 92% yield) as an orange solid. LCMS [ESI, M+1] + :264.8 / 266.8. 1 H NMR(400MHz,CDCl3) δ=7.22(d,J=8.4Hz,1H),6.93(d,J=8.4Hz,1H),2.89(s,3H).

[0096] Step 4: To a solution of 3-bromo-6-chloro-N-methyl-2-nitroaniline (90.0 mg, 339 μmol, 1.00 equiv) in ethyl acetate (1.20 mL) and water (0.04 mL), acetic acid (420 mg, 6.99 mmol, 0.40 mL, 20.6 equiv) was added. The mixture was warmed to 50° C. Iron powder (75.7 mg, 1.36 mmol, 4.00 equiv) was added to the mixture at 50° C. The resulting mixture was stirred at 80° C. for 2 h. The mixture was poured into water (10.0 mL) and extracted with ethyl acetate (10.0 mL×3). The combined organic layers were washed with water (10.0 mL×3) and brine (10.0 mL). The organic layer was separated, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give 3-bromo-6-chloro-N1-methyl-benzene-1,2-diamine (54.0 mg, 224 μmol, 66% yield) as a pale yellow solid. LCMS [ESI, M+1] + :234.9 / 236.9

[0097] Step 5: To a solution of 3-bromo-6-chloro-N1-methyl-benzene-1,2-diamine (150 mg, 637 μmol, 1.00 equiv.) in water (3.00 mL) and tetrahydrofuran (0.30 mL), cyanogen bromide (81.0 mg, 764 μmol, 56.2 μL, 1.20 equiv.) was added. The resulting mixture was stirred at 50° C. for 6 h. The mixture was diluted with water (10.0 mL) and extracted with a mixture of 3:1 chloroform / isopropanol (10 mL×5). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give 4-bromo-7-chloro-1-methyl-benzimidazol-2-amine, intermediate D (140 mg, 521 μmol, 82% yield) as a yellow solid. LCMS [ESI, M+1] + :262.0. 1 H NMR(400MHz,CD3OD) δ=7.38(d,J=8.4Hz,1H),7.15(d,J=8.4Hz,1H),3.94(s,3H).

[0098] Step 6: A mixture of 4-bromo-7-chloro-1-methyl-benzimidazol-2-amine (2.00 g, 7.68 mmol, 1.00 equiv), hexane-2,5-dione (4.38 g, 38.4 mmol, 4.50 mL, 5.00 equiv), and 4-methylbenzenesulfonic acid (79.3 mg, 461 μmol, 0.06 equiv) in toluene (20.0 mL) was stirred at 130° C. for 16 h. Then, hexane-2,5-dione (2.63 g, 23.0 mmol, 2.70 mL, 3.00 equiv) and 4-methylbenzenesulfonic acid (39.7 mg, 230 μmol, 0.03 equiv) were added and the resulting solution was stirred at 130° C. for 20 h. The reaction mixture was concentrated under vacuum. The crude was then diluted with water (60.0 mL) and extracted with ethyl acetate (20.0 mL x 3). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (ethyl acetate in petroleum ether 0-30%) to give 4-bromo-7-chloro-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazole, intermediate E (330 mg, 870 μmol, 11% yield) as a black oil; LCMS [ESI, M+1] + :338.1 / 340.1. 1 H NMR(400MHz,CDCl3) δ=7.44(d,J=8.4Hz,1H),7.19(d,J=8.4Hz,1H),5.93(s,2H),3.71(s,3H),2.05(s,6H).

[0099] Step 7: To a solution of 4-bromo-7-chloro-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazole (330 mg, 975 μmol, 1.00 equiv) in tetrahydrofuran (5.00 mL) was added n-butyllithium (2.5 M, 585 μL, 1.50 equiv) at −70° C. under nitrogen atmosphere. The mixture was stirred at −70° C. for 1 h under nitrogen atmosphere. Triisopropyl borate (403 μL, 1.75 mmol, 1.80 equiv) in tetrahydrofuran (1.00 mL) was added to the mixture at −70° C. under nitrogen atmosphere. The mixture was stirred at −70° C. for 0.5 h, then slowly warmed to 10° C. and stirred at 10° C. for 16 h. The mixture was quenched with saturated ammonium chloride solution (20.0 mL) and extracted with ethyl acetate (20.0 mL×3). The combined organic layers were washed with water (20.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography (ethyl acetate in petroleum ether 30%) to give [7-chloro-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]boronic acid, intermediate E-1 (58.0 mg, 173 μmol, 18% yield) as a yellow solid. LCMS [ESI, M+1] + :304.1.

[0100] Intermediate F and F-1 [ka] Step 1: To a solution of 5-bromo-1-chloro-2-fluoro-3-nitrobenzene (2.00 g, 7.86 mmol, 1.00 equiv) in ethanol (20.0 mL) was added methylamine / ethanol (10.0 g, 96.6 mmol, 30% methylamine, 12.3 equiv). The mixture was stirred at 20 °C for 12 h. The mixture was concentrated under vacuum. The crude product was triturated with water (20.0 mL) at 15 °C for 15 min to give 4-bromo-2-chloro-N-methyl-6-nitroaniline, intermediate F (2.20 g, crude) as a red solid. 1H NMR (400MHz, CDCl3-d) δ=8.05(d,J=2.4Hz,1H),7.60(d,J=2.4Hz,1H),6.91-6.60(m,1H),3.11(s,3H).

[0101] Step 2: To a solution of 4-bromo-2-chloro-N-methyl-6-nitroaniline (1.10 g, 4.14 mmol, 1.00 equiv) in tetrahydrofuran (20.0 mL) was added 4-dimethylaminopyridine (50.6 mg, 414 μmol, 0.10 equiv), triethylamine (1.73 mL, 12.4 mmol, 3.00 equiv) and di-tert-butyl dicarbonate (1.90 mL, 8.29 mmol, 2.00 equiv). The mixture was stirred at 50° C. for 12 h. After cooling to room temperature, the mixture was concentrated under vacuum. The residue was diluted with ethyl acetate (30.0 mL) and water (30.0 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (3×50.0 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (0-10% ethyl acetate in petroleum ether) to give tert-butyl N-(4-bromo-2-chloro-6-nitro-phenyl)-N-methyl-carbamate, intermediate F-1 (1.50 g, 4.02 mmol, 97% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3-d) δ=7.93(d,J=2.4Hz,1H),7.85(d,J=2.4Hz,1H),3.16(s,3H),1.31(s,9H).

[0102] Intermediates G, H, G-1, and H-1 [ka] Step 1: To a solution of 5-bromo-2-(methylamino)benzonitrile (15.0 g, 71.1 mmol, 1.00 equiv) in acetonitrile (300 mL) was added nitronium tetrafluoroborate (8.78 mL, 85.3 mmol, 1.20 equiv) at 0 °C. The reaction was stirred at 20 °C for 14 h. The reaction mixture was diluted with water (100 mL) and stirred for 5 min. The aqueous phase was extracted with ethyl acetate (150 mL × 3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give a residue. The residue was purified by column chromatography (SiO2, ethyl acetate in petroleum ether / 1-33%) to give 5-bromo-2-(methylamino)-3-nitro-benzonitrile (6.00 g, crude) as a yellow solid. 1 H NMR(400MHz,DMSO-d6) δ=8.90-8.88(m,1H),8.87-8.85(m,1H),3.71(s,3H).

[0103] Step 2: To a solution of 5-bromo-2-(methylamino)-3-nitrobenzonitrile (5.00 g, 19.5 mmol, 1.00 equiv.) in ethyl acetate (50.0 mL) and water (1.50 mL), acetic acid (15.0 mL) and iron powder (10.9 g, 195 mmol, 10.0 equiv.) were added. The reaction was stirred at 60° C. for 1 h. The reaction mixture was diluted with water (100 mL) and stirred for 5 min. The aqueous phase was extracted with ethyl acetate (200 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give 3-amino-5-bromo-2-(methylamino)benzonitrile (4.10 g, 18.1 mmol, 93% yield) as a black-brown gum. LCMS [M+1] + =227.9. 1 H NMR(400MHz,DMSO-d6) δ=6.84(m,2H),5.31(br s,2H),4.48(m,1H),3.06(br d,J=4.8Hz,3H).

[0104] Step 3: To a solution of 3-amino-5-bromo-2-(methylamino)benzonitrile (4.10 g, 18.1 mmol, 1.00 equiv.) in ethyl alcohol (45.0 mL) was added cyanogen bromide (3.84 g, 36.3 mmol, 2.67 mL, 2.00 equiv.). The reaction was stirred at 20 °C for 2 h. The reaction mixture was then diluted with water (50.0 mL) and stirred for 5 min. The aqueous phase was extracted with ethyl acetate (40.0 mL × 3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give a residue. The residue was purified by column chromatography (SiO2, 30-50% ethyl acetate in petroleum ether, then 10% methanol in ethyl acetate) to give 2-amino-6-bromo-3-methyl-benzimidazole-4-carbonitrile, intermediate G (1.80 g, 6.77 mmol, 37% yield) as a dark brown solid. LCMS[M+1] + =252.8. 1 H NMR(400MHz,DMSO-d6) δ=7.54(d,J=1.6Hz,1H),7.44(d,J=2.0Hz,1H),7.10(s,2H),3.74(s,3H).

[0105] Step 4: A mixture of intermediate G (270 mg, 1.08 mmol, 1.00 equiv), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1.09 g, 4.30 mmol, 4.00 equiv), potassium acetate (211 mg, 2.15 mmol, 2.00 equiv), Pd(dppf)Cl2 (70.1 mg, 108 μmol, 0.10 equiv) in dioxane (5.00 mL) was degassed and stirred at 90 °C for 6 h under nitrogen atmosphere. After cooling to room temperature, the mixture was concentrated under vacuum. The residue was diluted with ethyl acetate (20.0 mL) and water (20.0 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (3 × 20.0 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude product was purified by reverse phase HPLC (0.1% FA condition) to give 2-amino-3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzimidazole-4-carbonitrile, intermediate H (140 mg, 470 μmol, 44% yield) as a dark brown solid. 1 H NMR(400MHz,DMSO-d6) δ=7.93(s,1H),7.83(s,1H),3.90(s,3H),1.35(s,12H).

[0106] Step 5: To a solution of 2-amino-6-bromo-3-methyl-benzimidazole-4-carbonitrile (300 mg, 1.19 mmol, 1.00 equiv) in toluene (18.0 mL) and N,N-dimethylformamide (6.00 mL), 4-methylbenzenesulfonic acid hydrate (13.6 mg, 71.7 μmol, 0.06 equiv) and hexane-2,5-dione (682 mg, 5.97 mmol, 701 μL, 5.00 equiv) were added at 10 °C. The mixture was stirred at 140 °C (reflux) with a Dean-Stark trap for 16 h. The mixture was poured into water (30.0 mL) and extracted with ethyl acetate (15.0 mL × 3). The combined organic layers were washed with water (10.0 mL) and brine (10.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography (20% ethyl acetate in petroleum ether) to give 6-bromo-2-(2,5-dimethylpyrrol-1-yl)-3-methyl-benzimidazole-4-carbonitrile, intermediate G-1 (150 mg, 454 μmol, 38% yield) as a white solid. LCMS [ESI, M+1] + :329.0 / 331.0. 1 H NMR(400MHz,CDCl3) δ=8.35(d,J=2.0Hz,1H),8.13(d,J=2.0Hz,1H),5.96(s,2H),3.66(s,3H),1.98(s,6H).

[0107] Step 6: To a solution of 6-bromo-2-(2,5-dimethylpyrrol-1-yl)-3-methyl-benzimidazole-4-carbonitrile (600 mg, 1.82 mmol, 1.00 equiv.) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (1.39 g, 5.47 mmol, 3.00 equiv.) in dioxane (9.00 mL), potassium acetate (537 mg, 5.47 mmol, 3.00 equiv.) was added, followed by [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (200 mg, 273 μmol, 0.15 equiv.) under nitrogen atmosphere at 15° C. The mixture was stirred at 80° C. for 16 h. The mixture was poured into water (20 ml) and extracted with ethyl acetate (20.0 mL x 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (ethyl acetate in petroleum ether 25%) to give 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzimidazole-4-carbonitrile, intermediate H-1 (710 mg, crude) as a white solid, which was used in the next step without further purification. LCMS [ESI, M+1] + :377.2 / 295.1. 1 H NMR(400MHz,CDCl3) δ=8.40(s,1H),8.06(s,1H),5.90(s,2H),3.67(s,3H),1.97(s,6H),1.31(s,12H).

[0108] Intermediates I, I-1, J, and J-1 [ka] Step 1: To a mixture of 1-bromo-2,4-difluoro-3-nitrobenzene (7.00 g, 29.4 mmol, 1.00 equiv.) in dimethylformamide (105 mL), diisopropylethylamine (11.4 g, 88.2 mmol, 15.4 mL, 3.00 equiv.) and methanamine hydrochloride (2.18 g, 32.3 mmol, 1.10 equiv.) were added. The reaction mixture was stirred at 15 °C for 16 h. The reaction mixture was poured into water (500 mL) and extracted with ethyl acetate (200 mL x 3). The combined organic layers were washed with brine (300 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (0-30% ethyl acetate in petroleum) to give 6-bromo-3-fluoro-N-methyl-2-nitroaniline, intermediate I-1 (5.00 g, 20.1 mmol, 68% yield) as a yellow solid. 1 H NMR(400MHz,CDCl3) δ=7.48(dd,J=5.6,8.8Hz,1H),6.46-6.41(m,1H),5.80(s br,1H),2.87(s,3H).

[0109] Step 2: To a mixture of 6-bromo-3-fluoro-N-methyl-2-nitroaniline (5.00 g, 20.1 mmol, 1.00 equiv) in ethyl acetate (50.0 mL) and water (1.80 mL), acetic acid (24.1 g, 401 mmol, 23.0 mL, 20.0 equiv) was added at 25° C. The mixture was warmed to 50° C. and iron powder (4.48 g, 80.3 mmol, 4.00 equiv) was added. The reaction mixture was then heated to 80° C. and stirred at 80° C. for 2 h. The reaction mixture was washed with water (200 mL) and extracted with ethyl acetate (100 mL×3). The combined organic layers were adjusted to pH=8 with saturated sodium bicarbonate, and the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to give 3-bromo-6-fluoro-N2-methyl-benzene-1,2-diamine (4.00 g, 18.3 mmol, 91% yield) as a black oil. 1 H NMR(400MHz,CDCl3) δ=6.84(dd,J=5.6,8.8Hz,1H),6.67-6.62(m,1H),3.96(s br,2H),2.70(s,3H).

[0110] Step 3: To a mixture of 3-bromo-6-fluoro-N2-methyl-benzene-1,2-diamine (2.00 g, 9.13 mmol, 1.00 equiv.) in ethyl alcohol (30.0 mL) and water (30.0 mL), cyanogen bromide (3.87 g, 36.5 mmol, 4.00 equiv.) was added. The reaction mixture was stirred at 50° C. for 2 h. The reaction mixture was adjusted to pH=12 using sodium hydroxide solution 2M to produce a solid. The precipitate was then filtered and concentrated to give 7-bromo-4-fluoro-1-methyl-benzimidazol-2-amine, intermediate I (900 mg, 3.49 mmol, 38% yield) as a brown solid. LCMS [ESI, M+1]: 244.1. 1 H NMR(400MHz,DMSO-d6) δ=6.97(dd,J=4.4,8.8Hz,1H),6.85-6.68(m,3H),3.76(s,3H)

[0111] Step 4: A mixture of 7-bromo-4-fluoro-1-methyl-benzimidazol-2-amine (600 mg, 2.46 mmol, 1.00 equiv), hexane-2,5-dione (1.40 g, 12.3 mmol, 1.44 mL, 5.00 equiv), and p-toluenesulfonic acid monohydrate (93.5 mg, 492 μmol, 0.20 equiv) in toluene (30.0 mL) was stirred at 130 °C for 16 h with a Dean-Stark trap. The mixture was washed with water (30.0 mL) and extracted with ethyl acetate (15 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (0-10% ethyl acetate in petroleum ether) to give 7-bromo-2-(2,5-dimethylpyrrol-1-yl)-4-fluoro-1-methyl-benzimidazole, intermediate J (400 mg, 1.19 mmol, 48% yield) as a yellow oil. LCMS [ESI, M+1]: 323.9. 1 H NMR(400MHz,CDCl3) δ=7.40(dd,J=4.4,8.4Hz,1H),6.93(dd,J=8.8,9.6Hz,1H),5.95(s,2H),3.72(s,3H),2.05(s,6H).

[0112] Step 5: To a mixture of intermediate J (300 mg, 931 mmol, 1.0 equiv.) in dimethylformamide (5 mL) at 20° C. under nitrogen atmosphere, tris(dibenzylideneacetone)dipalladium(0) (85 mg, 93 mmol, 0.1 equiv.), zinc cyanide (328 mg, 2.79 mmol, 3.0 equiv.), 1,1′-bis(diphenylphosphino)ferrocene (103 mg, 186 mmol, 0.2 equiv.), and zinc powder (61 mg, 931 mmol, 1.0 equiv.) were added. The reaction mixture was stirred at 100° C. under nitrogen atmosphere for 16 h. The reaction mixture was then washed with water (30 mL) and extracted with ethyl acetate (15 mL×4). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash silica gel chromatography (40 g silica flash column, 0-30% ethyl acetate / petroleum ether gradient elution) to give 2-(2,5-dimethylpyrrol-1-yl)-7-fluoro-3-methyl-benzimidazole-4-carbonitrile, intermediate J-1 (290 mg, 999 mmol, 99% yield) as a yellow solid. LCMS [ESI, M+1]: 269.2. 1 H NMR(400MHz,CDCl3) δ=7.67(dd,J=4.4,8.4Hz,1H),7.13-7.09(m,1H),6.00-5.94(m,2H),3.75(s,3H),2.07-2.04(m,6H).

[0113] Intermediate K [ka] Step 1: To a solution of 1-(difluoromethyl)-2-fluoro-3-nitro-benzene (300 mg, 1.57 mmol, 1.00 equiv.) and triethylamine (318 mg, 3.14 mmol, 437 μL, 2.00 equiv.) in ethanol (5.00 mL) at 25° C., methylamine hydrochloride (212 mg, 3.14 mmol, 2.00 equiv.) was added slowly. The reaction mixture was then stirred at 25° C. for 5 h. The reaction mixture was quenched by adding water (50.0 mL). The aqueous phase was extracted with dichloromethane (20.0 mL×3) and the combined organic extracts were dried over sodium sulfate, filtered, and concentrated under reduced pressure to give 2-(difluoromethyl)-N-methyl-6-nitroaniline (280 mg, 1.39 mmol, 88% yield) as a yellow solid. 1 H NMR (400MHz, CDCl3) δ=8.23(d,J=8.4Hz,1H),7.81(d,J=7.2Hz,1H),7.15-6.85(m,2H),3.15(s,3H).

[0114] Step 2: To a solution of 2-(difluoromethyl)-N-methyl-6-nitroaniline (140 mg, 693 μmol, 1.00 equiv.) in acetic acid (1.50 mL) at 25 °C, bromine (43.0 μL, 831 μmol, 1.20 equiv.) was added slowly. The reaction mixture was then stirred at 25 °C for 2 h before being quenched by adding concentrated aqueous sodium thiosulfate (10.0 mL). The aqueous phase was extracted with ethyl acetate (20.0 mL × 3) and the combined organic extracts were dried over sodium sulfate, filtered, and concentrated under reduced pressure to give 4-bromo-2-(difluoromethyl)-N-methyl-6-nitroaniline (176 mg, 595 μmol, 86% yield) as a red solid. 1 H NMR(400MHz,CDCl3) δ=8.36(d,J=2.4Hz,1H),7.88(d,J=2.4Hz,1H),7.76-7.49(s br,1H),6.96(t,J=54.4Hz,1H),3.15(s,3H).

[0115] Step 3: To a solution of 4-bromo-2-(difluoromethyl)-N-methyl-6-nitroaniline (176 mg, 626 μmol, 1.00 equiv.) and potassium acetate (92.0 mg, 939 μmol, 1.50 equiv.) in dioxane (2.00 mL), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (191 mg, 752 μmol, 1.20 equiv.) and Pd(dppf)Cl2 (46.0 mg, 63.0 μmol, 0.10 equiv.) were added. The mixture was stirred at 90° C. for 12 h under nitrogen. The reaction mixture was cooled, filtered, and then diluted with ice water (10.0 mL) and extracted with ethyl acetate (10.0 mL×3). The combined organic layers were washed with brine (10.0 mL x 2), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by preparative TLC (SiO2, petroleum ether / ethyl acetate 10:1) to give 2-(difluoromethyl)-N-methyl-6-nitro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, intermediate K (180 mg, 549 μmol, 88% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ=8.64(s,1H),8.11(s,1H),6.96(t,J=54.4Hz,1H),3.19(s,3H),1.35(s,12H).

[0116] Intermediate L [ka] A solution of 4-bromo-1-methyl-pyrazole (500 mg, 3.11 mmol, 1.00 equiv.) and 2-bromobenzonitrile (565 mg, 3.11 mmol, 1.00 equiv.) in N-methylpyrrolidone (7 mL) was degassed with nitrogen. Palladium acetate (7.0 mg, 31.1 μmol, 0.01 equiv.) and 2-(2-dicyclohexylphosphanylphenyl)-N,N-dimethyl-aniline (DavePhos) (24.0 mg, 62.1 μmol, 0.02 equiv.) were then added. To the resulting dark brown solution were added tetrabutylammonium acetate (1.87 g, 6.21 mmol, 2 mL, 2.00 equiv.) and pivalic acid (82.1 mg, 932 μmol, 86.4 μL, 0.30 equiv.) and the resulting solution was stirred at 100° C. for 10 h. After the reaction was complete, the mixture was cooled. Ethyl acetate (100 mL) was added and the resulting mixture was washed with brine (3×100 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated in vacuo to give a crude oil. The crude oil was purified by silica gel chromatography (ethyl acetate in petroleum ether, 30%) to give 2-(4-bromo-2-methyl-pyrazol-3-yl)benzonitrile, intermediate L (400 mg, 1.53 mmol, 49% yield) as a white solid. LCMS [M+1]=261.9. 1 H NMR(400MHz, CDCl3-d) δ=7.86(dd,J=0.8,7.6Hz,1H),7.76(dt,J=1.2,7.6Hz,1H),7.63(dt,J=1.2,7.6Hz,1H),7.60(s,1H),7.49(dd,J=0.8,7.6Hz,1H),3.81(s,3H).

[0117] Intermediate M [ka] Step 1: To a solution of 1-bromo-5-chloro-3-fluoro-2-nitro-benzene (2.30 g, 9.04 mmol, 1.00 equiv.) and methylamine hydrochloride (671 mg, 9.94 mmol, 1.10 equiv.) in N,N-dimethylformamide (45.0 mL), diisopropylethylamine (3.50 g, 27.1 mmol, 4.72 mL, 3.00 equiv.) was added and the resulting mixture was stirred at 25 °C for 12 h. The mixture was diluted with water (200 mL) and extracted with ethyl acetate (50.0 mL × 3). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (ethyl acetate in petroleum ether 5-10%) to give 3-bromo-5-chloro-N-methyl-2-nitro-aniline (1.10 g, 3.84 mmol, 42% yield) as a yellow solid. LCMS[ESI,M+1] + :265.0 / 267.0. 1 H NMR (400MHz, CDCl3) δ=6.97(d,J=2.0Hz,1H),6.73(d,J=2.0Hz,1H),6.20-5.98(m,1H),2.93(s,3H).

[0118] Step 2: A mixture of 3-bromo-5-chloro-N-methyl-2-nitro-aniline (1.10 g, 4.14 mmol, 1.00 equiv), iron powder (1.16 g, 20.7 mmol, 5.00 equiv), and saturated ammonium chloride (1.11 g, 20.7 mmol, 5.00 equiv) in ethanol (10.0 mL) and water (2.00 mL) was stirred at 80 °C for 1 h. The mixture was filtered and the filtrate was concentrated. The residue was purified by flash silica gel chromatography (10-20% ethyl acetate in petroleum ether) to give 3-bromo-5-chloro-N1-methyl-benzene-1,2-diamine (460 mg, 1.89 mmol, 46% yield) as a yellow solid. LCMS [ESI, M+1] + :237.0 / 235.0. 1 H NMR(400MHz,CDCl3) δ=7.03(br s,1H),6.70(d,J=2.0Hz,1H),2.89(br s,3H).

[0119] Step 3: To a mixture of 3-bromo-5-chloro-N1-methyl-benzene-1,2-diamine (570 mg, 2.42 mmol, 1.00 equiv.) in ethanol (6.00 mL) and water (6.00 mL), cyanogen bromide (513 mg, 4.84 mmol, 356 μL, 2.00 equiv.) was added. The resulting mixture was stirred at 50 °C for 12 h. The mixture was adjusted to pH 8-9 with saturated sodium bicarbonate and extracted with ethyl acetate (30.0 mL x 5). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give 4-bromo-6-chloro-1-methyl-benzimidazol-2-amine (400 mg, 1.53 mmol, 63% yield) as an off-white solid. LCMS [ESI, M+1] + :262.0 / 260.0. 1 H NMR(400MHz,DMSO-d6) δ=7.29(d,J=2.0Hz,1H),7.17(d,J=2.0Hz,1H),6.86(s,2H),3.49(s,3H).

[0120] Step 4: A mixture of 4-bromo-6-chloro-1-methyl-benzimidazol-2-amine (400 mg, 1.54 mmol, 1.00 equiv), hexane-2,5-dione (876 mg, 7.68 mmol, 901 μL, 5.00 equiv), and 4-methylbenzenesulfonic acid hydrate (29.2 mg, 154 μmol, 0.10 equiv) in toluene (10.0 mL) in N,N-dimethylformamide (2.00 mL) was stirred at 145 °C for 24 h with a Dean-Stark trap. The mixture was concentrated to remove toluene, and the residue was diluted with water (30.0 mL). The mixture was extracted with ethyl acetate (15.0 mL × 3). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (20% ethyl acetate in petroleum ether) to give 4-bromo-6-chloro-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazole (400 mg, 1.18 mmol, 77% yield) as a white solid. LCMS [ESI, M+1] + :338.0 / 340.0. 1H NMR(400MHz,CDCl3) δ=7.57(d,J=1.6Hz,1H),7.37(d,J=1.6Hz,1H),5.94(s,2H),3.46(s,3H),2.05(s,6H).

[0121] Step 5: To a mixture of 4-bromo-6-chloro-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazole (100 mg, 295 μmol, 1.00 equiv.) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (75.0 mg, 295 μmol, 1.00 equiv.) in dioxane (3.00 mL), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (21.6 mg, 29.5 μmol, 0.10 equiv.) and potassium acetate (72.5 mg, 738 μmol, 2.50 equiv.) were added. The mixture was degassed and stirred at 80° C. for 12 h under nitrogen atmosphere. The mixture was diluted with water (15.0 mL) and extracted with ethyl acetate (10.0 mL x 3). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (20-30% ethyl acetate in petroleum ether) to give 6-chloro-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzimidazole (108 mg, 264 μmol, 89% yield) as an off-white solid. LCMS [ESI, M-82] + :304.1. 1 H NMR(400MHz,DMSO-d6) δ=7.97-7.95(m,1H),7.54(d,J=2.0Hz,1H),5.95(s,2H),3.47(s,3H),1.95(s,6H),1.32(s,12H).

[0122] Step 6: To a mixture of 6-chloro-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzimidazole (108 mg, 280 μmol, 1.00 equiv.) and 2-(4-iodo-2-methyl-pyrazol-3-yl)benzonitrile (86.6 mg, 280 μmol, 1.00 equiv.) in dioxane (2.00 mL) and water (0.40 mL), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (20.5 mg, 28.0 μmol, 0.10 equiv.) and sodium carbonate (59.4 mg, 560 μmol, 2.00 equiv.) were added. The mixture was degassed with nitrogen and stirred at 80° C. under nitrogen atmosphere for 12 h. The mixture was filtered and the filtrate was concentrated. The residue was purified by silica gel chromatography (20-30% ethyl acetate in petroleum ether) to give 2-[4-[6-chloro-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]-2-methyl-pyrazol-3-yl]benzonitrile, intermediate M (50.0 mg, 108 μmol, 39% yield) as an off-white solid. LCMS [ESI, M+1] - :441.2.

[0123] Intermediate N [ka] Step 1: A mixture of 3-bromo-5,6,7,8-tetrahydroquinoline (140 mg, 660 μmol, 1.00 equiv), tributylstannylmethanol (424 mg, 1.32 mmol, 2.00 equiv), and Pd(PPh3)4 (76.3 mg, 66.0 μmol, 0.10 equiv) in dioxane (2.00 mL) was degassed and stirred at 100° C. for 16 h under nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by preparative TLC (SiO2, petroleum ether / ethyl acetate 1:100) to give 5,6,7,8-tetrahydroquinolin-3-ylmethanol (65.0 mg, 339 μmol, 51% yield) as a colorless oil.

[0124] 1 H NMR(400MHz,CDCl3) δ=8.10(d,J=1.6Hz,1H),7.32(s,1H),4.53(s br,3H),2.78-2.74(m,2H),2.65(t,J=6.4Hz,2H),1.79-1.73(m,2H),1.66(br s,2H).

[0125] Step 2: To a solution of 5,6,7,8-tetrahydroquinolin-3-ylmethanol (40.0 mg, 246 μmol, 1.00 equiv) in dichloromethane (0.50 mL) was added thionyl chloride (58.3 mg, 490 μmol, 35.6 μL, 2.00 equiv) and dimethylformamide (0.05 mL). The mixture was stirred at 0° C. for 2 h, followed by stirring at 20° C. for 1 h. The reaction mixture was concentrated under reduced pressure to give 3-(chloromethyl)-5,6,7,8-tetrahydroquinoline, intermediate N (30.0 mg, 165 μmol, 67% yield) as a yellow oil. LC-MS [M+1] + =182.2.

[0126] Intermediate O [ka] Step 1: To a solution of methyl 3-amino-4-(methylamino)benzoate (500 mg, 2.77 mmol, 1 equiv) in MeOH (10 mL) was slowly added BrCN (588 mg, 5.55 mmol, 408 μL, 2.00 equiv). The mixture was stirred at 20° C. for 12 h. The reaction mixture was then concentrated under reduced pressure to give a residue. The residue was triturated with ethyl acetate (10 mL). The solid was collected by filtration and dried in vacuum to give methyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate (870 mg, crude) as a brown solid. LCMS [M+1] + =206.0. 1H NMR(400MHz,DMSO-d6) δ=12.74(br s,1H),8.91(s,2H),7.93-7.85(m,2H),7.61(d,J=8.4Hz,1H),3.86(s,3H),3.66(s,3H).

[0127] Step 2: To a solution of methyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate (400 mg, 1.95 mmol, 1 equiv.) in MeOH (8 mL) and HO (2 mL) was added LiOH·HO (409 mg, 9.75 mmol, 5.00 equiv.). The mixture was stirred at 70 °C for 12 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was diluted with water (10 mL), the pH was adjusted to 3 with 1N aqueous HCl, and the precipitate was collected by filtration and dried in vacuum to give 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid, intermediate O (150 mg, 785 μmol, 40.3% yield) as a red solid. LCMS [M+1] + =192.0. 1 H NMR(400MHz,DMSO-d6) δ=7.72(s,1H),7.62(dd,J=1.2,8.4Hz,1H),7.23(d,J=8.0Hz,1H),6.87(br s,2H),3.55(s,3H).

[0128] Intermediates P-1 and P-2 [ka] Step 1: A mixture of 5-bromo-5,6,7,8-tetrahydroquinoxaline (625 mg, 1.00 equiv.), [5-(trifluoromethyl)-2-pyridyl]methanamine hydrochloride (748 mg, 3.00 mmol, 1.02 equiv.) and potassium carbonate (1.62 g, 11.7 mmol, 4.00 equiv.) in dimethylformamide (15.0 mL) was degassed and stirred under nitrogen atmosphere at 40° C. for 2 h. The mixture was extracted with ethyl acetate (30.0 mL×3), washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (neutral conditions) to give N-[[5-(trifluoromethyl)-2-pyridyl]methyl]-5,6,7,8-tetrahydroquinoxalin-5-amine (150 mg, 48.0% yield) as a yellow oil. LCMS(ESI,M+1):m / z=309.0. 1 H NMR(400MHz,CDCl3) δ=8.85(s,1H),8.39(s,2H),7.90(dd,J=2.0,8.4Hz,1H),7.57(d,J=8.4Hz,1H),4.19(s,2H),3.96(br t,J=6.4Hz,1H),3.04-2.97(m,2H),2.26-2.11(m,2H),1.90-1.81(m,2H)

[0129] Step 2: Racemic N-[[5-(trifluoromethyl)-2-pyridyl]methyl]-5,6,7,8-tetrahydroquinoxalin-5-amine (150 mg) was separated by SFC (Conditions: Column: DAICEL CHIRALPAK IC (250 mm*30 mm, 5 um); Mobile phase: [ACN / IPA (0.1% NH3H2O)]; B%: 20%-20%, 6 min) to obtain peak 1 (5S)-N-[[5-(trifluoromethyl)-2-pyridyl]methyl]-5,6,7,8-tetrahydroquinoxalin-5-amine, intermediate P-1 (50.0 g, yield 28.2%, purity 84.6%) as a white solid. LCMS (ESI, M+1): m / z=309.0. 1H NMR (400 MHz, CDCl3) δ = 8.85 (s, 1H), 8.39 (s, 2H), 7.90 (dd, J = 1.8, 8.2 Hz, 1H), 7.57 (d, J = 8.2 Hz, 1H), 4.19 (s, 2H), 3.99-3.92 (m, 1H), 3.04-2.95 (m, 2H), 2.25-2.12 (m, 2H), 1.93-1.79 (m, 2H) and peaks 2(5R)-N-[[5-(trifluoromethyl)-2-pyridyl]methyl]-5,6,7,8-tetrahydroquinoxalin-5-amine, intermediate P-2 (50 mg, 26.7% yield) as a white solid. LCMS (ESI, M+1): m / z = 309.0. 1 H NMR(400MHz,CDCl3) δ=8.85(s,1H),8.39(s,2H),7.90(dd,J=1.7,8.1Hz,1H),7.58(d,J=8.3Hz,1H),4.20(s,2H),3.96(br t,J=6.4Hz,1H),3.06-2.97(m,2H),2.26-2.11(m,2H),1.93-1.80(m,2H).

[0130] Intermediates R-1 and R-2 [ka] Step 1: To a solution of (5-bromo-2-pyridyl)methanamine (1.60 g, 8.55 mmol, 1.0 equiv.) and 1-pyrimidin-2-ylethanone (1.25 g, 10.3 mmol, 1.2 equiv.) in dichloromethane (20 mL), potassium acetate (1.26 g, 12.8 mmol, 1.5 equiv.) was added. The mixture was stirred at 25° C. for 0.5 h. Then, NaBH(OAc)3 (2.72 g, 12.8 mmol, 1.5 equiv.) was added and the mixture was stirred at 25° C. for 1.5 h. The mixture was diluted with water (50 mL) and the pH was adjusted to about 4 with HCl (aq., 1.0 M). The mixture was washed with dichloromethane (50 mL×2). The aqueous phase was then basified with sodium hydroxide (aqueous, 10%) to pH 9 and extracted with dichloromethane (100 mL×3). The combined organic layers were washed with brine (30 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give N-[(5-bromo-2-pyridyl)methyl]-1-pyrimidin-2-yl-ethanamine (2.12 g, 7.23 mmol, 84.5% yield) as a yellow oil.

[0131] Step 2: Racemic N-[(5-bromo-2-pyridyl)methyl]-1-pyrimidin-2-yl-ethanamine was separated by preparative SFC (Column: DAICEL CHIRALPAK AD (250mm*30mm, 10um); Mobile phase: [0.1% NH3H2O ​​ETOH]; B%: 40%-40%, 4min) to give peak 1 (S)-N-((5-bromopyridin-2-yl)methyl)-1-(pyrimidin-2-yl)ethan-1-amine, intermediate R-1, LCMS (ESI, M+1): m / z=293.1 and peak 2 (R)-N-((5-bromopyridin-2-yl)methyl)-1-(pyrimidin-2-yl)ethan-1-amine, intermediate R-2, LCMS (ESI, M+1): m / z=293.1

[0132] General Coupling Method for Preparation of Library Examples 1-1 to 1-84 [ka] Coupling method 1-A (CM1-A): To a mixture of boronate or boronic acid (1.5 eq.), 4-bromo-1-methyl-1H-1,3-benzodiazol-2-amine (1 eq.) in dry dioxane (approximately 0.7 mL per 100 mg of product), XPhos Pd G3 (0.05 eq.) (as a 0.2 M solution in dioxane) and sodium carbonate (2.5 eq.) (as a 1 M stock solution in water) were added under inert atmosphere. The reaction mixture was sealed and heated at 100° C. for 16 h. The mixture was cooled to ambient temperature and treated with TFA dropwise until pH approx. 7. The mixture was evaporated under reduced pressure and the residue was dissolved in DMSO (approximately 1 mL per 100 mg of product). The DMSO solution was treated with SiliaMetS DMT scavenger, filtered and purified by preparative HPLC (DI water / methanol (+0.05% NH4OH)) to give the product.

[0133] [ka] Coupling method 1-B (CM1-B): To a mixture of boronate or boronic acid (1.5 eq.), 5-bromo-1-methyl-1H-1,3-benzodiazol-2-amine (1 eq.) in dry dioxane (approximately 0.7 mL per 100 mg of product), XPhos Pd G3 (0.05 eq.) (as a 0.2 M solution in dioxane) and sodium carbonate (2.5 eq.) (as a 1 M stock solution in water) were added under inert atmosphere. The reaction mixture was sealed and heated at 100° C. for 16 h, the mixture was cooled to ambient temperature and treated with TFA dropwise until pH approx. 7. The mixture was evaporated under reduced pressure and the residue was dissolved in DMSO (approximately 1 mL per 100 mg of product). The DMSO solution was treated with SiliaMetS DMT scavenger, filtered and purified by preparative HPLC (DI water / methanol (+0.05% NH4OH)) to give the product.

[0134] [ka] Coupling method 1-C (CM1-C): To a mixture of intermediate A (1 eq.) and amine (1.3 eq.) in dry dioxane (approx. 0.5 mL per 100 mg of product), BrettPhos Pd G4 (0.1 eq. as a stock solution in dioxane, approx. 0.05 mL per 100 mg of product), BrettPhos (0.1 eq. as a stock solution in dioxane, approx. 0.05 mL per 100 mg of product), and t-BuONa (2.5 eq. as a stock solution in THF, approx. 0.15 mL per 100 mg of product) were added under inert atmosphere. The reaction mixture was sealed and heated with shaking at 100° C. for 15 h. The mixture was cooled to ambient temperature and concentrated to dryness in vacuo. The residue was treated with concentrated aqueous HCl-MeOH mixture (1:6, 4 mL), heated at 50° C. until reaction completion (LCMS control, 16-48 h), cooled to room temperature, and evaporated to dryness under reduced pressure. The residue was dissolved in DMSO (approximately 1 mL per 100 mg of product) and the resulting solution was treated with SiliaMetS DMT scavenger, filtered, and purified by preparative HPLC (DI water / methanol (+0.05% NH4OH)) to give the product.

[0135] [ka] Coupling method 1-D (CM1-D): To a mixture of intermediate B (1 eq.) and amine (1.3 eq.) in dry dioxane (approx. 0.5 mL per 100 mg of product), BrettPhos Pd G4 (0.1 eq. as a stock solution in dioxane, approx. 0.05 mL per 100 mg of product), BrettPhos (0.1 eq. as a stock solution in dioxane, approx. 0.05 mL per 100 mg of product), and t-BuONa (2.5 eq. as a stock solution in THF, approx. 0.15 mL per 100 mg of product) were added under inert atmosphere. The reaction mixture was sealed and heated with shaking at 100° C. for 15 h. The mixture was cooled to ambient temperature and concentrated to dryness in vacuo. The residue was treated with concentrated aqueous HCl-MeOH mixture (1:6, 4 mL), heated at 50° C. until reaction completion (LCMS control, 16-48 h), cooled to room temperature, and evaporated to dryness under reduced pressure. The residue was dissolved in DMSO (approximately 1 mL per 100 mg of product) and the resulting solution was treated with SiliaMetS DMT scavenger, filtered, and purified by preparative HPLC (DI water / methanol (+0.05% NH4OH)) to give the product.

[0136] Following the teachings of the reaction schemes provided above, coupling methods CM1-A, CM1-B, CM1-C, and CM1-D, and intermediates disclosed herein, Examples 1-1 through 1-84 were prepared as shown in Table 1, or using analogous methods. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5]

Table 1-6

Table 1-7

Table 1-8

Table 1-9

Table 1-10

Table 1-11

Table 1-12

Table 1-13

Table 1-14

Table 1-15

Table 1-16

Table 1-17

Table 1-18

Table 1-19

[0137] Examples 1-85 [ka] Step 1: A mixture of intermediate C (250 mg, 821 μmol, 1.00 equiv), potassium (((tert-butoxycarbonyl)amino)methyl)trifluoroborate (487 mg, 2.05 mmol, 2.50 equiv), sodium carbonate (261 mg, 2.47 mmol, 3.00 equiv), and CataCXium A Pd G3 (59.9 mg, 82.2 μmol, 0.10 equiv) in dioxane (5.00 mL) and water (1.00 mL) was degassed and stirred at 80° C. for 2 h under nitrogen atmosphere. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (0-50% ethyl acetate in petroleum ether) to give tert-butyl N-[[2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]methyl]carbamate (100 mg, 264 μmol, 32% yield) as a yellow solid. LCMS [M+1]+=355.2. 1 H NMR(400MHz,CDCl3-d) δ=7.38-7.28(m,3H),5.97(s,2H),4.76(br d,J=6.0Hz,2H),3.49(s,3H),2.06(s,6H),1.44(s,9H).

[0138] Step 2: A mixture of tert-butyl N-[[2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]methyl]carbamate (90.0 mg, 254 μmol, 1.00 equiv.) in trifluoroacetic acid (0.50 mL) and dichloromethane (1.50 mL) was stirred at 25° C. for 1 h under nitrogen atmosphere. The mixture was concentrated under reduced pressure to give a residue. The crude product was purified by reverse phase HPLC (0.1% formic acid condition) to give [2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]methanamine (40.0 mg, 146 μmol, 58% yield) as a white solid. LCMS [M-16]+=238.0

[0139] Step 3: A mixture of 2-iodonaphthalene-1-carbonitrile (32.9 mg, 118 μmol, 1.20 equiv.), [2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]methanamine (25.0 mg, 98.3 μmol, 1.00 equiv.), Pd(dppf)Cl2 (7.19 mg, 9.83 μmol, 0.10 equiv.), sodium tert-butoxide (28.3 mg, 295 μmol, 3.00 equiv.), and DPPF (16.35 mg, 29.49 μmol, 0.3 equiv.) in dioxane (2.00 mL) was degassed and stirred under nitrogen atmosphere at 100° C. for 2 h. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by preparative TLC (SiO2, petroleum ether / ethyl acetate 5:1) to give -[[2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]methylamino]naphthalene-1-carbonitrile (25.0 mg, 55.1 μmol, 56% yield) as a white solid. LCMS [M+1] + =406.2.

[0140] Step 4: To a solution of 2-[[2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]methylamino]naphthalene-1-carbonitrile (25.0 mg, 61.7 μmol, 1.00 equiv.) in dimethylformamide (1.00 mL) at 0° C., sodium hydride (7.40 mg, 185 μmol, 60.0% in mineral oil, 3.00 equiv.) was added followed by acetyl chloride (14.5 mg, 185 μmol, 13.2 μL, 3.00 equiv.) and the mixture was stirred for 2 h at 25° C. The mixture was quenched with water (0.50 mL) and stirred for 10 min, then filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC (0.1% formic acid condition) to give N-(1-cyano-2-naphthyl)-N-[[2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]methyl]acetamide (15.0 mg, 32.2 μmol, 65% yield) as a white solid. LCMS [M+1]+=448.3.

[0141] Step 5: To a solution of N-(1-cyano-2-naphthyl)-N-[[2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]methyl]acetamide (10.0 mg, 22.3 μmol, 1.00 equiv.) in ethyl alcohol (2.00 mL) was added concentrated hydrochloric acid (0.25 mL). The mixture was stirred in a microwave reactor at 120° C. for 3 h and then concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (0.1% formic acid condition) to give N-[(2-amino-1-methyl-benzimidazol-4-yl)methyl]-N-(1-cyano-2-naphthyl)acetamide, Example 1-85 (2.71 mg, 7.28 μmol, 33% yield) as a white solid. LCMS [M+1] + =370.1. 1H NMR(400MHz,MeOD-d4) δ=8.56-8.43(m,1H),8.20(d,J=8.8Hz,1H),8.07-8.02(m,2H),7.79-7.69(m,2H),7.42(d,J=8.8Hz,1H),7.24(d,J=8. 0Hz,1H),7.04(t,J=7.6Hz,1H),6.94(d,J=7.6Hz,1H),5.38-5.33(m,1H),5.25-5.19(m,1H),3.59(s,3H),1.96(s,3H).

[0142] Examples 1-86 [ka] Step 1: To a mixture of methyl 4-(methylamino)-3-nitro-benzoate (5.00 g, 23.8 mmol, 1.00 equiv.) in ethanol (60.0 mL) and water (12.0 mL), iron powder (6.64 g, 119 mmol, 5.00 equiv.) and ammonium chloride (6.36 g, 119 mmol, 5.00 equiv.) were added. The reaction mixture was stirred at 80° C. for 1 h. The reaction mixture was filtered and the filtrate was concentrated to remove ethyl alcohol. The resulting aqueous mixture was extracted with ethyl acetate (30.0 mL×3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give methyl 3-amino-4-(methylamino)benzoate (4.10 g, 20.2 mmol, 85% yield) as a black solid. LCMS [ESI, M+1]: 181.1. 1 H NMR(400MHz,CDCl3) δ=7.61(dd,J=1.2,8.4Hz,1H),7.40(d,J=1.2Hz,1H),6.58(d,J=8.4Hz,1H),3.84(s,3H),3.34-3.06(m,3H),2.91(s,3H).

[0143] Step 2: To a mixture of methyl 3-amino-4-(methylamino)benzoate (2.00 g, 11.1 mmol, 1.00 equiv.) in ethyl alcohol (20.0 mL) and water (20.0 mL) was added cyanogen bromide (4.70 g, 44.4 mmol, 4.00 equiv.). The reaction mixture was stirred at 50° C. for 16 h. The reaction mixture was adjusted to pH=8 with saturated aqueous sodium bicarbonate and concentrated to remove ethyl alcohol. The aqueous residual mixture was lyophilized. The crude was purified by reverse phase HPLC (0.1% ammonium hydroxide condition) to give methyl 2-amino-1-methyl-benzimidazole-5-carboxylate (1.90 g, 9.12 mmol, 82% yield) as a white solid. LCMS [ESI, M+1]: 206.1. 1 H NMR(400MHz,MeOD-d4) δ=7.88(d,J=1.2Hz,1H),7.75(dd,J=1.6,8.4Hz,1H),7.21(d,J=8.4Hz,1H),3.89(s,3H),3.59(s,3H).

[0144] Step 3: A mixture of methyl 2-amino-1-methyl-benzimidazole-5-carboxylate (1.40 g, 6.82 mmol, 1.00 equiv), hexane-2,5-dione (3.89 g, 34.1 mmol, 4.00 mL, 5.00 equiv), and p-toluenesulfonic acid monohydrate (259 mg, 1.36 mmol, 0.20 equiv) in toluene (90.0 mL) and dimethylformamide (30.0 mL) was stirred at 130 °C for 16 h with a Dean-Stark trap. The reaction mixture was washed with water (200 mL) and extracted with ethyl acetate (40.0 mL × 4). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (ethyl acetate gradient 0-40% in petroleum ether) to give methyl 2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazole-5-carboxylate (1.90 g, 6.69 mmol, 98% yield) as a yellow oil. LCMS [ESI, M+1]: 284.2. 1H NMR(400MHz,DMSO) δ=8.31(d,J=1.2Hz,1H),8.00(dd,J=1.6,8.4Hz,1H),7.77(d,J=8.4Hz,1H),5.95(s,2H),3.89(s,3H),3.52(s,3H),1.97(s,6H).

[0145] Step 4: To a mixture of methyl 2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazole-5-carboxylate (1.90 g, 6.71 mmol, 1.00 equiv.) in tetrahydrofuran (30.0 mL) was added lithium aluminum hydride (509 mg, 13.4 mmol, 2.00 equiv.) dropwise at 0° C. After the addition was complete, the mixture was stirred at 0° C. for 1 h. The reaction mixture was quenched with sodium sulfate decahydrate (500 mg), diluted with ethyl acetate (20.0 mL), and filtered. The filtrate was concentrated to give [2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-5-yl]methanol (1.40 g, 5.31 mmol, 80% yield) as a colorless oil. LCMS [ESI, M+1]: 256.2. 1 H NMR (400MHz, CDCl3) δ=7.80(d,J=0.8Hz,1H),7.44-7.35(m,2H),5.94(s,2H),4.81(d,J=3.6Hz,2H),3.46(s,3H),2.03(s,6H).

[0146] Step 5: To a mixture of [2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-5-yl]methanol (600 mg, 2.35 mmol, 1.00 equiv.) in ethyl acetate (10.0 mL), 1-hydroxy-1,2-benziodoxol-3(1H)-one 1-oxide (1.32 g, 4.70 mmol, 2.00 equiv.) was added. The mixture was stirred at 80 °C for 2 h. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by silica gel chromatography (0-60% ethyl acetate in petroleum ether) to give 2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-5-carbaldehyde (300 mg, 1.18 mmol, 50% yield) as a white solid. LCMS [ESI, M+1]: 254.0. 1 H NMR (400MHz, CDCl3-d) δ=10.11(s,1H),8.32(d,J=1.2Hz,1H),7.98-7.96(m,1H),7.50(d,J=8.4Hz,1H),5.97(s,2H),3.52(s,3H),2.05(s,6H).

[0147] Step 6: To a mixture of 2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazole-5-carbaldehyde (300 mg, 1.18 mmol, 1.00 equiv.) and 2-aminonaphthalene-1-carbonitrile (199 mg, 1.18 mmol, 1.00 equiv.) in toluene (9.00 mL) was added titanium(IV) isopropoxide (673 mg, 2.37 mmol, 699 μL, 2.00 equiv.). The reaction mixture was stirred at 110° C. for 16 h and then concentrated to give 2-[[2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-5-yl]methyleneamino]naphthalene-1-carbonitrile (460 mg, crude) as a yellow oil.

[0148] Step 7: To a mixture of 2-[[2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-5-yl]methyleneamino]naphthalene-1-carbonitrile (460 mg, 1.14 mmol, 1.00 equiv) in tetrahydrofuran (10.0 mL) at 0° C., sodium cyanoborohydride (107 mg, 1.71 mmol, 1.50 equiv) was added. The mixture was stirred at 50° C. for 2 h. The reaction mixture was quenched with saturated aqueous ammonium chloride (15.0 mL) and extracted with ethyl acetate (10.0 mL×4). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (0-60% ethyl acetate in petroleum ether) and further purified by preparative HPLC (0.225% formic acid condition) to give 2-[[2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-5-yl]methylamino]naphthalene-1-carbonitrile (90.0 mg, 203 μmol, 18% yield) as a yellow oil. LCMS [ESI, M+1]: 406.3. 1 H NMR(400MHz,MeOD-d4) δ=7.84-7.78(m,2H),7.74-7.69(m,2H),7.59-7.48(m,3H),7.31-7.23(m,1H),7.1 0-6.99(m,1H),6.00-5.90(m,2H),4.82(s,2H),3.50(s,3H),2.01(d,J=5.6Hz,6H).

[0149] Step 8: To a mixture of 2-[[2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-5-yl]methylamino]naphthalene-1-carbonitrile (50.0 mg, 123 μmol, 1.00 equiv) in tetrahydrofuran (1.50 mL) at 0° C., KHMDS (1.00 M, 493 μL, 4.00 equiv) was added under nitrogen atmosphere. The reaction mixture was stirred at 0° C. for 0.5 h. Then, acetyl chloride (48.4 mg, 616 μmol, 44.0 μL, 5.00 equiv) was added and the mixture was warmed to 25° C. and stirred at 25° C. for 2 h. The reaction mixture was quenched by water (10.0 mL) and extracted with ethyl acetate (5.00 mL×3). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (0-80% ethyl acetate in petroleum ether) to give N-(1-cyano-2-naphthyl)-N-[[2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-5-yl]methyl]acetamide (20.0 mg, 44.7 μmol, 36% yield) as a yellow oil. LCMS [ESI, M+1]: 448.3.

[0150] Step 9: To a mixture of N-(1-cyano-2-naphthyl)-N-[[2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-5-yl]methyl]acetamide (20.0 mg, 44.7 μmol, 1.00 equiv.) in ethyl alcohol (1.00 mL) was added 12 M hydrochloric acid (0.10 mL). The mixture was stirred in a microwave reactor at 120° C. for 0.5 h. The reaction mixture was adjusted to pH=8 with ammonium hydroxide and concentrated. The residue was purified by preparative HPLC (ammonium bicarbonate condition) to give N-[(2-amino-1-methyl-benzimidazol-5-yl)methyl]-N-(1-cyano-2-naphthyl)acetamide, Example 1-86 (1.90 mg, 4.78 μmol, 11% yield) as an off-white solid. LCMS[ESI,M+1]:370.1. 1H NMR(400MHz,MeOD) δ=8.12(dd,J=8.4,13.2Hz,2H),8.02(d,J=8.0Hz,1H),7.81-7.74(m,1H),7.73-7.65(m,1H),7.24(d,J=8.8Hz ,1H),7.02(d,J=8.0Hz,1H),6.96(s,1H),6.93-6.84(m,1H),5.28(d,J=14.0Hz,2H),3.50(s,3H),1.92(s,3H).

[0151] Examples 1-87 [ka] Step 1: To a solution of intermediate C (100 mg, 329 μmol, 1.00 equiv.) and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (125 mg, 493 μmol, 1.50 equiv.) in dioxane (2.50 mL) was added potassium acetate (80.7 mg, 822 μmol, 2.50 equiv.) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (12.0 mg, 16.4 μmol, 0.05 equiv.). The mixture was stirred under nitrogen atmosphere at 80° C. for 16 h. The mixture was concentrated. The residue was purified by silica gel chromatography (5-20% ethyl acetate in petroleum ether) to give 2-(2,5-dimethyl-1H-pyrrol-1-yl)-1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazole (90.0 mg, crude) as a pale yellow oil. LCMS [ESI, M+1] + =270.2. 1 HNMR(400MHz,CDCl3) δ=7.92-7.84(m,1H),7.59-7.48(m,2H),6.00(s,1H),5.93(s,1H),3.54(s,3H),2.08-2.06(m,6H),1.42(s,3H).

[0152] Step 2: To a solution of intermediate L (50.0 mg, 162 μmol, 1.00 equiv.) and 2-(2,5-dimethyl-1H-pyrrol-1-yl)-1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazole (68.2 mg, 194 μmol, 1.20 equiv.) in dioxane (1.50 mL) and water (0.30 mL) was added sodium carbonate (42.9 mg, 404 μmol, 2.50 equiv.) and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (11.8 mg, 16.2 μmol, 0.10 equiv.). The mixture was stirred at 80° C. for 3 h under nitrogen atmosphere, then diluted with water (30.0 mL) and extracted with ethyl acetate (10.0 mL×2). The organic layer was washed with brine (10.0 mL), dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (5-20% ethyl acetate in petroleum ether) to give 2-(4-(2-(2,5-dimethyl-1H-pyrrol-1-yl)-1-methyl-1H-benzo[d]imidazol-4-yl)-1-methyl-1H-pyrazol-5-yl)benzonitrile (50.0 mg, 114 μmol, 71% yield) as a pale yellow oil. LCMS [ESI, M+1] + =407.2.

[0153] Step 3: To a solution of 2-(4-(2-(2,5-dimethyl-1H-pyrrol-1-yl)-1-methyl-1H-benzo[d]imidazol-4-yl)-1-methyl-1H-pyrazol-5-yl)benzonitrile (50.0 mg, 123 μmol, 1.00 equiv.) in ethanol (2.00 mL) was added concentrated hydrochloric acid (12.0 M, 0.20 mL, 19.5 equiv.). The mixture was stirred in a microwave reactor at 120° C. for 1 h. The mixture was concentrated. The residue was purified by preparative HPLC (HCl condition) to give 2-(4-(2-amino-1-methyl-1H-benzo[d]imidazol-4-yl)-1-methyl-1H-pyrazol-5-yl)benzonitrile hydrochloride, Example 1-87 (28.3 mg, 77.4 μmol, 63% yield) as a white solid. LCMS[ESI,M+1] + =329.2.1 HNMR(400MHz,DMSO-d6) δ=12.80(s,1H),8.33(s,2H),7.95-7.83(m,3H),7.83-7.78(m,1H),7.68(dt,J=1.2,7.6Hz,1H),7 .36(d,J=8.0Hz,1H),7.08(t,J=8.0Hz,1H),6.56(dd,J=0.8,7.6Hz,1H),3.78(s,3H),3.64(s,3H).

[0154] Examples 1-88 [ka] Step 1: To a solution of 1-bromo-2,4-difluoro-3-nitro-benzene (6.70 g, 28.2 mmol, 1.00 equiv) in dimethylformamide (80.0 mL) was added diisopropylethylamine (10.9 g, 84.5 mmol, 14.7 mL, 3.00 equiv) and methanamine (3.80 g, 56.3 mmol, 2.00 equiv, hydrochloride salt) at 20 °C. The mixture was then stirred at 20 °C for 16 h. The residue was diluted with ethyl acetate (30.0 mL) and water (30.0 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (80.0 mL x 3). The combined organic extracts were washed with brine (60.0 mL x 3), then dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to give a residue. The residue was purified by silica gel chromatography (0-5% ethyl acetate in petroleum ether). The residue was further purified by preparative TLC (SiO2, petroleum ether / ethyl acetate 5:1) to give the compound 4-bromo-3-fluoro-N-methyl-2-nitro-aniline (778 mg, 3.12 mmol, 11% yield) as a yellow solid. 1 H NMR(400MHz,CDCl3-d) δ=7.54-7.45(m,1H),7.20(s br,1H),6.53(d,J=9.2Hz,1H),2.98(br,J=4.8Hz,3H).

[0155] Step 2: To a solution of 4-bromo-3-fluoro-N-methyl-2-nitro-aniline (778 mg, 3.12 mmol, 1.00 equiv) in methanol (8.00 mL) was added sodium methoxide (5.40 M, 5.79 mL, 10.0 equiv) at 20° C., and the mixture was then stirred at 20° C. for 16 h. The residue was diluted with ethyl acetate (20.0 mL) and water (20.0 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (3×20 mL). The combined organic extracts were washed with brine (30.0 mL), then dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by silica gel chromatography (0-50% ethyl acetate in petroleum ether) to give 4-bromo-3-methoxy-N-methyl-2-nitro-aniline (760 mg, 2.91 mmol, 93% yield) as an orange solid. LCMS [M+1] + :263.0. 1 H NMR(400MHz,CDCl3-d) δ=7.48(d,J=9.2Hz,1H),6.46(d,J=9.2Hz,1H),6.05(s,br 1H),3.98(s,3H),2.91(d,J=5.2Hz,3H).

[0156] Step 3: A solution of 4-bromo-3-methoxy-N-methyl-2-nitro-aniline (100 mg, 383 μmol, 1.00 equiv.), tributyl(3-pyridylmethyl)stannane (190 mg, 498 μmol, 1.30 equiv.), and bis(triphenylphosphine)palladium(II) chloride (53.8 mg, 76.6 μmol, 0.20 equiv.) in dimethylformamide (2.00 mL) was degassed and heated to 110° C. for 6 h. After cooling to room temperature, the mixture was diluted with ethyl acetate (10.0 mL) and water (10.0 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (20.0 mL×3). The combined organic extracts were washed with brine (20.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by preparative TLC (SiO2, petroleum ether / ethyl acetate 1:1) to give 3-methoxy-N-methyl-2-nitro-4-(3-pyridylmethyl)aniline (150 mg, crude) as a yellow solid. LCMS [M+1] +:273.8. 1 H NMR(400MHz, CDCl3-d) δ=8.49(d,J=2.0Hz,1H),8.45(dd,J=1.4,4.8Hz,1H),7.70-7.67(m,1H),7.20(dd,J=4.8,8.0Hz,1 H),7.11(d,J=8.8Hz,1H),6.49(d,J=8.8Hz,1H),3.91(s,2H),3.75(s,3H),2.90(d,J=5.2Hz,3H).

[0157] Step 4: A solution of 3-methoxy-N-methyl-2-nitro-4-(3-pyridylmethyl)aniline (75.0 mg, 274 μmol, 1.00 equiv.), platinum dioxide (75.0 mg, 330 μmol, 1.20 equiv.) in methanol (2.00 mL) was degassed and charged with hydrogen three times, then stirred at 20° C. for 2 h. The mixture was used in the next step without workup. LCMS [M+1] + :244.0

[0158] Step 5: To a solution of 3-methoxy-N1-methyl-4-(3-pyridylmethyl)benzene-1,2-diamine (66.0 mg, 272 μmol, 1.00 equiv.) in methanol (2.00 mL) was added cyanogen bromide (57.5 mg, 543 μmol, 39.9 μL, 2.00 equiv.) at 20° C., and the mixture was stirred at 20° C. for 16 h under nitrogen atmosphere. The reaction mixture was filtered and then concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (HCl condition) to give 4-methoxy-1-methyl-5-(3-pyridylmethyl)benzimidazol-2-amine hydrochloride, Example 1-88 (6.54 mg, 23.9 μmol, 9% yield) as an off-white solid. LCMS [M+1] + :268.9. 1 H NMR(400MHz,MeOD-d4) δ=8.77(s,1H),8.71(d,J=5.6Hz,1H),8.48(d,J=8.0Hz,1H),8.00(dd,J=6.0,8.0Hz ,1H),7.33-7.28(m,1H),7.26-7.21(m,1H),4.34(s,2H),3.95(s,3H),3.67(s,3H).

[0159] Examples 1-89 [ka] To a solution of intermediate O (30.0 mg, 1.00 equiv.) in N,N-dimethylacetamide (0.60 mL) was added intermediate P-1 (53.2 mg, 1.10 equiv.), triethylamine (39.7 mg, 2.50 equiv.), and PyBOP (98.0 mg, 1.20 equiv.). The mixture was stirred at 25° C. for 48 h. The reaction mixture was diluted with water (10.0 mL) and extracted with ethyl acetate (3×10.0 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to provide a residue. The residue was purified by preparative HPLC (HCl conditions) to give (S)-2-amino-1-methyl-N-(5,6,7,8-tetrahydroquinoxalin-5-yl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1H-benzo[d]imidazole-5-carboxamide, Example 1-89 (5.00 mg, 7% yield) as a yellow solid. LCMS [M+1] + =482.0. 1 H NMR(400MHz,DMSO-d6) δ=8.82(s,1H),8.67(br s,2H),8.49-8.41(m,2H),8.12(dd,J=2.0,8.4Hz,1H),7.72(d,J=8.0Hz,1H),7.65-7.45(m,3H),5.28-5.09(m,1H),4.81(br d,J=17.0Hz,1H),3.65(s,3H),3.01-2.91(m,1H),2.87-2.76(m,1H),2.23(br d,J=2.0Hz,1H),2.16-2.05(m,1H),2.03-1.94(m,1H),1.77-1.60(m,1H).

[0160] Examples 1-90 [ka] To a solution of intermediate O (55.0 mg, 1.00 equiv.) in N,N-dimethylacetamide (1.10 mL) was added intermediate P-2 (97.6 mg, 1.10 equiv.), triethylamine (72.8 mg, 2.50 equiv.), and PyBOP (180 mg, 1.20 equiv.). The mixture was stirred at 40° C. for 16 h. The mixture was diluted with water (10.0 mL) and extracted with ethyl acetate (3×10.0 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (TFA conditions). The desired fractions were collected, neutralized with solid sodium bicarbonate, and concentrated under vacuum to remove acetonitrile. The aqueous layer was extracted with ethyl acetate (3×20.0 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give (R)-2-amino-1-methyl-N-(5,6,7,8-tetrahydroquinoxalin-5-yl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1H-benzo[d]imidazole-5-carboxamide, Example 1-90 (5.90 mg, 4% yield) as a yellow oil. LCMS [M+1] + =482.1. 1 H NMR(400MHz,MeOD-d4) δ=8.91-8.69(m,1H),8.49(br s,1H),8.42-8.32(m,1H),8.10(dd,J=2.3,8.4Hz,1H),7.97-7.74(m,1H),7.63-7.15(m,3H),5.41-5.05(m,1H),4.94(br s,1H),4.16(br d,J=16.6Hz,1H),3.63-3.53(m,3H),3.04-2.80(m,2H),2.36-2.28(m,1H),2.13-2.00(m,2H),1.65-1.56(m,1H).

[0161] Examples 1-91 [ka] To a solution of intermediate O (30.0 mg, 157 μmol, 1.00 equiv) in N,N-dimethylacetamide (0.60 mL) was added intermediate R-1 (50.6 mg, 173 μmol, 1.10 equiv), triethylamine (39.7 mg, 392 μmol, 54.6 μL, 2.50 equiv), and PyBOP (98.0 mg, 188 μmol, 1.20 equiv). The mixture was stirred at 25° C. for 12 h. The reaction mixture was quenched by adding water (10.0 mL) and extracted with ethyl acetate (10.0 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (ammonium hydroxide conditions) to give (S)-2-amino-N-((5-bromopyridin-2-yl)methyl)-1-methyl-N-(1-(pyrimidin-2-yl)ethyl)-1H-benzo[d]imidazole-5-carboxamide, Example 1-91 (6.30 mg, 8.50% yield, 98.0% purity) as a yellow solid. LCMS [M+1] + =466.0. 1 H NMR(400MHz,MeOD-d4) δ=8.72(br d,J=4.8Hz,2H),8.50(br s,1H),7.93-7.86(m,1H),7.46(br s,1H),7.38(d,J=8.4Hz,1H),7.31(t,J=4.8Hz,1H),7.25(br d,J=4.0Hz,2H),5.70-5.44(m,1H),4.94(br d,J=16.8Hz,1H),4.64-4.49(m,1H),3.57(br s,3H),1.64(br d,J=6.5Hz,3H).

[0162] Examples 1-92 [ka] To a solution of intermediate O (30.0 mg, 157 μmol, 1.00 equiv) in DMA (0.60 mL) was added intermediate R-2 (50.6 mg, 172 μmol, 1.10 equiv), EtN (39.7 mg, 392 μmol, 54.6 μL, 2.50 equiv), and PyBop (97.9 mg, 188 μmol, 1.20 equiv). The mixture was stirred at 25° C. for 12 h. The reaction mixture was diluted with water (10 mL) and ethyl acetate (10 mL) and filtered. The filtrate was extracted with ethyl acetate (10 mL×2). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (ammonium hydroxide conditions) to give (R)-2-amino-N-((5-bromopyridin-2-yl)methyl)-1-methyl-N-(1-(pyrimidin-2-yl)ethyl)-1H-benzo[d]imidazole-5-carboxamide, Example 1-92 (8.00 mg, 16.8 μmol, 10.7% yield) as a white solid. LCMS [M+1] + =466.0. 1 H NMR(400MHz,METHANOL-d4) δ=8.75(br d,J=4.8Hz,2H),8.52(br s,1H),7.92(br d,J=7.6Hz,1H),7.54-7.37(m,2H),7.33(t,J=4.8Hz,1H),7.31-7.09(m,2H),5.77-5.41(m,1H),4.96(br d,J=16.4Hz,1H),4.69-4.45(m,1H),3.59(br s,3H),1.66(br d,J=6.4Hz,3H)

[0163] Example 2-1 [ka] To a solution of intermediate D (50.0 mg, 192 μmol, 1.00 equiv) and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (59.9 mg, 288 μmol, 1.50 equiv) in N,N-dimethylformamide (2.00 mL) was added potassium carbonate (79.6 mg, 576 μmol, 3.00 equiv), followed by [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (14.0 mg, 19.2 μmol, 0.10 equiv) under nitrogen atmosphere at 10° C. The mixture was stirred at 90° C. for 16 h. The mixture was filtered and the filtrate was purified by preparative HPLC (HCl conditions) and then further purified by preparative HPLC (ammonium bicarbonate conditions) to give 7-chloro-1-methyl-4-(1-methylpyrazol-4-yl)benzimidazol-2-amine hydrochloride, Example 2-1 (10.4 mg, 39.2 μmol, 20% yield) as a white solid. LCMS [ESI, M+1] - :262.1. 1 H NMR(400MHz,MeOD) δ=7.53(d,J=2.0Hz,1H),7.08-7.02(m,1H),7.02-6.97(m,1H),6.38(d,J=2.0Hz,1H),3.92(s,3H),3.77(s,3H).

[0164] Example 2-2 [ka] Step 1: To a solution of intermediate E-1 (58.0 mg, 191 μmol, 1.00 equiv.) and 3-fluoro-2-(4-iodo-2-methyl-pyrazol-3-yl)naphthalene-1-carbonitrile (see WO2021 / 050915) (108 mg, 287 μmol, 1.50 equiv.) in dioxane (0.90 mL) and water (0.18 mL), sodium bicarbonate (64.2 mg, 764 μmol, 29.7 μL, 4.00 equiv.) was added, followed by 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane (31.2 mg, 38.2 μmol, 0.20 equiv.) under nitrogen atmosphere at 10° C. The mixture was stirred at 80° C. for 16 hours. The mixture was concentrated in vacuo. The residue was purified by flash silica gel chromatography (ethyl acetate 30% in petroleum ether) to give 2-[4-[7-chloro-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]-2-methyl-pyrazol-3-yl]-3-fluoro-naphthalene-1-carbonitrile (52.0 mg, 87.8 μmol, 46% yield) as a yellow oil. LCMS [ESI, M+1] + :509.3.

[0165] Step 2: A mixture of 2-[4-[7-chloro-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]-2-methyl-pyrazol-3-yl]-3-fluoro-naphthalene-1-carbonitrile (24.0 mg, 47.2 μmol, 1.00 equiv.), hydrochloric acid (12 M, 480 μL, 122 equiv.), and ethanol (9.40 mL) was heated in a microwave reactor at 120° C. for 30 min. The mixture was concentrated in vacuo. The residue was purified by preparative HPLC (HCl conditions) to give 2-[4-(2-amino-7-chloro-1-methyl-benzimidazol-4-yl)-2-methyl-pyrazol-3-yl]-3-fluoro-naphthalene-1-carbonitrile hydrochloride, Example 2-2 (23.4 mg, 49.9 μmol, 53% yield) as an off-white solid. LCMS [ESI, M+1] + :430.9. 1H NMR(400MHz,MeOD) δ=8.20(d,J=10.0Hz,1H),8.14-8.06(m,2H),7.98(s,1H),7.81-7.72(m,2H),7 .03(d,J=8.4Hz,1H),6.62(d,J=8.0Hz,1H),3.98(s,3H),3.90(d,J=0.4Hz,3H).

[0166] Example 2-3 [ka] Step 1: A mixture of intermediate N (30.0 mg, 165 μmol, 1 equiv.), intermediate E-1 (65.2 mg, 215 μmol, 1.30 equiv.), potassium carbonate (45.7 mg, 332 μmol, 2.00 equiv.), and Pd(dppf)Cl2 (12.1 mg, 16.5 μmol, 0.10 equiv.) in dimethylformamide (0.50 mL) was degassed and stirred at 100 °C under nitrogen atmosphere for 4 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by preparative TLC (SiO2, petroleum ether / ethyl acetate 1:1) to give 3-[[7-chloro-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]methyl]-5,6,7,8-tetrahydroquinoline (45.0 mg, 108 μmol, 66% yield) as a yellow oil. LC-MS[M+1] + =405.3. 1 H NMR(400MHz,CHLOROFORM-d) δ=8.34(d,J=2.0Hz,1H),7.38(s,1H),7.21(d,J=8.0Hz,1H),6.98(d,J=8.0Hz,1H),5.97(s,2H),4.31(s,2H) ),3.72(s,3H),2.89-2.85(m,2H),2.68(t,J=6.3Hz,2H),2.08(s,6H),1.89-1.83(m,2H),1.80-1.74(m,2H).

[0167] Step 2: To a solution of 3-[[7-chloro-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]methyl]-5,6,7,8-tetrahydroquinoline (22.0 mg, 54.3 μmol, 1.00 equiv.) in ethyl alcohol (0.50 mL), hydrochloric acid (12 M, 91 μL, 1.09 mmol, 20.0 equiv.) was added. The mixture was stirred in a microwave reactor at 120° C. for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by preparative HPLC (HCl condition) to give 7-chloro-1-methyl-4-(5,6,7,8-tetrahydroquinolin-3-ylmethyl)benzimidazol-2-amine hydrochloride, Example 2-3 (10.0 mg, 30.0 μmol, 55% yield) as a white solid. LC-MS [M+1] + =327.1. 1 H NMR(400MHz,MeOH-d4) δ=8.46(s,1H),8.12(s,1H),7.30(d,J=8.4Hz,1H),7.13(d,J=8.4Hz,1H),4.39(s,2H),3.98 (s,3H),3.08(t,J=6.4Hz,2H),2.92(t,J=6.4Hz,2H),2.03-1.94(m,2H),1.93-1.85(m,2H).

[0168] Examples 2-4 [ka] Step 1: To a solution of intermediate E (300 mg, 886 μmol, 1.00 equiv.) and 5,6,7,8-tetrahydroquinolin-3-amine (158 mg, 1.06 mmol, 1.20 equiv.) in tert-butanol (6.00 mL), 2-(dicyclohexylphosphino)-2,4,6-triisopropylbiphenyl (84.5 mg, 177 μmol, 0.20 equiv.), cesium carbonate (866 mg, 2.66 mmol, 3.00 equiv.), and tris(dibenzylideneacetone)dipalladium(0) (81.1 mg, 88.6 μmol, 0.10 equiv.) were added. The mixture was stirred at 100° C. for 3 h under nitrogen atmosphere. The mixture was diluted with water (30.0 mL) and extracted with ethyl acetate (10.0 mL×3). The organic layer was washed with brine (20.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by flash silica gel chromatography (ethyl acetate in petroleum ether 5-30%) to give N-(7-chloro-2-(2,5-dimethyl-1H-pyrrol-1-yl)-1-methyl-1H-benzo[d]imidazol-4-yl)-5,6,7,8-tetrahydroquinolin-3-amine (300 mg, 698 μmol, 79% yield) as a yellow oil. LCMS [ESI, M+1]: 406.3. 1 H NMR(400MHz, CDCl3) δ=8.37(d,J=2.0Hz,1H),7.32(d,J=1.6Hz,1H),7.15(d,J=8.4Hz,1H),6.95(d,J=8.4Hz,1H),6.78(s,1H),5.98(s,2H) ,3.72(s,3H),2.91(t,J=6.4Hz,2H),2.78(t,J=6.0Hz,2H),2.08(s,6H),1.92(quin,J=6.0Hz,2H),1.87-1.79(m,2H).

[0169] Step 2: To a solution of N-(7-chloro-2-(2,5-dimethyl-1H-pyrrol-1-yl)-1-methyl-1H-benzo[d]imidazol-4-yl)-5,6,7,8-tetrahydroquinolin-3-amine (60.0 mg, 148 μmol, 1.00 equiv.) in ethyl alcohol (2.00 mL), hydrochloric acid (12.0 M, 0.20 mL, 16.2 equiv.) was added. The mixture was stirred in a microwave reactor at 120° C. for 1 h. The mixture was concentrated. The residue was purified by preparative HPLC (HCl condition) and lyophilized to give 7-chloro-1-methyl-N 4 -(5,6,7,8-Tetrahydroquinolin-3-yl)-1H-benzo[d]imidazole-2,4-diamine hydrochloride, Example 2-4 (18.5 mg, 50.9 μmol, 34% yield) was obtained as a yellow solid. LCMS [ESI, M+1]: 328.0. 1 H NMR(400MHz,DMSO-d6) δ=9.37(br s,1H),8.89-8.26(m,2H),8.06(d,J=2.4Hz,1H),7.65(s,1H),7.25(d,J=8.8Hz,1H),7.14(d,J=8.8Hz,1H),3.87(s,3H),2.93(br t,J=6.0Hz,2H),2.81(br t,J=6.0Hz,2H),1.88-1.79(m,2H),1.79-1.70(m,2H).

[0170] Examples 2-5 [ka] Step 1: A mixture of intermediate E-1 (200 mg, 591 μmol, 1.00 equiv.), 1-methyl-5-oxo-pyrrolidine-2-carboxylic acid (254 mg, 1.77 mmol, 3.00 equiv.), Ir[dF(CF3)ppy]2(dtbpy)(PF6) (6.63 mg, 5.91 μmol, 0.01 equiv.), NiCl2.dtbbpy (11.8 mg, 29.5 μmol, 0.05 equiv.), and cesium carbonate (288 mg, 886 μmol, 1.50 equiv.) in N,N-dimethylacetamide (5.00 mL) was degassed and irradiated for 16 h under nitrogen atmosphere with two 34 W blue LED lamps approximately 7 cm away from the light source and with a cooling fan to maintain the reaction temperature at 25 °C. The reaction mixture was poured into water (50.0 mL) and extracted with trichloromethane / isopropyl alcohol=3 / 1 (10.0 mL×4). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash silica gel chromatography (ethyl acetate in petroleum ether 0-80%) to give 5-[7-chloro-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]-1-methyl-pyrrolidin-2-one (60.0 mg, 155 μmol, 26% yield) as a yellow oil. LCMS [ESI, M+1]: 357.2. 1 H NMR(400MHz, CDCl3) δ=7.26(s,1H),6.95(d,J=8.0Hz,1H),5.92(s,2H),5.35-5.33(m,1H),3.70(s,3H),2.73 (s,3H),2.64-2.49(m,2H),2.47-2.35(m,1H),2.34-2.14(m,1H),2.02(d,J=6.4Hz,6H).

[0171] Step 2: To a solution of 5-[7-chloro-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]-1-methyl-pyrrolidin-2-one (30.0 mg, 84.1 μmol, 1.00 equiv.) in ethyl alcohol (2.00 mL), concentrated hydrochloric acid (12.0 M, 0.20 mL, 28.5 equiv.) was added. The mixture was stirred in a microwave reactor at 120° C. for 0.5 h. The reaction mixture was concentrated under vacuum. The crude was purified by preparative HPLC (HCl conditions) and lyophilized to give 5-(2-amino-7-chloro-1-methyl-benzimidazol-4-yl)-1-methyl-pyrrolidin-2-one hydrochloride, Example 2-5 (5.35 mg, 18.9 μmol, 23% yield) as a white solid. LCMS[ESI,M+1]:279.1. 1 H NMR(400MHz,MeOD) δ=7.36(d,J=8.4Hz,1H),7.09(d,J=8.4Hz,1H),5.06(t,J=6.8Hz,1H),4.00( s,3H),2.70(s,3H),2.67-2.54(m,2H),2.54-2.43(m,1H),2.01-1.86(m,1H).

[0172] Examples 2-6 [ka] Step 1: In a 40 mL vial equipped with a stir bar, add tert-butyl 2-(bromomethyl)morpholine-4-carboxylate (827 mg, 2.95 mmol, 2.00 equiv.), Intermediate E (500 mg, 1.48 mmol, 1.00 equiv.), (4,4-di-tert-butyl-2,2-bipyridine)bis[3,5-difluoro-2-[5-trifluoromethyl-2-pyridinyl-kappaN)phenyl-kappaC]iridium(III) hexafluorophosphate (16.6 mg, 14.8 μmol, 0.01 equiv), [4,4'-bis(1,1-dimethylethyl)-2,2'-bipyridine]nickel(II) dichloride (2.94 mg, 7.38 μmol, 0.005 equiv), 1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilane (367 mg, 1.48 mmol, 456 μL, 1.00 equiv), sodium carbonate (313 mg, 2.95 mmol, 2.00 equiv), and 1,2-dimethoxyethane (2.00 mL) were added. The vial was sealed under a nitrogen atmosphere. The reaction was stirred and irradiated with a 34 W blue LED lamp (7 cm away) for 14 h, using a cooling fan to maintain the reaction temperature at 25 °C. The mixture was concentrated in vacuo. The residue was purified by flash silica gel chromatography (22% ethyl acetate in petroleum ether) to give tert-butyl 2-[[7-chloro-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]methyl]morpholine-4-carboxylate (500 mg, 796 μmol, 54% yield) as a yellow oil. LCMS [ESI, M+1] - :459.2.

[0173] Step 2: To a solution of tert-butyl 2-[[7-chloro-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]methyl]morpholine-4-carboxylate (60.0 mg, 95.5 μmol, 73.0% purity, 1.00 equiv.) in methanol (0.50 mL) was added HCl / methanol (4 M, 0.50 mL, 21.0 equiv.) at 10° C. The mixture was stirred at 10° C. for 1 h and then concentrated in vacuo. The residue was diluted with methanol (1.00 mL) and basified with saturated solid sodium bicarbonate to pH 8. The mixture was filtered to obtain the filtrate. The filtrate was concentrated in vacuo to give 2-[[7-chloro-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]methyl]morpholine (40.0 mg, 78.6 μmol, 82% yield) as a yellow oil. LCMS [ESI, M+1] + :359.2.

[0174] Step 3: To a solution of 2-[[7-chloro-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]methyl]morpholine (20.0 mg, 39.3 μmol, 70.5% purity, 1.00 equiv.) in methanol (0.60 mL) was added sodium cyanoborohydride (3.70 mg, 58.9 μmol, 1.50 equiv.), acetic acid (5.90 mg, 98.2 μmol, 5.62 μL, 2.50 equiv.), and formaldehyde (37% purity, 14.6 μL, 196 μmol, 5.00 equiv.) at 10° C. The mixture was stirred at 10° C. for 16 h. The mixture was concentrated in vacuo. The residue was purified by flash silica gel chromatography (methanol / ethyl acetate 8:1) to give 2-[[7-chloro-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]methyl]-4-methyl-morpholine (30.0 mg, 60.5 μmol, 77% yield) as a white solid. LCMS [ESI, M+1] - :373.2.

[0175] Step 4: To a solution of 2-[[7-chloro-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-4-yl]methyl]-4-methyl-morpholine (30.0 mg, 80.5 μmol, 1.00 equiv.) in ethyl alcohol (1.50 mL) was added hydrochloric acid (12 M, 0.15 mL, 22.4 equiv.) at 10° C. The sealed vial was heated in a microwave reactor at 120° C. for 2 h. The mixture was basified with ammonium hydroxide until pH 8. The resulting mixture was purified by preparative HPLC (ammonium bicarbonate conditions) to give 7-chloro-1-methyl-4-[(4-methylmorpholin-2-yl)methyl]benzimidazol-2-amine, Example 2-6 (7.48 mg, 25.2 μmol, 42% yield) as an off-white solid. LCMS[ESI,M+1] + :295.1. 1 H NMR(400MHz,MeOD-d4) δ=6.91-6.82(m,2H),3.93-3.82(m,4H),3.60(dt,J=2.0,11.6Hz,1H),3.04(dd,J=6.8,14.0Hz,1H),2.94-2.85(m,1H),2.72(br dd,J=5.2,11.2Hz,2H),2.27(s,3H),2.21(dt,J=3.2,11.6Hz,1H),1.98(t,J=10.8Hz,1H).

[0176] Examples 2-7 [ka] Step 1: To a solution of 4-bromo-7-chloro-1-methyl-benzimidazol-2-amine (200 mg, 768 μmol, 1.00 equiv.) and N,N'-dimethylethane-1,2-diamine (40.6 mg, 460 μmol, 49.6 μL, 0.60 equiv.) in dioxane (4.00 mL), copper iodide (43.9 mg, 230 μmol, 0.30 equiv.) and sodium iodide (575 mg, 3.84 mmol, 5.00 equiv.) were added. The mixture was stirred at 120° C. for 16 h. The reaction was poured into water (10.0 mL), extracted with ethyl acetate (20.0 mL×3), and the combined organic layers were concentrated in vacuo. The residue was purified by silica gel chromatography (0-100% ethyl acetate in petroleum ether) to give 7-chloro-4-iodo-1-methyl-benzimidazol-2-amine (180 mg, 585 μmol, 76% yield) as a yellow solid. 1 H NMR(400MHz,DMSO-d6) δ=7.29(d,J=8.4Hz,1H),6.93(s,2H),6.69(d,J=8.4Hz,1H),3.75(s,3H).

[0177] Step 2: To a solution of 7-chloro-4-iodo-1-methyl-benzimidazol-2-amine (80.0 mg, 260 μmol, 1.00 equiv.) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (254 mg, 1.30 mmol, 5.00 equiv.) in dioxane (1.00 mL) was added Pd(dppf)Cl2 (25.4 mg, 39.0 μmol, 0.15 equiv.) and potassium phosphate (166 mg, 780 μmol, 3.00 equiv.). The mixture was stirred at 40° C. for 2 h, then filtered through Celite and concentrated in vacuo. The residue was purified by silica gel chromatography (0-100% methanol in ethyl acetate) and then further repurified by preparative TLC (100% ethyl acetate) to give 7-chloro-4-isoxazol-4-yl-1-methyl-benzimidazol-2-amine, Example 2-7 (4.38 mg, 16.8 μmol, 6% yield) as a yellow gum. LCMS [ESI, M+1]+=249. 1H NMR(400MHz,MeOD-d4) δ=9.19(s,1H),8.87(s,1H),7.36(s,1H),7.34-7.30(m,1H),3.99(s,3H).

[0178] Examples 2-8 [ka] Step 1: A mixture of intermediate D (180 mg, 690 μmol, 1.00 equiv.), 2-(2,5-dihydrofuran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (203 mg, 1.04 mmol, 1.50 equiv.), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)dichloromethane (75.8 mg, 103 μmol, 0.15 equiv.), potassium carbonate (286 mg, 2.07 mmol, 3.00 equiv.) in dioxane (0.50 mL) and water (0.10 mL) was degassed and stirred at 90° C. for 3 h under nitrogen atmosphere. The mixture was poured into water (10.0 mL) and extracted with dichloromethane (50.0 mL×3). The combined organic layers were concentrated under vacuum. The crude product was purified by preparative HPLC (TFA conditions) to give 7-chloro-4-(2,5-dihydrofuran-3-yl)-1-methyl-benzimidazol-2-amine trifluoroacetate (60.0 mg, 240 μmol, 35% yield) as a yellow solid. LCMS [ESI, M+1]: 250.0.

[0179] Step 2: To a solution of 7-chloro-4-(2,5-dihydrofuran-3-yl)-1-methyl-benzimidazol-2-amine (40.0 mg, 160.2 μmol, 1.00 equiv) in ethyl acetate (1.00 mL) was added palladium on carbon (10.0%, 10.0 mg) and the resulting mixture was stirred under hydrogen atmosphere (1 atm) for 10 minutes and then filtered. The filtrate was concentrated in vacuo to give a residue. The crude product was purified by preparative HPLC (HCl conditions) and lyophilized to give 7-chloro-1-methyl-4-tetrahydrofuran-3-yl-benzimidazol-2-amine hydrochloride, Example 2-8 (8.01 mg, 30.6 μmol, 19% yield) as an off-white solid. LCMS [ESI, M+1]: 252.0. 1 H NMR(400MHz,MeOD) δ=7.35-7.08(m,2H),5.06-4.92(m,1H),4.17-4.05(m,2H),4.01-3.96(m,3H) ,3.93-3.87(m,1H),3.80-3.67(m,1H),2.57-2.38(m,1H),2.11-1.91(m,1H).

[0180] Examples 2-9 [ka] Step 1: A mixture of intermediate F-1 (400 mg, 1.09 mmol, 1.00 equiv), N-methylpyridin-3-amine (118 mg, 1.09 mmol, 1.00 equiv), methanesulfonate (2-dicyclohexylphosphino-2,6-di-i-propoxy-1,1-biphenyl) (2-amino-1,1-biphenyl-2-yl) palladium(II) (45.8 mg, 54.7 μmol, 0.05 equiv), and cesium carbonate (1.07 g, 3.28 mmol, 3.00 equiv) in toluene (5.00 mL) was degassed and stirred at 90° C. for 5 h under nitrogen atmosphere. After cooling to room temperature, the mixture was concentrated under vacuum. The residue was diluted with ethyl acetate (20.0 mL) and water (20.0 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (3 x 20.0 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography (0-50% ethyl acetate in petroleum ether) to give tert-butyl N-[2-chloro-4-[methyl(3-pyridyl)amino]-6-nitro-phenyl]-N-methyl-carbamate (300 mg, 725 μmol, 66% yield) as a yellow oil. 1 H NMR(400MHz, CDCl3-d) δ=8.54-8.49(m,2H),7.57-7.51(m,1H),7.42-7.36(m,1H),7.15(d,J=2 .8Hz,1H),7.03(d,J=2.8Hz,1H),3.39(s,3H),3.15(s,3H),1.31(s,9H).

[0181] Step 2: To a solution of tert-butyl N-[2-chloro-4-[methyl(3-pyridyl)amino]-6-nitro-phenyl]-N-methyl-carbamate (150 mg, 381 μmol, 1.00 equiv.) in ethyl acetate (5.00 mL), iron powder (128 mg, 2.29 mmol, 6.00 equiv.), acetic acid (1.00 mL), and water (0.10 mL) were added. The mixture was stirred at 60° C. for 3 h. The resulting mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure. The residue was partitioned between ethyl acetate (30.0 mL) and 1N aqueous sodium hydroxide solution (30.0 mL). The organic phase was separated, and the aqueous layer was extracted with ethyl acetate (3×20.0 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give tert-butyl N-[2-amino-6-chloro-4-[methyl(3-pyridyl)amino]phenyl]-N-methyl-carbamate (150 mg, crude) as a yellow oil. 1 H NMR(400MHz, CDCl3-d) δ=8.40-8.35(m,1H),8.27-8.19(m,1H),7.39-7.33(m,1H),7.25-7.18(m,1H),6.42(d,J =2.4Hz,1H),6.23(d,J=2.4Hz,1H),3.83(s,2H),3.29(s,3H),3.09(s,3H),1.38(s,9H).

[0182] Step 3: To a solution of tert-butyl N-[2-amino-6-chloro-4-[methyl(3-pyridyl)amino]phenyl]-N-methyl-carbamate (150 mg, 413 μmol, 1.00 equiv.) in dichloromethane (10.0 mL), trifluoroacetic acid (1.54 g, 13.5 mmol, 1.00 mL, 32.7 equiv.) was added. The mixture was stirred at 15° C. for 1 h. The reaction mixture was diluted with dichloromethane (10.0 mL) and added very slowly to saturated aqueous sodium bicarbonate solution (20.0 mL). The mixture was extracted with dichloromethane (3×20.0 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to give 6-chloro-N1,N4-dimethyl-N4-(3-pyridyl)benzene-1,2,4-triamine (150 mg, crude) as a yellow oil. 1H NMR(400MHz, CDCl3-d) δ=8.19(d,J=2.4Hz,1H),8.04(d,J=4.6Hz,1H),7.16-7.00(m,2H),6.44(d,J=2 .4Hz,1H),6.29(d,J=2.4Hz,1H),4.12-3.77(m,2H),3.25(s,3H),2.62(s,3H).

[0183] Step 4: To a solution of 6-chloro-N1,N4-dimethyl-N4-(3-pyridyl)benzene-1,2,4-triamine (150 mg, 571 μmol, 1.00 equiv.) in ethanol (5.00 mL) was added cyanogen bromide (121 mg, 1.14 mmol, 2.00 equiv.). The mixture was stirred at 15° C. for 3 h and then concentrated under vacuum. The residue was purified by preparative HPLC (HCl conditions) and then further re-purified by preparative HPLC (ammonium bicarbonate conditions) to give 7-chloro-N5-1-dimethyl-N5-(3-pyridyl)benzimidazole-2,5-diamine hydrochloride, Example 2-9 (6.29 mg, 21.64 μmol, 4% yield) as a white solid. LCMS [M+1] + =287.9. 1 H NMR(400MHz,MeOD-d4) δ=7.97(d,J=2.4Hz,1H),7.89(dd,J=1.6,4.0Hz,1H),7.24-7.15(m,2H),6.98(d,J=2.0Hz,1H),6.80(d,J=2.0Hz,1H),3.87(s,3H),3.30(s,3H).

[0184] Example 2-10 [ka] Step 1: A mixture of intermediate F (1.00 g, 3.77 mmol, 1.00 equiv), iron powder (1.26 g, 22.6 mmol, 6.00 equiv), acetic acid (5.00 mL), and water (0.50 mL) in ethyl acetate (15.0 mL) was stirred at 70° C. for 2 h. The resulting mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure. The residue was partitioned between ethyl acetate (30.0 mL) and 1N aqueous sodium hydroxide solution (30.0 mL). The organic phase was separated, and the aqueous phase was extracted with ethyl acetate (3×20.0 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under vacuum to give 5-bromo-3-chloro-N2-methyl-benzene-1,2-diamine (1 g, crude) as a yellow oil. LCMS [M+3] + :237.0. 1 H NMR(400MHz,CDCl3-d) δ=6.74(d,J=2.0,1H),6.70(d,J=2.0,1H),5.32(s,2H),3.88(q,J=5.6Hz,1H),2.58(d,J=5.6Hz,3H).

[0185] Step 2: To a solution of 5-bromo-3-chloro-N2-methyl-benzene-1,2-diamine (1.20 g, 5.10 mmol, 1.00 equiv) in ethanol (15.0 mL) was added cyanogen bromide (811 mg, 7.66 mmol, 1.50 equiv). The mixture was stirred at 15° C. for 6 h. The mixture was concentrated in vacuo to give 5-bromo-7-chloro-1-methyl-benzimidazol-2-amine (1.5 g, crude) as a yellow solid. LCMS [M+3] + :261.9. 1 H NMR(400MHz,CDCl3-d) δ=8.70(s,2H),7.50(s,2H),3.82(s,3H).

[0186] Step 3: To a solution of 5-bromo-7-chloro-1-methyl-benzimidazol-2-amine (500 mg, 1.92 mmol, 1.00 equiv) in tetrahydrofuran (20.0 mL) was added N,N-dimethylpyridin-4-amine (46.9 mg, 384 μmol, 0.20 equiv), triethylamine (971 mg, 9.60 mmol, 1.34 mL, 5 equiv), and di-tert-butyl dicarbonate (1.26 g, 5.76 mmol, 1.32 mL, 3.00 equiv). The mixture was stirred at 40° C. for 12 h. The residue was diluted with ethyl acetate (10.0 mL) and water (10.0 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (3×10.0 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by silica gel column chromatography (10-20% ethyl acetate in petroleum ether) to give tert-butyl N-(5-bromo-7-chloro-1-methyl-benzimidazol-2-yl)carbamate (530 mg, 1.47 mmol, 77% yield) as a white solid. LCMS [M+3] + :362.0. 1 H NMR(400MHz,DMSO-d6) δ=12.34-9.94(m,1H),7.75-7.35(m,2H),3.86-3.64(m,3H),1.48-1.46(m,9H).

[0187] Step 4: To a solution of tert-butyl N-(5-bromo-7-chloro-1-methyl-benzimidazol-2-yl)carbamate (300 mg, 832 μmol, 1.00 equiv.) and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (253 mg, 998 μmol, 1.20 equiv.) in dioxane (5.00 mL), Pd(dppf)Cl2 (60.9 mg, 83.2 μmol, 0.10 equiv.) and potassium acetate (245 mg, 2.50 mmol, 3.00 equiv.) were added. The mixture was degassed and stirred at 90° C. for 14 h. The mixture was quenched with saturated aqueous ammonium chloride solution (5.00 mL) and then extracted with ethyl acetate (20.0 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give 7-chloro-1-ethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzimidazol-2-amine (350 mg, crude) as a brown gum. LCMS [M+1] + :308.3.

[0188] Step 5: A mixture of 3-(chloromethyl)pyridine (70.5 mg, 553 μmol, 1.00 equiv), 7-chloro-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzimidazol-2-amine (170 mg, 553 μmol, 1.00 equiv), Pd(dppf)Cl2 (40.4 mg, 55.3 μmol, 0.10 equiv), and potassium carbonate (229 mg, 1.66 mmol, 3.00 equiv) in dioxane (5.00 mL) and water (1.00 mL) was degassed and stirred at 100° C. for 4 h. The reaction mixture was diluted with ethyl acetate (30.0 mL) and water (30.0 mL). The organic layer was separated, dried over sodium sulfate, and then concentrated under vacuum. The residue was purified by silica gel column chromatography (3-10% methanol in dichloromethane) to give the crude product (28 mg, 63% purity), which was further re-purified by preparative HPLC (HCl conditions) to give 7-chloro-1-methyl-5-(3-pyridylmethyl)benzimidazol-2-amine hydrochloride, Example 2-10 (10.7 mg, 33.8 μmol, 33% yield) as a yellow solid. LCMS [M+3] + :273.2. 1 H NMR(400MHz,DMSO-d6) δ=8.89(s,2H),8.87(s,1H),8.35(d,J=8.0Hz,1H),7.89(dd,J=5.6,8.0Hz,1H),7.35(s,1H),7.33(s,1H),4.23(s,2H),3.83(s,3H).

[0189] Example 2-11 [ka] Step 1: A mixture of intermediate F-1 (600 mg, 1.64 mmol, 1.00 equiv), pyridin-3-ol (312.14 mg, 3.28 mmol, 2.00 equiv), copper iodide (31.3 mg, 164 μmol, 0.10 equiv), potassium phosphate (1.05 g, 4.92 mmol, 3.00 equiv), and 2-(dimethylamino)acetic acid (16.9 mg, 164 μmol, 0.10 equiv) in N-methylpyrrolidone (10.0 mL) was degassed and stirred at 120° C. for 4 h under nitrogen atmosphere. After cooling to room temperature, the mixture was concentrated under vacuum. The residue was diluted with ethyl acetate (20.0 mL) and water (20.0 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (3×20.0 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by column chromatography on silica gel (30-50% ethyl acetate in petroleum ether) to give tert-butyl N-[2-chloro-6-nitro-4-(3-pyridyloxy)phenyl]-N-methyl-carbamate (100 mg, 263.3 μmol, 16% yield) as a yellow oil. 1 H NMR(400MHz,CDCl3-d)=8.57-8.46(m,2H),7.48-7.36(m,3H),7.32-7.28(m,1H),3.18(s,3H),1.32(s,9H).

[0190] Step 2: To a solution of tert-butyl N-[2-chloro-6-nitro-4-(3-pyridyloxy)phenyl]-N-methyl-carbamate (80.0 mg, 211 μmol, 1.00 equiv.) in ethyl acetate (5.00 mL) was added iron powder (70.0 mg, 1.25 mmol, 5.95 equiv.), acetic acid (1.00 mL), and water (0.10 mL). The mixture was stirred at 60° C. for 5 h. The resulting mixture was filtered through Celite and the filtrate was concentrated under reduced pressure. The filtrate was partitioned between ethyl acetate (30.0 mL) and 1N aqueous sodium hydroxide solution (30.0 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (3×20.0 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give tert-butyl N-[2-amino-6-chloro-4-(3-pyridyloxy)phenyl]-N-methyl-carbamate (100 mg, crude) as a yellow oil.

[0191] 1 H NMR(400MHz, CDCl3-d) δ=8.41(s,2H),7.37-7.29(m,2H),6.43(d,J=2.4Hz,1H),6.28(d,J=2.8Hz,1H),4.06-3.86(m,2H),3.09(s,3H),1.38(s,9H).

[0192] Step 3: To a solution of tert-butyl N-[2-amino-6-chloro-4-(3-pyridyloxy)phenyl]-N-methyl-carbamate (100 mg, 286 μmol, 1.00 equiv.) in dioxane (2.00 mL) was added HCl in dioxane (4 M, 2.00 mL, 27.9 equiv.). The mixture was stirred at 15° C. for 1 h. The mixture was concentrated under vacuum to give 3-chloro-N 2 100 mg crude) was obtained as a yellow oil. LCMS [M+1] + =250.0.

[0193] Step 4: To a solution of 3-chloro-N2-methyl-5-(3-pyridyloxy)benzene-1,2-diamine (50.0 mg, 200 μmol, 1.00 equiv.) in ethanol (2.00 mL), cyanogen bromide (29.5 μL, 400 μmol, 2.00 equiv.) and triethylamine (40.5 mg, 400 μmol, 55.7 μL, 2.00 equiv.) were added. The mixture was stirred at 15° C. for 2 h. After cooling to room temperature, the mixture was concentrated under vacuum. The residue was purified by preparative HPLC (HCl condition). The desired fractions were collected, lyophilized, and further repurified by preparative HPLC (ammonium bicarbonate condition) to give 7-chloro-1-methyl-5-(3-pyridyloxy)benzimidazol-2-amine, Example 2-11 (6 mg, 21.4 μmol, 11% yield) as a white solid. LCMS [M+1] + =275.0. 1 H NMR(400MHz,MeOD-d4) δ=8.30-8.22(m,2H),7.44-7.36(m,2H),6.85(d,J=2.0Hz,1H),6.73(d,J=2.0Hz,1H),3.86(s,3H).

[0194] Example 2-12 [ka] Step 1: To a solution of m-chloroperoxybenzoic acid (36.2 g, 178 mmol, 85.0% purity, 4.00 equiv.) in dichloromethane (300 mL) was added a solution of 4-bromo-3-chloro-2-fluoro-aniline (10.0 g, 44.6 mmol, 1.00 equiv.) in dichloromethane (100 mL). The reaction was stirred at 85 °C for 10 h. The mixture was quenched by adding a solution of saturated sodium sulfite (200 mL). The aqueous phase was extracted with dichloromethane (150 mL x 3). The combined organic phase was washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give 1-bromo-2-chloro-3-fluoro-4-nitro-benzene (10.5 g, crude) as a yellow solid. 1H NMR(400MHz,DMSO-d6) δ=8.10(dd,J=7.8,8.8Hz,1H),7.95-7.86(m,1H).

[0195] Step 2: To a solution of 1-bromo-2-chloro-3-fluoro-4-nitro-benzene (5.00 g, 19.7 mmol, 1.00 equiv) in ethanol (50.0 mL) was added methanamine in ethanol (33.0%, 41.5 mL, 333 mmol, 17.0 equiv). The reaction was stirred at 20 °C for 12 h. The reaction mixture was diluted with water (30.0 mL) and stirred for 5 min. The aqueous phase was extracted with ethyl acetate (40.0 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (100% dichloromethane) to give 3-bromo-2-chloro-N-methyl-6-nitro-aniline (5.00 g, 18.8 mmol, 96% yield) as a yellow solid. 1H NMR (400MHz, DMSO-d6) δ=7.67(d,J=8.8Hz,1H),7.15-7.08(m,1H),6.93(br s,1H),2.71(d,J=5.2Hz,3H).

[0196] Step 3: To a solution of 3-bromo-2-chloro-N-methyl-6-nitro-aniline (1.50 g, 5.65 mmol, 1.00 equiv) in tetrahydrofuran (30.0 mL) was added di-tert-butyl dicarbonate (2.47 g, 11.3 mmol, 2.60 mL, 2.00 equiv), N,N-dimethylpyridin-4-amine (69.0 mg, 565 μmol, 0.10 equiv), and triethylamine (1.14 g, 11.3 mmol, 1.57 mL, 2.00 equiv). The reaction was stirred at 50 °C for 2 h. The reaction mixture was concentrated under reduced pressure. The crude was purified by silica gel column chromatography (1-2% ethyl acetate in petroleum ether). The residue was repurified by preparative HPLC (formic acid conditions) to give tert-butyl N-(3-bromo-2-chloro-6-nitro-phenyl)-N-methyl-carbamate (1.60 g, crude) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ = 7.76-7.73 (m, 1H), 7.72-7.68 (m, 1H), 3.20 (s, 3H), 1.31 (s, 9H).

[0197] Step 4: To a solution of tributyl(methoxymethyl)stannane (289 mg, 862 μmol, 1.50 equiv.) in dioxane (4.00 mL), tert-butyl N-(3-bromo-2-chloro-6-nitro-phenyl)-N-methyl-carbamate (210 mg, 574 μmol, 1.00 equiv.), lithium chloride (73.1 mg, 1.72 mmol, 3.00 equiv.), and tetrakis(triphenylphosphine)palladium(0) (66.4 mg, 57.4 μmol, 0.10 equiv.) were added. The mixture was purged with nitrogen and stirred at 100° C. under nitrogen atmosphere for 12 h. The reaction mixture was quenched by adding a solution of potassium fluoride (30.0 mL) and then diluted with ethyl acetate (20.0 mL). The aqueous phase was extracted with ethyl acetate (20.0 mL×3). The combined organic phase was washed with brine (30.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by preparative TLC (SiO2, petroleum ether / ethyl acetate 10:1) to give tert-butyl N-[2-chloro-3-(methoxymethyl)-6-nitro-phenyl]-N-methyl-carbamate (157 mg, 456 μmol, 79% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ=7.94-7.83(m,1H),7.63(d,J=8.4Hz,1H),4.66-4.53(m,2H),3.57-3.51(m,3H),3.21-3.17(m,3H),1.30(s,9H).

[0198] Step 5: To a solution of tert-butyl N-[2-chloro-3-(methoxymethyl)-6-nitro-phenyl]-N-methyl-carbamate (50.0 mg, 151 μmol, 1.00 equiv.) in dichloromethane (1.00 mL), trifluoroacetic acid (770 mg, 6.75 mmol, 0.50 mL, 44.7 equiv.) was added. The reaction was stirred at 18 °C for 1 h and then concentrated under reduced pressure. Water (20.0 mL) was then added and the mixture was neutralized with aqueous sodium bicarbonate to pH = 7-8. The aqueous phase was extracted with ethyl acetate (20.0 mL x 3). The combined organic phase was washed with brine (20.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give 2-chloro-3-(methoxymethyl)-N-methyl-6-nitro-aniline (47.0 mg, crude) as a yellow oil. 1 H NMR(400MHz,CDCl3) δ=7.93(d,J=8.8Hz,1H),7.00(d,J=8.8Hz,1H),6.58(br s,1H),4.55(s,2H),3.53-3.48(m,3H),3.11-3.03(m,3H).

[0199] Step 6: To a solution of 2-chloro-3-(methoxymethyl)-N-methyl-6-nitro-aniline (47.0 mg, 204 μmol, 1.00 equiv.) in ethyl acetate (1.50 mL) was added iron powder (68.3 mg, 1.22 mmol, 6.00 equiv.), water (0.10 mL), and acetic acid (0.50 mL). The reaction was stirred at 70° C. for 2 h. The reaction mixture was diluted with ethyl acetate (20.0 mL) and filtered. The filtrate was extracted with ethyl acetate (30.0 mL×3). The combined organic phase was washed with brine (40.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give 3-chloro-4-(methoxymethyl)-N2-methyl-benzene-1,2-diamine (48.0 mg, crude) as a yellow oil.

[0200] 1H NMR(400MHz,CDCl3) δ=6.95(d,J=8.4Hz,1H),6.62(d,J=8.4Hz,1H),6.65-6.59(m,1H),4.5(s,2H),3.93(br s,2H),3.40(s,3H),2.70(s,3H).

[0201] Step 7: To a solution of 3-chloro-4-(methoxymethyl)-N2-methyl-benzene-1,2-diamine (40.0 mg, 127 μmol, 1.00 equiv.) in ethyl alcohol (2.00 mL) was added cyanogen bromide (26.9 mg, 254 μmol, 2.00 equiv.). The reaction was stirred at 20° C. for 6 h. The reaction mixture was concentrated under reduced pressure and the crude product was purified by preparative HPLC (HCl conditions) to give 7-chloro-6-(methoxymethyl)-1-methyl-benzimidazol-2-amine hydrochloride, Example 2-12 (6.38 mg, 27.1 μmol, 21% yield) as a white solid.

[0202] LCMS[M+1] + :226.3. 1 H NMR(400MHz,DMSO-d6) δ=8.77(s,2H),7.35(s,2H),4.54(s,2H),3.87(s,3H),3.33-3.33(m,3H).

[0203] Example 3-1 [ka] Step 1: To a solution of 2-chloro-3-nitro-benzonitrile (250 mg, 1.37 mmol, 1.00 equiv) in ethanol (2.50 mL) was added methylamine in ethanol (42.5 mg, 1.37 mmol, 2.5 M, 10.0 equiv). The reaction mixture was stirred at 15° C. for 12 h. The mixture was concentrated under vacuum. The residue was diluted with water (50.0 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (60.0 mL). The organic layer was dried over sodium sulfate, filtered and concentrated in vacuo to give 2-(methylamino)-3-nitro-benzonitrile (240 mg, crude) as a yellow solid. 1H NMR(400MHz,CDCl3) δ=8.51(s,1H),8.39(d,J=8.8Hz,1H),7.76(d,J=7.6Hz,1H),6.72(t,J=8.0Hz,1H),3.49(d,J=5.2Hz,3H).

[0204] Step 2: To a solution of 2-(methylamino)-3-nitro-benzonitrile (240 mg, 1.35 mmol, 1.00 equiv) in water (3.00 mL) was added iron powder (378 mg, 6.77 mmol, 5.00 equiv) and hydrochloric acid (6.00 M, 903 μL, 4.00 equiv). The reaction mixture was stirred at 15° C. for 12 h. The mixture was concentrated under vacuum. The residue was diluted with water (50.0 mL) and extracted with ethyl acetate (100 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo to give 3-amino-2-(methylamino)benzonitrile (140 mg, 951 μmol, 70% yield) as a black solid. 1 H NMR(400MHz,CDCl3) δ=6.99(dd,J=1.6,7.6Hz,1H),6.91-6.85(m,1H),6.84-6.77(m,1H),4.06-3.42(m,2H),3.32-3.08(m,1H),3.01(s,3H).

[0205] Step 3: To a solution of 3-amino-2-(methylamino)benzonitrile (140 mg, 951 μmol, 1.00 equiv) in ethanol (3.00 mL) was added cyanogen bromide (202 mg, 1.90 mmol, 2.00 equiv). The reaction mixture was stirred at 15° C. for 2 h. The mixture was concentrated under vacuum and the residue was diluted with water (50.0 mL) and extracted with ethyl acetate (100 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by preparative HPLC (HCl condition) to give 2-amino-3-methyl-1,2-dihydrobenzimidazole-4-carbonitrile hydrochloride, Example 3-1 (30.0 mg, 171 μmol, 18% yield) as a white solid.

[0206] LCMS[M+3] + :173.0. 1H NMR(400MHz,DMSO-d6) δ=13.26(s,1H),9.07(s,2H),7.78-7.60(m,2H),7.39(t,J=8.0Hz,1H),3.85(s,3H).

[0207] General Coupling Method for Preparation of Examples 3-2 to 3-10 [ka] Coupling method 3-A (CM3-A): To a solution of intermediate H-1 (120 mg, 319 μmol, 1.00 equiv.) and R-Hal (Hal=Cl or I) (478 μmol, 1.50 equiv.) in N,N-dimethylformamide (2.00 mL) was added potassium carbonate (132 mg, 957 μmol, 3.00 equiv.), followed by [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (35.0 mg, 47.8 μmol, 0.15 equiv.) at 15° C. The mixture was stirred at 100° C. for 16 h. The mixture was concentrated in vacuo. The residue was purified by flash silica gel chromatography to give the intermediate product. To a solution of this intermediate product (174 μmol, 1.00 equiv.) in ethanol (1.00 mL) was added hydrochloric acid (12 M, 0.10 mL, 6.89 equiv.). The mixture was stirred in a microwave reactor at 120° C. for 1.5 h. The mixture was basified with ammonium hydroxide to pH 8 and concentrated in vacuo. The residue was purified by preparative HPLC to give the desired product.

[0208] [ka] Coupling method 3-B (CM3-B): A mixture of intermediate H (100 mg, 335 μmol, 1.00 equiv), R-Cl (402 μmol, 1.20 equiv), potassium carbonate (139 mg, 1.01 mmol, 3.00 equiv), [1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (24.5 mg, 33.5 μmol, 0.10 equiv), and water (0.2 mL) in dioxane (2.00 mL) was degassed and stirred at 100° C. for 4 h under nitrogen atmosphere. After cooling to room temperature, the mixture was concentrated in vacuo. The residue was purified by preparative HPLC and / or preparative TLC (dichloromethane / methanol 8:1) to give the product.

[0209] Following the teachings of the reaction schemes provided herein, coupling methods CM3-A and CM3-B and intermediates disclosed herein, Examples 3-2 through 3-10 were prepared as shown in Table 2, or using analogous methods. [Table 2-1] [Table 2-2] [Table 2-3]

[0210] Examples 3-11 [ka] A mixture of intermediate G (100 mg, 398 μmol, 1.00 equiv), 2-benzyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (174 mg, 797 μmol, 2.00 equiv), cataCXium A Pd G3 (29.0 mg, 39.8 μmol, 0.10 equiv), and potassium carbonate (165 mg, 1.19 mmol, 3.00 equiv) in dioxane (3.00 mL) and water (0.60 mL) was degassed and stirred at 90° C. for 12 h under nitrogen atmosphere. The reaction mixture was diluted with water (20.0 mL) and extracted with ethyl acetate (30.0 mL). The combined organic layers were washed with brine (20.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (HCl conditions) to give 2-amino-5-benzyl-1-methyl-1H-benzo[d]imidazole-7-carbonitrile hydrochloride, Example 3-11 (11.2 mg, 37.5 μmol, 9% yield) as a white solid. LCMS [M+1] + =263.1. 1 H NMR(400MHz,DMSO-d6) δ=13.12(br s,1H),8.92(br s,2H),7.61(s,1H),7.50(s,1H),7.34-7.23(m,4H),7.23-7.16(m,1H),4.06(s,2H),3.80(s,3H).

[0211] Example 3-12 [ka] Step 1: Under nitrogen atmosphere, to a mixture of intermediate G1 (300 mg, 911 μmol, 1.00 equiv) in tetrahydrofuran (4.00 mL) at −60° C., n-butyllithium (2.50 M, 729 μL, 2.00 equiv) was added. The mixture was stirred at −60° C. for 0.5 h. Then, 2-bromoacetic acid (506 mg, 3.65 mmol, 262 μL, 4.00 equiv) in tetrahydrofuran (1.00 mL) was added, and the resulting mixture was warmed to 30° C. and stirred for an additional 0.5 h. The reaction mixture was quenched with water (1.00 mL) and purified by preparative HPLC (formic acid condition) to give 2-[7-cyano-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-5-yl]acetic acid (35.0 mg, 106 μmol, 12% yield) as a white solid. LCMS[ESI,M+1]:309.2. 1 H NMR(400MHz,MeOD-d4) δ=7.95(d,J=1.2Hz,1H),7.75(d,J=1.2Hz,1H),5.98(s,2H),3.83(s,2H),3.77(s,3H),2.04(s,6H).

[0212] Step 2: To a mixture of 2-[7-cyano-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-5-yl]acetic acid (35.0 mg, 114 μmol, 1.00 equiv.) and aniline (31.1 μL, 340 μmol, 3.00 equiv.) in dimethylformamide (1.00 mL), N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (32.6 mg, 170 μmol, 1.50 equiv.), 1-hydroxybenzotriazole (23.0 mg, 170 μmol, 1.50 equiv.), and N,N-diisopropylethylamine (44.0 mg, 340 μmol, 59.3 μL, 3.00 equiv.) were added. The mixture was stirred at 30° C. for 16 h. The reaction mixture was concentrated and purified by preparative TLC (SiO2, petroleum ether / ethyl acetate 3:1) to give 2-[7-cyano-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-5-yl]-N-phenyl-acetamide (40.0 mg, 100 μmol, 89% yield) as a yellow oil. LCMS [ESI, M+1]: 384.3.1 H NMR(400MHz, CDCl3) δ=8.01(d,J=1.2Hz,1H),7.71(d,J=1.2Hz,1H),7.48(d,J=7.6Hz,2H),7.33-7.2 9(m,3H),7.17-7.09(m,1H),5.98(s,2H),3.87(s,2H),3.74(s,3H),2.05(s,6H).

[0213] Step 3: A mixture of 2-[7-cyano-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-5-yl]-N-phenyl-acetamide (30.0 mg, 78.2 μmol, 1.00 equiv.) in trifluoroacetic acid (2.00 mL) was stirred at 80° C. for 16 h. The mixture was concentrated. The crude was purified by preparative HPLC (HCl conditions) to give 2-(2-amino-7-cyano-1-methyl-benzimidazol-5-yl)-N-phenyl-acetamide hydrochloride, Example 3-12 (7.52 mg, 21.4 μmol, 27% yield) as a pale green solid. LCMS [ESI, M+1]: 306.2. 1 H NMR(400MHz,MeOD) δ=7.66(dd,J=1.2,14.8Hz,2H),7.55(dd,J=1.2,8.8Hz,2H),7.35-7.25(m,2H),7.13-7.05(m,1H),3.93(s,3H),3.84(s,2H).

[0214] Examples 3-13 [ka] Step 1: To a solution of intermediate G-1 (150 mg, 455 μmol, 1.00 equiv.) pyridin-3-ol (130 mg, 1.37 mmol, 3.00 equiv.) and pyridin-3-ol (130 mg, 1.37 mmol, 3.00 equiv.) and 2-(dimethylamino)acetic acid (18.8 mg, 182 μmol, 0.40 equiv.) in dimethyl sulfoxide (3.00 mL), copper iodide (17.4 mg, 91.1 μmol, 0.20 equiv.) and potassium phosphate (290 mg, 1.37 mmol, 3.00 equiv.) were added. The mixture was stirred at 120° C. for 16 h. The reaction was poured into water (20.0 mL), extracted with ethyl acetate (50.0 mL×3), and the combined organic layers were concentrated under vacuum. The residue was purified by silica gel chromatography (ethyl acetate in petroleum ether gradient 0-100%) to give 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-6-(3-pyridyloxy)benzimidazole-4-carbonitrile (100 mg, 291 μmol, 64% yield) as a yellow solid. LCMS [ESI, M+1]: 344.2

[0215] Step 2: To a solution of 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-6-(3-pyridyloxy)benzimidazole-4-carbonitrile (50.0 mg, 146 μmol, 1.00 equiv.) in ethanol (1.50 mL) was added hydrochloric acid (12.0 M, 375 μL, 30.9 equiv.). The mixture was stirred in a microwave reactor at 120° C. for 2 h. The solution was treated with ammonium hydroxide (0.10 mL) to adjust the pH to 7. The mixture was concentrated under vacuum. The crude product was purified by preparative HPLC (NH4HCO3 condition) to give 2-amino-3-methyl-6-(3-pyridyloxy)benzimidazole-4-carbonitrile, Example 3-13 (8.28 mg, 30.6 μmol, 21% yield) as a white solid. LCMS[ESI,M+1]:266.0. 1 H NMR(400MHz,MeOD-d4) δ=8.32-8.24(m,2H),7.41(d,J=1.6,3.2Hz,2H),7.16(d,J=2.4Hz,1H),7.05(d,J=2.4Hz,1H),3.85(s,3H).

[0216] Examples 3-14 [ka] Step 1: To a solution of intermediate G-1 (100 mg, 303 μmol, 1.00 equiv) in tetrahydrofuran (2.00 mL) was added n-butyllithium (2.50 M, 145 μL, 1.20 equiv) at −65° C. The mixture was stirred at −65° C. for 0.5 h. A solution of 3,3′-dithiodipyridine (80.3 mg, 364 μmol, 1.20 equiv) in tetrahydrofuran (0.50 mL) was added at −65° C. The mixture was stirred at −65° C. for 0.5 h, then slowly warmed to 25° C. and stirred for an additional 0.5 h. The mixture was diluted with saturated ammonium chloride (50.0 mL), extracted with ethyl acetate (50.0 mL), dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (0-50% ethyl acetate in petroleum ether) to give 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-6-(3-pyridylsulfanyl)benzimidazole-4-carbonitrile (37.0 mg, 85.4 μmol, 28% yield) as a yellow gum. LCMS [ESI, M+1] + =360.

[0217] Step 2: To a solution of 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-6-(3-pyridylsulfanyl)benzimidazole-4-carbonitrile (32.0 mg, 89.0 μmol, 1.00 equiv.) in ethyl alcohol (0.50 mL) was added 12 M hydrochloric acid (0.05 mL, 503 μmol, 5.60 equiv.). The mixture was stirred in a microwave reactor at 120° C. for 1 h and then concentrated. The residue was purified by preparative HPLC (HCl conditions) to give 2-amino-3-methyl-6-(3-pyridylsulfanyl)benzimidazole-4-carbonitrile hydrochloride, Example 3-14 (13.9 mg, 43.1 μmol, 48% yield) as a white solid. LCMS [ESI, M+1]+=282. 1H NMR(400MHz,MeOD) δ=8.72(s,1H),8.69(br d,J=5.2Hz,1H),8.37(br d,J=8.0Hz,1H),7.98(s,2H),7.94(s,1H),3.99(s,3H).

[0218] Examples 3-15 [ka] Step 1: A mixture of 1-(3-pyridyl)ethanone (1.30 g, 10.7 mmol, 1.18 mL, 1.00 equiv) and 4-methylbenzenesulfonohydrazide (2.00 g, 10.7 mmol, 1.00 equiv) in methanol (20.0 mL) was heated to 60° C. for 14 h. The reaction mixture was filtered and the solid was washed with methanol (20.0 mL). The precipitate was dried in vacuum to give 4-methyl-N-[(E)-1-(3-pyridyl)ethylideneamino]benzenesulfonamide (2.00 g, 6.91 mmol, 64% yield) as a white solid.

[0219] 1 H NMR(400MHz,DMSO-d6) δ=10.69(s,1H),8.77(d,J=1.6Hz,1H),8.58-8.51(m,1H),8.02-7.94(m, 1H),7.81(d,J=8.0Hz,2H),7.48-7.35(m,3H),2.37(s,3H),2.20(s,3H).

[0220] Step 2: To a mixture of 4-methyl-N-[(E)-1-(3-pyridyl)ethylideneamino]benzene-sulfonamide (65.9 mg, 228 μmol, 1.50 equiv.), intermediate G-1 (50.0 mg, 152 μmol, 1.00 equiv.) in dioxane (3.00 mL), bis(triphenylphosphine)palladium(II) chloride (10.7 mg, 15.2 μmol, 0.10 equiv.) was added. The reaction mixture was degassed and heated to 100° C. Then, lithium tert-butyl alcohol (48.6 mg, 606 μmol, 54.8 μL, 4.00 equiv.) was added, and the reaction mixture was heated to 100° C. for 2 h. Water (30.0 mL) was added, and the mixture was extracted with ethyl acetate (20.0 mL×2). The combined organic layers were dried over sodium sulfate and then concentrated under vacuum. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate 2:1) to give 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-6-[1-(3-pyridyl)vinyl]benzimidazole-4-carbonitrile (35.0 mg, 99.0 μmol, 65% yield) as a brown solid. 1 H NMR(400MHz, CDCl3-d) δ=8.68(s,2H),8.12-8.02(m,1H),7.95(d,J=1.6Hz,1H),7.74-7.63(m,1H),7. 62-7.59(m,1H),6.01(s,2H),5.79(d,J=7.6Hz,2H),3.78(s,3H),2.09(s,6H).

[0221] Step 3: To a solution of 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-6-[1-(3-pyridyl)vinyl]benzimidazole-4-carbonitrile (35.0 mg, 99.0 μmol, 1.00 equiv) in ethyl acetate (5.00 mL) was added palladium on carbon (10%, 35.0 mg) at 20° C. The mixture was then degassed and charged with hydrogen three times, then stirred under hydrogen (1 atm) at 20° C. for 2 h. The mixture was filtered and the filtrate was concentrated in vacuo to give 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-6-[1-(3-pyridyl)ethyl]benzimidazole-4-carbonitrile (34.0 mg, crude) as a white solid. LCMS [M+1] + :356.3.

[0222] Step 4: To a solution of 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-6-[1-(3-pyridyl)ethyl]benzimidazole-4-carbonitrile (30.0 mg, 84.4 μmol, 1.00 equiv.) in ethanol (1.50 mL) was added hydrochloric acid (12.0 M, 0.15 mL, 21.3 equiv.) at 20° C. The sealed tube was heated in a microwave reactor at 120° C. for 1.5 h. The mixture was basified with sodium bicarbonate until pH 8. The resulting mixture was concentrated in vacuo to remove ethanol. The residue was purified by preparative HPLC (HCl condition) to give 2-amino-3-methyl-6-[1-(3-pyridyl)ethyl]benzimidazole-4-carbonitrile hydrochloride, Example 3-15 (14.1 mg, 44.2 μmol, 52% yield) as an off-white solid. LCMS[M+1] + :278.2. 1 H NMR(400MHz,MeOD-d4) δ=8.88(s,1H),8.76(d,J=6.0Hz,1H),8.59(d,J=8.0Hz,1H),8.06(dd,J=6.0,8.0Hz,1H),7.70(d ,J=1.2Hz,1H),7.66(d,J=1.2Hz,1H),4.68(d,J=7.2Hz,1H),3.93(s,3H),1.81(d,J=7.2Hz,3H).

[0223] Examples 3-16 and 3-17 [ka] Step 1: To a solution of intermediate G-1 (75.0 mg, 228 μmol, 1.00 equiv.) and N-methoxy-N-methyl-pyridine-3-carboxamide (41.7 mg, 251 μmol, 1.10 equiv.) in tetrahydrofuran (1.00 mL), n-butyllithium (2.5 M, 182 μL, 2.00 equiv.) was added slowly at −70° C. under nitrogen atmosphere. The mixture was stirred at −70° C. for 1 h. The mixture was poured slowly into saturated ammonium chloride solution (5.00 mL) and extracted with ethyl acetate (3.00 mL×3). The combined organic layer was washed with brine (5.00 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography (ethyl acetate / petroleum ether 4:3) to give 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-6-(pyridine-3-carbonyl)benzimidazole-4-carbonitrile (20.0 mg, 50.5 μmol, 22% yield) as a yellow oil. LCMS [ESI, M+1] + :356.1

[0224] Step 2: To a solution of 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-6-(pyridine-3-carbonyl)benzimidazole-4-carbonitrile (20.0 mg, 50.5 μmol, 1.00 equiv.) in ethanol (1.00 mL) was added hydrochloric acid (12 M, 0.10 mL, 23.8 equiv.) at 10° C. The mixture was stirred in a microwave reactor at 120° C. for 1.5 h. The mixture was basified with ammonium hydroxide until pH 8. The resulting mixture was concentrated in vacuo to remove ethanol. The residue was purified by preparative HPLC (ammonium bicarbonate conditions) to give 2-amino-3-methyl-6-(pyridine-3-carbonyl)benzimidazole-4-carbonitrile, Example 3-16 (6.08 mg, 21.8 μmol, 43% yield) as a yellow solid. LCMS [ESI, M+1] + :278.0. 1H NMR(400MHz,DMSO-d6) δ=8.86(d,J=2.0Hz,1H),8.83(dd,J=1.2,4.8Hz,1H),8.11(td,J=1.6,8.0Hz,1H),7.73(d, J=1.2Hz,1H),7.66(d,J=1.2Hz,1H),7.60(dd,J=4.8,7.6Hz,1H),7.20(s,2H),3.82(s,3H).

[0225] Step 3: To a solution of 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-6-(pyridine-3-carbonyl)benzimidazole-4-carbonitrile (130 mg, 366 μmol, 1.00 equiv.) in dichloromethane (2.00 mL) was added bis(2-methoxyethyl)aminosulfur trifluoride (809 mg, 3.66 mmol, 801 μL, 10.0 equiv.) under nitrogen atmosphere at 0° C. The mixture was stirred at 40° C. for 3 h and then at 15° C. for an additional 16 h. The mixture was poured into ice water (10.0 mL) and extracted with dichloromethane (10.0 mL×3). The combined organic layers were washed with brine (10.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography (ethyl acetate / petroleum ether 1:2) to give 6-[difluoro(3-pyridyl)methyl]-2-(2,5-dimethylpyrrol-1-yl)-3-methyl-benzimidazole-4-carbonitrile (23.0 mg, 60.0 μmol, 16% yield) as a yellow oil. LCMS [ESI, M+1] + :378.1. 1 H NMR(400MHz,CDCl3) δ=8.82-8.69(m,2H),8.16(d,J=0.8Hz,1H),7.91(br d,J=8.0Hz,1H),7.85(d,J=0.8Hz,1H),7.44(dd,J=4.8,8.0Hz,1H),5.99(s,2H),3.77(s,3H),2.10-1.99(m,6H). 19 F NMR(400MHz,CDCl3) δ=-88.04(s,2F).

[0226] Step 4: To a solution of 6-[difluoro(3-pyridyl)methyl]-2-(2,5-dimethylpyrrol-1-yl)-3-methyl-benzimidazole-4-carbonitrile (11.0 mg, 29.2 μmol, 1.00 equiv.) in ethanol (0.50 mL) was added hydrochloric acid (12 M, 0.05 mL, 20.6 equiv.). The mixture was stirred in a microwave reactor at 120° C. for 1 h. The resulting mixture was basified with ammonium hydroxide solution until pH 8. The mixture was purified by preparative HPLC (ammonium bicarbonate conditions) to give 2-amino-6-[difluoro(3-pyridyl)methyl]-3-methyl-benzimidazole-4-carbonitrile, Example 3-17 (5.43 mg, 17.8 μmol, 31% yield) as an off-white solid. LCMS [ESI, M+1] + :300.0. 1 H NMR(400MHz,MeOD-d4) δ=8.70(br d,J=19.6Hz,2H),8.01(br d,J=8.0Hz,1H),7.58-7.51(m,2H),7.45(s,1H),3.87(s,3H). 19 F NMR(400MHz,MeOD-d4) δ=-89.55(s,2F).

[0227] Example 3-18 [ka] To a mixture of intermediate I (100 mg, 410 μmol, 1.00 equiv.) in dimethylformamide (2.00 mL) under nitrogen atmosphere, tris(dibenzylideneacetone)dipalladium(0) (75.0 mg, 82.0 μmol, 0.20 equiv.), zinc cyanide (385 mg, 3.27 mmol, 8.00 equiv.), 1,1'-bis(diphenylphosphino)ferrocene (90.8 mg, 164 μmol, 0.40 equiv.), and zinc powder (21.4 mg, 246 μmol, 1.20 equiv.) were added. The reaction mixture was stirred at 100° C. under nitrogen atmosphere for 48 h. The reaction mixture was filtered, purified by HPLC (formic acid conditions), and lyophilized. The product was then re-purified by reverse-phase-HPLC (ammonia hydroxide conditions) to give 2-amino-7-fluoro-3-methyl-benzimidazofur-4-carbonitrile, Example 3-18 (11.4 mg, 58.5 μmol, 14% yield) as an off-white solid. LCMS [ESI, M+1]: 191.0. 1 H NMR(400MHz,MeOD) δ=7.30(dd,J=4.4,8.4Hz,1H),6.93(dd,J=8.4,10.2Hz,1H),3.85(s,3H).

[0228] Example 3-19 [ka] Step 1: To intermediate J (300 mg, 931 μmol, 1.00 equiv.) in dimethylformamide (5.00 mL) at 20° C. under nitrogen atmosphere, tris(dibenzylideneacetone)dipalladium(0) (85.3 mg, 93.1 μmol, 0.10 equiv.), zinc cyanide (328 mg, 2.79 mmol, 3.00 equiv.), 1,1′-bis(diphenylphosphino)ferrocene (103 mg, 186 μmol, 0.20 equiv.), and zinc powder (60.9 mg, 931 μmol, 1.00 equiv.) were added. The reaction mixture was stirred at 100° C. under nitrogen atmosphere for 16 h. The mixture was washed with water (30.0 mL) and extracted with ethyl acetate (15 mL×4). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (0-30% ethyl acetate in petroleum ether) to give 2-(2,5-dimethylpyrrol-1-yl)-7-fluoro-3-methyl-benzimidazole-4-carbonitrile (290 mg, 999 μmol, 99% yield) as a yellow solid. LCMS [ESI, M+1]: 269.2. 1 H NMR(400MHz,CDCl3) δ=7.67(dd,J=4.4,8.4Hz,1H),7.13-7.09(m,1H),6.00-5.94(m,2H),3.75(s,3H),2.07-2.04(m,6H).

[0229] Step 2: To a mixture of 2-(2,5-dimethylpyrrol-1-yl)-7-fluoro-3-methyl-benzimidazole-4-carbonitrile (130 mg, 484 μmol, 1.00 equiv.) and cesium carbonate (474 ​​mg, 1.45 mmol, 3.00 equiv.) in dimethyl sulfoxide (2.00 mL), pyrazolidin-3-one hydrochloride (89.1 mg, 727 μmol, 1.50 equiv.) was added and the mixture was stirred at 100° C. for 16 h. The reaction mixture was filtered. The crude was purified by reverse phase HPLC (formic acid condition) and lyophilized to give 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-7-(3-oxopyrazolidin-1-yl)benzimidazole-4-carbonitrile (110 mg, 329 μmol, 68% yield) as a brown solid. 1H NMR(400MHz, CDCl3) δ=11.08-10.54(m,1H),7.56(d,J=8.4Hz,1H),6.45(d,J=8.4Hz,1H),5.9 9(s,2H),4.06-4.02(m,2H),3.72(s,3H),2.84-2.80(m,2H),2.04(s,6H).

[0230] Step 3: To a mixture of 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-7-(3-oxopyrazolidin-1-yl)benzimidazole-4-carbonitrile (30.0 mg, 89.7 μmol, 1.00 equiv.) and potassium carbonate (16.1 mg, 116 μmol, 1.30 equiv.) in dimethylformamide (0.50 mL), methyl iodide (50.9 mg, 359 μmol, 22.3 μL, 4.00 equiv.) was added under nitrogen atmosphere. The reaction mixture was stirred at 30° C. for 2 h. The mixture was washed with water (3.00 mL) and extracted with ethyl acetate (1.00 mL×3). The combined organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (ethyl acetate gradient 0-60%) in petroleum ether to give 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-7-(2-methyl-3-oxo-pyrazolidin-1-yl)benzimidazole-4-carbonitrile (20.0 mg, 57.4 μmol, 64% yield) as a colorless oil. 1 H NMR(400MHz, CDCl3) δ=7.61(d,J=8.4Hz,1H),6.72(d,J=8.4Hz,1H),5.97(s,2H),4.36-4.32(m,2H),3.73(s,3H),3.18(s,3H),2.59-2.55(m,2H),2.06(s,6H).

[0231] Step 4: To a mixture of 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-7-(2-methyl-3-oxo-pyrazolidin-1-yl)benzimidazole-4-carbonitrile (15.0 mg, 43.0 μmol, 1.00 equiv.) in ethyl alcohol (1.00 mL) was added hydrochloric acid (12 M, 0.10 mL). The mixture was stirred in a microwave reactor at 120° C. for 1 h. The reaction mixture was concentrated and then adjusted to pH 8 with ammonium hydroxide. The crude material was purified by preparative HPLC (0.1% ammonia hydroxide condition) and lyophilized to give 2-amino-3-methyl-7-(2-methyl-3-oxo-pyrazolidin-1-yl)benzimidazole-4-carbonitrile, Example 3-19 (3.41 mg, 12.3 μmol, 29% yield) as a white solid. LCMS[ESI,M+1]:271.2. 1 H NMR(400MHz,MeOD) δ=7.42(d,J=8.4Hz,1H),6.72(d,J=8.4Hz,1H),4.01-3.97(m,2H),3.89(s,3H),3.07(s,3H),2.57-2.53(m,2H).

[0232] Example 3-20 [ka] Step 1: A mixture of 5,6,7,8-tetrahydroquinolin-3-amine (66.3 mg, 447 μmol, 1.50 equiv.) and potassium tert-butoxide (60.2 mg, 537 μmol, 1.80 equiv.) in dimethyl sulfoxide (2.00 mL) was stirred at 20° C. for 0.5 h. Then, a solution of intermediate J (80.0 mg, 298 μmol, 1.00 equiv.) in dimethyl sulfoxide (2.00 mL) was added to the reaction, and the resultant was stirred at 60° C. for 3 h. The mixture was diluted with water (30.0 mL) and the pH was adjusted to 7 with 1 M aqueous hydrochloric acid. The mixture was extracted with ethyl acetate (10 mL×3). The organic layer was washed with brine (20.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash silica gel chromatography (ethyl acetate / petroleum ether 0-30%) to give 2-(2,5-dimethyl-1H-pyrrol-1-yl)-1-methyl-4-((5,6,7,8-tetrahydroquinolin-3-yl)amino)-1H-benzo[d]imidazole-7-carbonitrile (65.0 mg, 164 μmol, 55% yield) as a pale yellow solid. LCMS [ESI, M+1]: 397.1. 1 H NMR(400MHz,CDCl3) δ=8.44(s,1H),7.55(d,J=8.4Hz,1H),7.46(br s,1H),7.35(br s,1H),6.99(d,J=8.4Hz,1H),6.00(s,2H),3.74(s,3H),3.08-2.97(m,2H), 2.85-2.80(m,2H),2.11-2.05(m,6H),1.99-1.91(m,2H),1.90-1.83(m,2H).

[0233] Step 2: To a solution of 2-(2,5-dimethyl-1H-pyrrol-1-yl)-1-methyl-4-((5,6,7,8-tetrahydroquinolin-3-yl)amino)-1H-benzo[d]imidazole-7-carbonitrile (50.0 mg, 126 μmol, 1.00 equiv.) in ethyl alcohol (2.00 mL) was added hydrochloric acid (12.0 M, 0.20 mL, 19.0 equiv.). The mixture was stirred in a microwave reactor at 120° C. for 1 h. The reaction mixture was concentrated under vacuum. The residue was purified by preparative HPLC (HCl conditions) and lyophilized to give 2-amino-1-methyl-4-((5,6,7,8-tetrahydroquinolin-3-yl)amino)-1H-benzo[d]imidazole-7-carbonitrile hydrochloride, Example 3-20 (27.4 mg, 75.9 μmol, 60% yield) as a yellow solid. LCMS [ESI, M+1]: 319.2. 1 H NMR(400MHz,DMSO-d6) δ=10.05(br s,1H),8.91-8.55(m,2H),8.34(d,J=2.4Hz,1H),7.91(s,1H),7.58(d,J=8.4Hz,1H),7.19(d,J=8.4Hz,1H),3.83(s,3H),2.97(br t,J=6.0Hz,2H),2.86(br t,J=6.0Hz,2H),1.90-1.81(m,2H),1.81-1.73(m,2H).

[0234] Example 3-21 [ka] Step 1: To a solution of intermediate I-1 (690 mg, 2.77 mmol, 1.00 equiv) in methanol (5.00 mL) was added sodium methanolate (5.40 M, 5.13 mL, 10.0 equiv) at 20 °C, and the resulting mixture was stirred at 20 °C for 16 h. The mixture was diluted with water (60.0 mL) and extracted with ethyl acetate (40.0 mL × 3). The combined organic extracts were washed with brine (60.0 mL), then dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (0-20% ethyl acetate in petroleum ether) to give 6-bromo-3-methoxy-N-methyl-2-nitro-aniline, intermediate I-2 (700 mg, 2.68 mmol, 97% yield) as a yellow solid. 1 H NMR(400MHz,CDCl3) δ=7.41(d,J=8.8Hz,1H),6.24(d,J=8.8Hz,1H),3.83(s,3H),2.86(s,3H).

[0235] Step 2: To a solution of 6-bromo-3-methoxy-N-methyl-2-nitro-aniline (700 mg, 2.68 mmol, 1.00 equiv) in dimethylformamide (5.00 mL) was added zinc cyanide (630 mg, 5.36 mmol, 340 μL, 2.00 equiv) and tetrakis(triphenylphosphine)palladium(0) (310 mg, 268 μmol, 0.10 equiv) at 20° C. The mixture was then degassed and stirred at 95° C. for 16 h. The reaction mixture was quenched with additional sodium hypochlorite solution (5.00 mL) at 20° C., diluted with water (50.0 mL), and extracted with ethyl acetate (30.0 mL×3). The combined organic layers were washed with brine (60.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (0-20% ethyl acetate in petroleum ether) to give 4-methoxy-2-(methylamino)-3-nitro-benzonitrile (550 mg, 2.58 mmol, 96% yield) as a yellow solid. 1H NMR(400MHz,CDCl3) δ=7.49(d,J=8.8Hz,1H),6.37(d,J=8.8Hz,1H),3.92(s,3H),3.16(s,3H)

[0236] Step 3: To a solution of 4-methoxy-2-(methylamino)-3-nitro-benzonitrile (550 mg, 2.65 mmol, 1.00 equiv) in ethyl acetate (10.0 mL) was added iron powder (741 mg, 13.3 mmol, 5.00 equiv), acetic acid (3.20 mL), and water (0.32 mL) at 20° C. The mixture was then degassed and filled with nitrogen three times and then stirred at 70° C. for 16 h. The mixture was neutralized to pH 9 with 1 M sodium hydroxide solution. The resulting mixture was filtered through Celite and the filtrate was extracted with ethyl acetate (30.0 mL×3). The combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo to give 3-amino-4-methoxy-2-(methylamino)benzonitrile (376 mg, crude) as a yellow oil. 1 H NMR(400MHz,DMSO-d6) δ=6.85(d,J=8.4Hz,1H),6.50(d,J=8.4Hz,1H),5.04-4.96(m,1H),4.49(s,2H),3.80(s,3H),3.01(d,J=5.2Hz,3H).

[0237] Step 4: To a solution of 3-amino-4-methoxy-2-(methylamino)benzonitrile (376 mg, 2.12 mmol, 1.00 equiv) in ethanol (4.00 mL) was added cyanogen bromide (450 mg, 4.24 mmol, 312 μL, 2.00 equiv). The mixture was stirred at 20° C. for 2 h. The mixture was concentrated under vacuum. The residue was diluted with water (50.0 mL) and extracted with ethyl acetate (100 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by preparative HPLC (HCl condition) to give 2-amino-4-methoxy-1-methyl-1H-benzo[d]imidazole-7-carbonitrile hydrochloride, Example 3-21 (10.8 mg, 44.7 μmol, 2% yield) as an off-white solid. LCMS [M+1] + :203.1. 1H NMR(400MHz,DMSO-d6) δ=8.60(s,2H),7.71(d,J=8.8Hz,1H),7.10(d,J=8.8Hz,1H),4.02(s,3H),3.81(s,3H).

[0238] Example 3-22 [ka] Step 1: To a solution of intermediate I-2 (1.36 g, 6.56 mmol, 1.00 equiv) in dimethylformamide (10.0 mL) was added N-bromosuccinimide (1.17 g, 6.56 mmol, 1.00 equiv) and acetic acid (1.00 mL) at 20 °C. The mixture was then stirred at 20 °C for 4 h and then concentrated in vacuo. The residue was partitioned between ethyl acetate (30.0 mL) and water (30.0 mL). The aqueous layer was extracted with ethyl acetate (60.0 mL × 3). The combined organic extracts were washed with brine (20.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography (0-20% ethyl acetate in petroleum) to give 5-bromo-4-methoxy-2-(methylamino)-3-nitro-benzonitrile (1.65 g, 5.77 mmol, 88% yield) as a yellow solid. LCMS[M+1] + :288.0. 1 HNMR(400MHz,MeOD-d4) δ=7.84(s,1H),3.96(s,3H),3.06(s,3H).

[0239] Step 2: To a solution of 5-bromo-4-methoxy-2-(methylamino)-3-nitro-benzonitrile (800 mg, 2.80 mmol, 1.00 equiv) in ethyl acetate (15.0 mL) was added iron powder (781 mg, 14.0 mmol, 5.00 equiv), acetic acid (3.20 mL), and water (0.32 mL) at 20 °C. The mixture was then degassed and stirred at 70 °C for 12 h. The pH was adjusted to 7-8 using aqueous sodium bicarbonate. The resulting mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure. The mixture was diluted with water (50.0 mL) and extracted with ethyl acetate (20.0 mL x 3). The combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo to give 3-amino-5-bromo-4-methoxy-2-(methylamino)benzonitrile (700 mg, crude) as a yellow solid. LCMS [M+1] + :258.0

[0240] Step 3: To a solution of 3-amino-5-bromo-4-methoxy-2-(methylamino)benzonitrile (700 mg, 2.73 mmol, 1.00 equiv) in ethanol (10.0 mL) was added cyanogen bromide (579 mg, 5.47 mmol, 402 μL, 2.00 equiv) at 20 °C. The mixture was then stirred at 20 °C for 12 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (0-100% ethyl acetate in petroleum) to give 2-amino-6-bromo-7-methoxy-3-methyl-benzimidazole-4-carbonitrile (731 mg, 2.60 mmol, 95% yield) as an off-white solid.

[0241] LCMS[M+3] + :283.0. 1 H NMR(400MHz,MeOD-d4) δ=7.78(s,1H),4.10(s,3H),3.89(s,3H).

[0242] Step 4: To a solution of 2-amino-6-bromo-7-methoxy-3-methyl-benzimidazole-4-carbonitrile (200 mg, 711 μmol, 1.00 equiv.) in dimethylformamide (1.00 mL) and toluene (4.00 mL), hexane-2,5-dione (122 mg, 1.07 mmol, 125 μL, 1.50 equiv.) and 4-methylbenzenesulfonic acid (1.23 mg, 7.11 μmol, 0.01 equiv.) were added at 20° C. The mixture was then stirred at 120° C. for 5 h. The reaction was diluted with water (30.0 mL) and extracted with ethyl acetate (20.0 mL×3). The combined organic extracts were washed with brine (10.0 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography (0-50% ethyl acetate in petroleum) to give 6-bromo-2-(2,5-dimethylpyrrol-1-yl)-7-methoxy-3-methyl-benzimidazole-4-carbonitrile (120 mg, 334 μmol, 47% yield) as an off-white solid. LCMS [M+1] + :359.1. 1 H NMR (400MHz, CDCl3-d) δ=7.82(s,1H),5.99(s,2H),4.60(s,3H),3.71(s,3H),2.06(s,6H).

[0243] Step 5: A solution of 6-bromo-2-(2,5-dimethylpyrrol-1-yl)-7-methoxy-3-methyl-benzimidazole-4-carbonitrile (120 mg, 334 μmol, 1.00 equiv.), potassium acetate (98.4 mg, 1.00 mmol, 3.00 equiv.), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (127 mg, 501 μmol, 1.50 equiv.), [1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (24.4 mg, 33.4 μmol, 0.10 equiv.) in dioxane (3.00 mL) was degassed and stirred at 95 °C for 4 h. The residue was diluted with water (40.0 mL) and extracted with ethyl acetate (30.0 mL x 3). The combined organic extracts were washed with brine (10.0 mL x 3), then dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a residue. The residue was purified by silica gel chromatography (ethyl acetate in petroleum 0-30%) to give 2-(2,5-dimethylpyrrol-1-yl)-7-methoxy-3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzimidazole-4-carbonitrile (140 mg, crude) as a brown solid. LCMS [M+1] + :407.1. 1 H NMR (400MHz, CDCl3-d) δ=7.99(s,1H),5.97(s,2H),4.51(s,3H),3.70(s,3H),2.04(s,6H),1.38(s,12H).

[0244] Step 6: To a solution of 2-(2,5-dimethylpyrrol-1-yl)-7-methoxy-3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzimidazole-4-carbonitrile (140 mg, 345 μmol, 1.00 equiv.) and 3-(chloromethyl)pyridine (65.9 mg, 517 μmol, 1.50 equiv.) in dioxane (3.00 mL) and water (0.10 mL) was added potassium carbonate (143 mg, 1.03 mmol, 3.00 equiv.) and [1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (25.2 mg, 34.5 μmol, 0.10 equiv.). The mixture was degassed and stirred at 90° C. for 2 h, then concentrated. The residue was partitioned between ethyl acetate (20.0 mL) and water (20.0 mL). The aqueous layer was extracted with ethyl acetate (20.0 mL x 3). The combined organic extracts were washed with brine (10.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by preparative TLC (SiO2, petroleum ether / ethyl acetate 3:1) to give 2-(2,5-dimethylpyrrol-1-yl)-7-methoxy-3-methyl-6-(3-pyridylmethyl)benzimidazole-4-carbonitrile (63.0 mg, 170 μmol, 49% yield) as a brown solid. 1 H NMR (400MHz, CDCl3-d) δ=8.63(s,2H),7.49(s,1H),7.41(s,2H),5.97(s,2H),4.60(s,2H),4.49(s,3H),3.69(s,3H),2.05(s,6H).

[0245] Step 7: To a solution of 2-(2,5-dimethylpyrrol-1-yl)-7-methoxy-3-methyl-6-(3-pyridylmethyl)benzimidazole-4-carbonitrile (40.0 mg, 108 μmol, 1.00 equiv.) in ethanol (2.00 mL) was added hydrochloric acid (12 M, 0.2 mL, 22.3 equiv.) at 20° C. The sealed tube was heated in a microwave reactor at 120° C. for 40 min. The mixture was basified with aqueous sodium bicarbonate until pH 8. The resulting mixture was concentrated and the residue was purified by preparative HPLC (HCl condition) to give 2-amino-7-methoxy-3-methyl-6-(3-pyridylmethyl)benzimidazole-4-carbonitrile hydrochloride, Example 3-22 (2.27 mg, 6.84 μmol, 6% yield) as a white solid. LCMS [M+1] + :294.2. 1 H NMR(400MHz,MeOD-d4) δ=8.81(s,1H),8.74(d,J=6.0Hz,1H),8.50(d,J=8.4Hz,1H),8.02(dd,J=5.6,8.0Hz,1H),7.69(s,1H),4.35(s,2H),4.04(s,3H),3.94(s,3H).

[0246] Example 3-23 [ka] Step 1: To a solution of [5-(difluoromethyl)-1-methyl-triazol-4-yl]methanamine (37.0 mg, 186 μmol, 1.00 equiv., hydrochloride salt) and intermediate G-1 (49.1 mg, 149 μmol, 0.80 equiv.) in dioxane (1.00 mL), cesium carbonate (182 mg, 559 μmol, 3.00 equiv.) and methanesulfonate 2-dicyclohexylphosphino-3,6-dimethoxy-2-4-6-tri-i-propyl-1,1-biphenyl)(2-amino-1,1-biphenyl-2-yl)palladium(II) (16.9 mg, 18.6 μmol, 0.10 equiv.) were added under nitrogen atmosphere. The mixture was stirred at 100° C. for 12 hours. The mixture was filtered to remove insoluble material. The filtrate was concentrated and the residue was purified by preparative HPLC (TFA conditions) and lyophilized to give 5-(((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methyl)amino)-2-(2,5-dimethyl-1H-pyrrol-1-yl)-1-methyl-1H-benzo[d]imidazole-7-carbonitrile (50.0 mg, 122 μmol, 65.4% yield, 99.9% purity) as a white solid. LCMS [ESI, M+1]+=411.1.

[0247] Step 2: To a solution of 5-(((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methyl)amino)-2-(2,5-dimethyl-1H-pyrrol-1-yl)-1-methyl-1H-benzo[d]imidazole-7-carbonitrile (50.0 mg, 122 μmol, 1.00 equiv.) in ethanol (2.00 mL) was added hydrochloric acid (12 M, 0.20 mL). The mixture was stirred at 120° C. for 1 h under microwave irradiation. The pH of the reaction solution was adjusted to about 7 with diisopropylethylamine and concentrated. The crude was purified by preparative HPLC (formic acid) and lyophilized to give 2-amino-5-(((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methyl)amino)-1-methyl-1H-benzo[d]imidazole-7-carbonitrile, Example 3-23 (11.9 mg, 31.2 μmol, 25.7% yield, 99.7% purity, formate salt) as an off-white solid. LCMS [ESI, M+1] + =333.0. 1 H NMR(400MHz,DMSO-d6) δ=8.14(s,1H),7.50(t,J=52.1Hz,1H),6.80(d,J=1.8Hz,1H),6.68(br s,2H),6.56(d,J=1.8Hz,1H),5.93(br s,1H),4.39(br s,2H),4.11(s,3H),3.63(s,3H)

[0248] Example 3-24 [ka] Example 3-24 was synthesized from intermediate G-1 and (4-ethyl-4H-1,2,4-triazol-3-yl)methanamine following the two-step procedure described for Example 3-23 to give 2-amino-5-(((4-ethyl-4H-1,2,4-triazol-3-yl)methyl)amino)-1-methyl-1H-benzo[d]imidazole-7-carbonitrile, Example 3-24 (4.08 mg, 13.5 μmol, 14% yield for two steps) as a white solid. LCMS [ESI, M+1] +=297.1. 1 H NMR(400MHz,DMSO-d6) δ=8.50(s,1H),6.93(br s,2H),6.88(d,J=2.0Hz,1H),6.65(d,J=1.8Hz,1H),6.13(br s,1H),4.43(br s,2H),4.05(d,J=7.2Hz,2H),3.65(s,3H),1.31(s,3H)

[0249] Example 3-25 [ka] Step 1: To a solution of intermediate G-1 (700 mg, 2.13 mmol, 1.00 equiv.) and tributylstannylmethanol (1.02 g, 3.19 mmol, 1.50 equiv.) in dioxane (14.0 mL), tetrakis[triphenylphosphine]palladium(0) (246 mg, 213 μmol, 0.10 equiv.) was added. The mixture was stirred at 80 °C under nitrogen atmosphere for 12 h. The mixture was concentrated under vacuum. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate 1:0 to 1:1) to give 2-(2,5-dimethylpyrrol-1-yl)-6-(hydroxymethyl)-3-methyl-benzimidazole-4-carbonitrile (280 mg, 999 μmol, 47.0% yield) as an off-white solid.

[0250] Step 2: To a solution of 2-(2,5-dimethylpyrrol-1-yl)-6-(hydroxymethyl)-3-methyl-benzimidazole-4-carbonitrile (120 mg, 428 μmol, 1.00 equiv.), N,N-4-dimethylaminopyridine (5.23 mg, 42.8 μmol, 0.10 equiv.), and methylsulfonylmethanesulfonate (89.5 mg, 514 μmol, 1.20 equiv.) in dichloromethane (4.00 mL), triethylamine (108 mg, 1.07 mmol, 149 μL, 2.50 equiv.) was added at 0° C. The resulting mixture was stirred at 0° C. for 0.5 h. The mixture was diluted with water (20.0 mL) and extracted with dichloromethane (10.0 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated. The residue was quickly purified by flash silica gel chromatography (50% ethyl acetate in petroleum ether) to give [7-cyano-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-5-yl]methyl methanesulfonate (120 mg, 335 μmol, 78.2% yield) as a colorless oil.

[0251] Step 3: To a solution of N-(1-cyano-2-naphthyl)acetamide (50.0 mg, 238 μmol, 1.00 equiv.) in tetrahydrofuran (2.00 mL), sodium hydride (9.51 mg, 238 μmol, 60% purity, 1.00 equiv.) was added at 0 °C, and the mixture was stirred at 0 °C for 1 h. Then, a solution of [7-cyano-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-5-yl]methyl methanesulfonate (111 mg, 309 μmol, 1.30 equiv.) in tetrahydrofuran (1.00 mL) was added. The resulting mixture was stirred at 0 °C for 1 h, then warmed to 20 °C and stirred at 10-20 °C for 16 h. The mixture was quenched with saturated ammonium chloride solution (20.0 mL) and extracted with ethyl acetate (10.0 mL × 3). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by flash silica gel chromatography (50-70% ethyl acetate in petroleum ether) to give N-[[7-cyano-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-5-yl]methyl]-N-(1-cyano-2-naphthyl)acetamide (103 mg, 207 μmol, 87.0% yield) as a colorless oil. LCMS [ESI, M+1] + =473.3.

[0252] Step 4: N-[[7-cyano-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-5-yl]methyl]-N-(1-cyano-2-naphthyl)acetamide (50.0 mg, 106 μmol, 1.00 equiv.) was taken in a microwave tube containing ethanol (1.00 mL) and hydrochloric acid (0.10 mL). The sealed tube was heated under microwave irradiation at 120° C. for 1 h. The pH of the mixture was adjusted to 8 with sodium hydroxide (4 M) and the resultant was filtered. The filtrate was concentrated. The residue was purified by preparative HPLC (formic acid conditions) and lyophilized to give N-[(2-amino-7-cyano-1-methyl-benzimidazol-5-yl)methyl]-N-(1-cyano-2-naphthyl)acetamide, Example 3-25 (21.1 mg, 53.6 μmol, 50.6% yield) as a white solid. LCMS [ESI, M+1] + =395.2. 1 H NMR(400MHz,DMSO-d6) δ=8.32(br d,J=8.8Hz,1H),8.18-8.10(m,1H),8.06(br d,J=8.2Hz,1H),7.82(br t,J=7.4Hz,1H),7.78-7.69(m,1H),7.45(br d,J=8.8Hz,1H),7.23(s,1H),7.11(s,1H),6.83(br s,2H),5.13(br d,J=14.8Hz,1H),4.99-4.87(m,1H),3.70(s,3H),1.86(s,3H)

[0253] Example 3-30 [ka] Step 1: A mixture of 5,6,7,8-tetrahydroquinolin-3-amine (66.3 mg, 447 mmol, 1.5 equiv) and potassium tert-butoxide (60 mg, 537 mmol, 1.8 equiv) in DMSO (2.0 mL) was stirred at 20° C. for 0.5 h. Then, a solution of intermediate J-1 (80 mg, 298 mmol, 1.0 equiv) in DMSO (2.0 mL) was added and stirred at 60° C. for 3 h. Then, the mixture was diluted with water (30 mL) and adjusted to pH=7 with aqueous hydrochloric acid (1 M). The mixture was extracted with ethyl acetate (10 mL×3). The organic layer was washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash silica gel chromatography (20 g silica, eluent 10-30% ethyl acetate / petroleum ether gradient) to give 2-(2,5-dimethyl-1H-pyrrol-1-yl)-1-methyl-4-((5,6,7,8-tetrahydroquinolin-3-yl)amino)-1H-benzo[d]imidazole-7-carbonitrile (65 mg, 164 mmol, 55% yield) as a pale yellow solid. LCMS [ESI, M+1]: 397.1. 1 H NMR(400MHz,CDCl3) δ=8.44(s,1H),7.55(d,J=8.4Hz,1H),7.46(br s,1H),7.35(br s,1H),6.99(d,J=8.4Hz,1H),6.00(s,2H),3.74(s,3H),3.08-2.97(m,2H), 2.85-2.80(m,2H),2.11-2.05(m,6H),1.99-1.91(m,2H),1.90-1.83(m,2H).

[0254] Step 2: To a solution of 2-(2,5-dimethyl-1H-pyrrol-1-yl)-1-methyl-4-((5,6,7,8-tetrahydroquinolin-3-yl)amino)-1H-benzo[d]imidazole-7-carbonitrile (50 mg, 126 mmol, 1.0 equiv.) in ethyl alcohol (2.0 mL) was added hydrochloric acid (12.0 M, 0.2 mL, 19 equiv.). The mixture was stirred at 120° C. for 1 h under microwave. The mixture was concentrated. The residue was purified by preparative HPLC (column: YMC Triart 30×150 mm×7 mm; mobile phase: [water (hydrochloric acid)-acetonitrile]; B%: 5%-25%, 7 min) and lyophilized to give 2-amino-1-methyl-4-((5,6,7,8-tetrahydroquinolin-3-yl)amino)-1H-benzo[d]imidazole-7-carbonitrile, Example 3-30 (27 mg, 75.9 mmol, 60% yield, hydrochloride salt) as a yellow solid. LCMS [ESI, M+1]: 319.2. 1 H NMR(400MHz,DMSO-d6) δ=10.05(br s,1H),8.91-8.55(m,2H),8.34(d,J=2.4Hz,1H),7.91(s,1H),7.58(d,J=8.4Hz,1H),7.19(d,J=8.4Hz,1H),3.83(s,3H),2.97(br t,J=6.0Hz,2H),2.86(br t,J=6.0Hz,2H),1.90-1.81(m,2H),1.81-1.73(m,2H).

[0255] Example 4-1 [ka] Step 1: To a solution of intermediate K (180 mg, 549 μmol, 1.00 equiv) and potassium carbonate (228 mg, 1.65 mmol, 3.00 equiv) in dioxane (6.00 mL) and water (2.00 mL), 3-(chloromethyl)pyridine (84.0 mg, 658 μmol, 1.20 equiv) and Pd(dppf)Cl2 (40.0 mg, 55.0 μmol, 0.10 equiv) were added. The mixture was stirred at 90 °C under nitrogen atmosphere for 4 h. The reaction mixture was cooled, filtered, and then diluted with water (10.0 mL) and extracted with ethyl acetate (10.0 mL x 3). The combined organic layers were washed with brine (10.0 mL x 2), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by preparative TLC (SiO 2 , petroleum ether / ethyl acetate 5:1) to give 2-(difluoromethyl)-N-methyl-6-nitro-4-(3-pyridylmethyl)aniline (130 mg, 443 μmol, 81% yield) as a yellow oil.

[0256] 1 H NMR(400MHz, CDCl3) δ=8.51-8.37(m,2H),8.01(s,1H),7.76-7.64(m,2H),7.40(dd,J=4.8,8.0Hz,1H),7.10(t,J=54.4Hz,1H),4.04(s,2H),3.01(s,3H).

[0257] Step 2: To a solution of 2-(difluoromethyl)-N-methyl-6-nitro-4-(3-pyridylmethyl)aniline (60.0 mg, 205 μmol, 1.00 equiv.) in methanol (2.00 mL) was added platinum dioxide (46.0 mg, 205 μmol, 1.00 equiv.) under nitrogen. The suspension was degassed under vacuum and purged with hydrogen three times. The mixture was stirred under hydrogen (1 atm) at 25° C. for 1 h. The reaction mixture was used directly in the next step.

[0258] Step 3: To a solution of 3-(difluoromethyl)-nitrogen-methyl-5-(3-pyridylmethyl)benzimidazol-2-amine (36.0 mg, 137 μmol, 1.00 equiv.) in methanol (2.00 mL) was added cyanogen bromide (0.32 g, 3.02 mmol, 222 μL, 22.1 equiv.). The mixture was stirred at 25° C. under nitrogen atmosphere for 1 h. The reaction mixture was filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC (NH3·H2O condition) to give 7-(difluoromethyl)-1-methyl-5-(3-pyridylmethyl)benzimidazol-2-amine, Example 4-1 (2.86 mg, 9.48 μmol, 7% yield) as a yellow solid. LCMS [M+1] + =289.2. 1 H NMR(400MHz, CDCl3) δ=8.44(s,1H),8.37(d,J=4.8Hz,1H),7.69(d,J=8.0Hz,1H),7.35(dd,J=4 .8,8.0Hz,1H),7.24(s,1H),7.17-6.88(m,2H),4.09(s,2H),3.71(s,3H).

[0259] Example 4-2 [ka] 7-(Difluoromethyl)-1-methyl-5-(2-pyridylmethyl)benzimidazol-2-amine, Example 4-1, was synthesized from intermediate K (150 mg, 457 μmol, 1.00 equiv.) and 2-(chloromethyl)pyridine (64.0 mg, 503 μmol, 1.10 equiv.) following the same three-step procedure as Example 4-1 to give the desired product (3.20 mg, 10.79 μmol, 2% yield for three steps) as a yellow solid. LCMS [ESI, M+1]: 289.2. 1 H NMR(400MHz,MeOD-d4) δ=8.50-8.43(m,1H),7.77(dt,J=1.6,7.6Hz,1H),7.36-7.23(m,3H),7.20-6.88(m,2H),4.21(s,2H),3.72(t,J=1.6Hz,3H).

[0260] Example 5-1 [ka] To a solution of N3-ethylpyridine-2,3-diamine (70.0 mg, 510 μmol, 1.00 equiv) in ethanol (1.00 mL) and water (1.00 mL) was added cyanogen bromide (162 mg, 1.53 mmol, 113 μL, 3.00 equiv). The mixture was stirred at 80° C. for 3 h. The pH of the reaction mixture was adjusted to 12 with 2 M sodium hydroxide solution and extracted with trichloromethane / isopropyl alcohol=3 / 1 (5.00 mL×4). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. The crude product was purified by preparative HPLC (ammonia hydroxide condition) and then further re-purified by preparative HPLC (HCl condition) to give 1-ethyl-1H-imidazo[4,5-b]pyridin-2-amine hydrochloride, Example 5-1 (36.6 mg, 226 μmol, 44% yield) as a yellow solid. LCMS[ESI,M+1]:163.2. 1 H NMR(400MHz,MeOD) δ=8.06(d,J=6.0Hz,1H),7.98(d,J=7.6Hz,1H),7.30(d,J=6.0,7.6Hz,1H),4.22(q,J=7.2Hz,2H),1.39(t,J=7.2Hz,3H).

[0261] Example 5-2 [ka] Step 1: To a mixture of 3-fluoro-2-nitro-pyridine (2.00 g, 14.1 mmol, 1.00 equiv) in ethyl alcohol (50.0 mL) was added benzylamine (7.54 g, 70.4 mmol, 7.67 mL, 5.00 equiv). The reaction mixture was stirred at 30° C. for 16 h. The resulting suspension was filtered and the filter cake was air-dried to give N-benzyl-2-nitro-pyridin-3-amine (2.80 g, 12.2 mmol, 87% yield) as a yellow solid. LCMS [ESI, M+1]: 230.0. 1H NMR(400MHz, CDCl3) δ=8.14(s,1H),7.89(dd,J=1.2,4.0Hz,1H),7.26(m,7H),4.55(d,J=5.6Hz,2H).

[0262] Step 2: To a mixture of N-benzyl-2-nitro-pyridin-3-amine (1.00 g, 4.36 mmol, 1.00 equiv) in ethyl acetate (10.0 mL) and water (0.36 mL), acetic acid (5.24 g, 87.2 mmol, 4.99 mL, 20.0 equiv) was added at 25 °C. The mixture was warmed to 50 °C, and iron powder (974 mg, 17.4 mmol, 4.00 equiv) was added. The reaction mixture was then stirred at 80 °C for 2 h. The mixture was filtered, and the filtrate was adjusted to pH 8 by saturated sodium bicarbonate solution and extracted with trichloromethane / isopropyl alcohol = 3 / 1 (10.0 mL x 4). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give N3-benzylpyridine-2,3-diamine (800 mg, 3.47 mmol, 80% yield) as a green oil. LCMS[ESI,M+1]:200.2. 1 H NMR(400MHz,CDCl3) δ=7.53(d,J=4.4Hz,1H),7.43-7.27(m,5H),6.79(d,J=7.2Hz,1H),6.65(dd,J=5.2,7.6Hz,1H),5.26-4.39(m br,2H),4.31(s,2H).

[0263] Step 3: To a mixture of N3-benzylpyridine-2,3-diamine (400 mg, 1.73 mmol, 1.00 equiv) in ethyl alcohol (5.00 mL) and water (5.00 mL), cyanogen bromide (551 mg, 5.20 mmol, 383 μL, 3.00 equiv) was added. The reaction mixture was stirred at 80° C. for 18 h. The reaction mixture was adjusted to pH 12 with 2 M sodium hydroxide and extracted with trichloromethane / isopropyl alcohol=3 / 1 (10.0 mL×4). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. The crude was purified by preparative HPLC (HCl condition) to give 1-benzylimidazo[4,5-b]pyridin-2-amine hydrochloride, Example 5-2 (39.1 mg, 165 μmol, 9% yield) as a yellow solid. LCMS [ESI, M+1]: 225.2. 1 H NMR(400MHz,MeOD) δ=8.03-8.02(m,1H),7.78-7.75(m,1H),7.44-7.30(m,3H),7.30-7.25(m,2H),7.22-7.20(m,1H),5.42(s,2H).

[0264] Example 5-3 [ka] Step 1: To a solution of 5-bromo-N2-methyl-pyridine-2,3-diamine (1.00 g, 4.95 mmol, 1.00 equiv.) in water (20.0 mL) and tetrahydrofuran (2.00 mL), cyanogen bromide (1.82 mL, 24.7 mmol, 5.00 equiv.) was added. The mixture was stirred at 100° C. for 16 h. The resulting solution was diluted with saturated sodium bicarbonate (300 mL), extracted with ethyl acetate (300 mL), dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (0-100% ethyl acetate in petroleum ether) to give 6-bromo-3-methyl-imidazo[4,5-b]pyridin-2-amine (1.80 g, 53% yield) as a pink solid. LCMS [ESI, M+1]+=229. 1H NMR(400MHz,CDCl3) δ=8.05(s,1H),7.64(s,1H),3.57(s,3H).

[0265] Step 2: To a solution of 6-bromo-3-methyl-imidazo[4,5-b]pyridin-2-amine (800 mg, 3.52 mmol, 1.00 equiv.) and hexane-2,5-dione (4.02 g, 35.2 mmol, 4.13 mL, 10.0 equiv.) in toluene (10.0 mL) and dimethylformamide (2.00 mL), p-toluenesulfonic acid monohydrate (67.0 mg, 352 μmol, 0.10 equiv.) was added. The mixture was stirred at 140 °C for 16 h with a Dean-Stark trap. The mixture was diluted with water (200 mL) and extracted with ethyl acetate (200 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated. The residue was purified by reverse phase chromatography (formic acid conditions) to give 6-bromo-2-(2,5-dimethylpyrrol-1-yl)-3-methyl-imidazo[4,5-b]pyridine (800 mg, 2.46 mmol, 70% yield) as a brown oil. LCMS [ESI, M+1]+=307.1. 1 H NMR(400MHz,CDCl3) δ=8.52(d,J=2.0Hz,1H),8.24(d,J=2.0Hz,1H),5.98(s,2H),3.56(s,3H),2.07-2.04(m,6H).

[0266] Step 3: To a solution of 6-bromo-2-(2,5-dimethylpyrrol-1-yl)-3-methyl-imidazo[4,5-b]pyridine (300 mg, 983 μmol, 1.00 equiv.) and pyridin-3-ol (140 mg, 1.47 mmol, 1.50 equiv.) in dimethylacetamide (8.00 mL), 2-(dimethylamino)acetic acid (40.5 mg, 393 μmol, 0.40 equiv.), cesium carbonate (960 mg, 2.95 mmol, 3.00 equiv.), and bis[(tetrabutylammonium iodide)copper(I) iodide] (220 mg, 196 μmol, 0.20 equiv.) were added. The mixture was stirred at 120° C. for 16 h, then diluted with water (50.0 mL), extracted with ethyl acetate (50.0 mL), dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (0-80% ethyl acetate in acetic acid-petroleum ether) to give 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-6-(3-pyridyloxy)imidazo[4,5-b]pyridine (100 mg, 288 μmol, 29% yield) as a brown solid. LCMS [ESI, M+1]+=320.1. 1 H NMR(400MHz,CDCl3) δ=8.46(d,J=1.6Hz,1H),8.40(br d,J=4.0Hz,1H),8.36(d,J=2.4Hz,1H),7.78(d,J=2.4Hz,1H),7.35-7.29(m,2H),5.98(s,2H),3.59(s,3H),2.09-2.08(m,6H).

[0267] Step 4: To a solution of 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-6-(3-pyridyloxy)imidazo[4,5-b]pyridine (80.0 mg, 250 μmol, 1.00 equiv.) in ethyl alcohol (2.00 mL) was added hydrochloric acid (12 M, 0.20 mL, 2.01 mmol, 8.04 equiv.). The mixture was stirred in a sealed tube in a microwave reactor at 120° C. for 1.5 h. The mixture was concentrated. The residue was purified by preparative HPLC (ammonia hydroxide condition) to give 3-methyl-6-(3-pyridyloxy)imidazo[4,5-b]pyridin-2-amine, Example 5-3 (15.5 mg, 63.0 μmol, 25% yield) as a white solid. LCMS [ESI, M+1]+=242.1. 1 H NMR(400MHz,MeOD) δ=8.29(s,1H),8.26(t,J=2.8Hz,1H),7.81(d,J=2.4Hz,1H),7.46-7.35(m,2H),7.26(d,J=2.4Hz,1H),3.61(s,3H).

[0268] Example 5-4 [ka] Step 1: To a solution of methanamine (30%, 30.0 mL, 17.3 mmol, 1.00 equiv) in ethanol was added 2-chloro-3-nitro-pyridin-4-amine (3.00 g, 17.3 mmol, 1.00 equiv) at 0° C. The mixture was stirred at 30° C. for 16 h. The mixture was concentrated in vacuum. The residue was triturated with tert-butyl methyl ether (15.0 mL) at 25° C. for 10 min and filtered. The filter cake was washed with tert-butyl methyl ether (3.00 mL×3), and then the filter cake was dried in vacuum to give N2-methyl-3-nitro-pyridine-2,4-diamine (3.45 g, crude) as a yellow solid. LCMS [ESI, M+1] + :169.1. 1H NMR(400MHz,DMSO-d6) δ=8.75(br d,J=4.0Hz,1H),8.15(br s,2H),7.66(d,J=6.0Hz,1H),6.11(d,J=5.6Hz,1H),2.92(d,J=4.8Hz,3H).

[0269] Step 2: To a solution of N2-methyl-3-nitro-pyridine-2,4-diamine (2.45 g, 14.6 mmol, 1.00 equiv.) and copper(I) bromide (4.18 g, 29.1 mmol, 888 μL, 2.00 equiv.) in acetonitrile (70.0 mL), tert-butylnitrile (3.76 g, 36.4 mmol, 4.33 mL, 2.50 equiv.) was added under nitrogen atmosphere at 0° C. The mixture was stirred at 25° C. for 16 h. The mixture was filtered. The filter cake was washed with dichloromethane (10.0 mL×3). The filtrate was concentrated in vacuum. The residue was purified by reverse phase (formic acid condition) and the collected eluate was concentrated in vacuum to remove acetonitrile. The resulting mixture was extracted with ethyl acetate (300 mL×3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give 4-bromo-N-methyl-3-nitro-pyridin-2-amine (1.40 g, 5.85 mmol, 40% yield) as a yellow oil. LCMS [ESI, M+1] + :232.1 / 234.1.

[0270] Step 3: To a solution of 4-bromo-N-methyl-3-nitro-pyridin-2-amine (1.40 g, 6.03 mmol, 1.00 equiv.) in ethanol (25.0 mL) and water (5.00 mL), iron powder (1.68 g, 30.2 mmol, 5.00 equiv.) and saturated ammonium chloride (1.61 g, 30.2 mmol, 5.00 equiv.) were added. The mixture was stirred at 80° C. for 1 h and then filtered. The filtrate was concentrated in vacuum. The residue was diluted with ethyl acetate (10.0 mL) and then filtered. The filter cake was washed with methanol (5.00 mL×2). The combined filtrate was concentrated in vacuum. The residue was purified by reverse phase (formic acid condition) to give -bromo-N2-methyl-pyridine-2,3-diamine (300 mg, 1.41 mmol, 28% yield) as a yellow solid. LCMS[ESI,M+1] + :201.9 / 203.9.

[0271] Step 4: To a solution of 4-bromo-N2-methyl-pyridine-2,3-diamine (300 mg, 1.48 mmol, 1.00 equiv) in water (5.00 mL) and tetrahydrofuran (1.00 mL) was added cyanogen bromide (328 μL, 4.45 mmol, 3.00 equiv) at 25° C. The mixture was stirred at 100° C. for 16 h. The mixture was cooled to ambient temperature and slowly basified to pH 10 with sodium hydroxide solution (2N). The resulting mixture was extracted with ethyl acetate (5.00 mL×3). The combined organic layers were washed with water (10.0 mL) and brine (10.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography (methanol / ethyl acetate 4:1). The collected mixture was concentrated in vacuo to give 7-bromo-3-methyl-imidazo[4,5-b]pyridin-2-amine (160 mg, 510 μmol, 34% yield) as a yellow solid. LCMS [ESI, M+1] + :227.0 / 229.0. 1 H NMR(400MHz,MeOD-d4) δ=7.76(d,J=5.4Hz,1H),7.22(d,J=5.4Hz,1H),3.59(s,3H).

[0272] Step 5: To a solution of 7-bromo-3-methyl-imidazo[4,5-b]pyridin-2-amine (250 mg, 1.10 mmol, 1.00 equiv) in toluene (20.0 mL) and N,N-dimethylformamide (6.00 mL), 4-methylbenzenesulfonic acid hydrate (12.6 mg, 66.1 μmol, 0.06 equiv) and hexane-2,5-dione (628 mg, 5.51 mmol, 646 μL, 5.00 equiv) were added at 25 °C. The mixture was stirred at 140 °C (reflux) with a Dean-Stark trap for 16 h. The mixture was concentrated in vacuo to remove toluene. The resulting mixture was diluted with water (20.0 mL) and extracted with ethyl acetate (15.0 mL × 3). The combined organic layers were washed with water (20.0 mL). The separated organic phase was dried over anhydrous sodium sulfate, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (18% ethyl acetate in petroleum ether). The collected mixture was concentrated in vacuum to give 7-bromo-2-(2,5-dimethylpyrrol-1-yl)-3-methyl-imidazo[4,5-b]pyridine (145 mg, 471 μmol, 43% yield) as a yellow oil. LCMS [ESI, M+1] + :305.0 / 307.0. 1 H NMR(400MHz,CDCl3) δ=8.33-8.19(m,1H),7.63-7.42(m,1H),6.01-5.85(m,2H),3.60-3.52(m,3H),2.10-2.02(m,6H).

[0273] Step 6: In a 15 mL vial equipped with a stir bar, add 7-bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)-3-methyl-3H-imidazo[4,5-b]pyridine (145 mg, 475 μmol, 1.00 equiv.), tert-butyl 2-(bromomethyl)morpholine-4-carboxylate (173 mg, 618 μmol, 1.30 equiv.), (4,4-di-tert-butyl-2,2-bipyridine)bis[3,5-difluoro-2-[5-trifluoromethyl-2-pyridinyl-kappaN)phenyl-kappaC]i Lithium(III) hexafluorophosphate (5.33 mg, 4.75 μmol, 0.01 equiv.), [4,4'-bis(1,1-dimethylethyl)-2,2'-bipyridine]nickel(II) dichloride (946 ug, 2.38 μmol, 0.005 equiv.), 1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilane (118 mg, 475 μmol, 147 μL, 1.00 equiv.), sodium carbonate (101 mg, 950 μmol, 2.00 equiv.), and 1,2-dimethoxyethane (2.00 mL) were added. The vial was sealed under a nitrogen atmosphere. The reaction was stirred and irradiated with a 34 W blue LED lamp (7 cm away) for 14 hours, using a cooling fan to maintain the reaction temperature at 25 °C. The mixture was concentrated in vacuo. The residue was purified by flash silica gel chromatography (57% ethyl acetate in petroleum ether). The collected mixture was concentrated in vacuo to give tert-butyl 2-((2-(2,5-dimethyl-1H-pyrrol-1-yl)-3-methyl-3H-imidazo[4,5-b]pyridin-7-yl)methyl)morpholine-4-carboxylate (58.0 mg, 112 μmol, 24% yield) as a yellow oil. LCMS [ESI, M+1] + :426.2. 1H NMR(400MHz,CDCl3) δ=8.38(d,J=5.2Hz,1H),7.22(br d,J=4.4Hz,1H),6.01-5.93(m,2H),5.19-5.07(m,1H),3.96(br d,J=12.4Hz,2H),3.85(m,3H),3.74(br t,J=4.8Hz,1H),3.58-3.54(m,4H),2.07(s,6H),1.47(s,6H),1.44(s,9H).

[0274] Step 7: To a solution of tert-butyl 2-((2-(2,5-dimethyl-1H-pyrrol-1-yl)-3-methyl-3H-imidazo[4,5-b]pyridin-7-yl)methyl)morpholine-4-carboxylate (58.0 mg, 112 μmol, 82.3% purity, 1.00 equiv.) in methanol (1.00 mL) was added HCl in methanol (4 M, 1.00 mL, 35.7 equiv.) at 25° C. The mixture was stirred at 25° C. for 1 h. The mixture was concentrated in vacuo. The residue was diluted with dichloromethane (3.00 mL) and basified with solid sodium bicarbonate until pH 8. The resulting mixture was filtered. The filter cake was washed with dichloromethane (3.00 mL×2). The combined filtrate was concentrated in vacuo to give 2-[[2-(2,5-dimethylpyrrol-1-yl)-3-methyl-imidazo[4,5-b]pyridin-7-yl]methyl]morpholine (50.0 mg, crude) as a yellow oil. LCMS [ESI, M+1] + :326.1.

[0275] Step 8: To a solution of 2-[[2-(2,5-dimethylpyrrol-1-yl)-3-methyl-imidazo[4,5-b]pyridin-7-yl]methyl]morpholine (30.0 mg, 65.0 μmol, approx. 70% purity, 1.00 equiv.) in methanol (1.00 mL) was added paraformaldehyde (100 mg, 65.0 μmol, 1.00 equiv.), sodium cyanoborohydride (6.13 mg, 97.5 μmol, 1.50 equiv.), and acetic acid (9.76 mg, 162 μmol, 9.29 μL, 2.50 equiv.) at 25° C. The mixture was stirred at 25° C. for 17 h. The mixture was concentrated in vacuo. The residue was purified by silica gel chromatography (methanol / ethyl acetate 8:1) to give 2-[[2-(2,5-dimethylpyrrol-1-yl)-3-methyl-imidazo[4,5-b]pyridin-7-yl]methyl]-4-methyl-morpholine (20.0 mg, 58.4 μmol, 54% yield) as a white solid. LCMS [ESI, M+1] + :340.2

[0276] Step 9: To a solution of 2-[[2-(2,5-dimethylpyrrol-1-yl)-3-methyl-imidazo[4,5-b]pyridin-7-yl]methyl]-4-methyl-morpholine (15.0 mg, 44.2 μmol, 1.00 equiv.) in ethanol (1.50 mL), hydrochloric acid (12 M, 0.10 mL, 27.2 equiv.) was added. The mixture was stirred in a microwave reactor at 120° C. for 1.5 h. The mixture was concentrated in vacuo. The residue was diluted with methanol (2.00 mL) and then basified with ammonium hydroxide solution until pH 8. The resulting mixture was purified by preparative HPLC (ammonium bicarbonate conditions) to give 3-methyl-7-[(4-methylmorpholin-2-yl)methyl]imidazo[4,5-b]pyridin-2-amine (3.57 mg, 13.5 μmol, 23% yield) as a yellow oil. LCMS[ESI,M+1] + :262.1. 1H NMR(400MHz,MeOD-d4) δ=7.85(d,J=5.2Hz,1H),6.97(d,J=5.2Hz,1H),3.95-3.87(m,1H),3.87-3.80(m,1H),3.66-3.53(m,4H),3.00(dq ,J=6.8,14.0Hz,2H),2.78-2.61(m,2H),2.24(s,3H),2.14(dt,J=3.2,11.6Hz,1H),1.93(dd,J=10.4,11.6Hz,1H).

[0277] Example 6-1 [ka] Step 1: To a solution of intermediate M (35.0 mg, 79.4 μmol, 1.00 equiv) in ethanol (0.70 mL) was added hydrochloric acid (12 M, 233 μL, 35.3 equiv). The mixture was stirred in a microwave reactor at 120° C. for 1.5 h. The mixture was concentrated in vacuo and then basified with ammonium hydroxide solution until pH 8. The residue was purified by preparative HPLC (ammonium bicarbonate conditions) to give 2-[4-(2-amino-6-chloro-1-methyl-benzimidazol-4-yl)-2-methyl-pyrazol-3-yl]benzonitrile (10.4 mg, 27.0 μmol, 24% yield) as an orange solid. LCMS [ESI, M+1] + :363.0. 1 H NMR(400MHz,MeOD-d4) δ=8.11(s,1H),7.88(d,J=8.0Hz,1H),7.78(dt,J=1.2,7.6Hz,1H),7.70-7.63(m,1H),7.6 0(d,J=7.6Hz,1H),7.03(d,J=2.0Hz,1H),6.43(d,J=2.0Hz,1H),3.79(s,3H),3.51(s,3H).

[0278] Example 6-2 [ka] Step 1: To a solution of intermediate M (100 mg, 227 μmol, 1.00 equiv.) and 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (285 mg, 1.13 mmol, 317 μL, 50% purity, 5.00 equiv.) in dioxane (1.20 mL), potassium carbonate (94.0 mg, 680 μmol, 3.00 equiv.) was added, followed by [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (33.2 mg, 45.4 μmol, 0.20 equiv.) under nitrogen atmosphere at 25° C. The mixture was stirred at 100° C. for 16 h. The resulting mixture was poured into water (10.0 mL) and then extracted with ethyl acetate (5.00 mL×3). The combined organic layer was washed with water (5.00 mL). The organic layer was separated, dried over anhydrous sodium sulfate, filtered and concentrated in vacuum. The residue was purified by silica gel chromatography (ethyl acetate in petroleum ether 65%). The collected mixture was concentrated in vacuum to give 2-[4-[2-(2,5-dimethylpyrrol-1-yl)-1,6-dimethyl-benzimidazol-4-yl]-2-methyl-pyrazol-3-yl]benzonitrile (120 mg, 267 μmol, 59% yield) as a yellow oil. LCMS [ESI, M+1] + :421.2.

[0279] Step 2: To a solution of 2-[4-[2-(2,5-dimethylpyrrol-1-yl)-1,6-dimethyl-benzimidazol-4-yl]-2-methyl-pyrazol-3-yl]benzonitrile (120 mg, 285 μmol, 1.00 equiv.) in ethanol (1.00 mL) was added hydrochloric acid (12 M, 0.10 mL, 4.21 equiv.) at 25° C. The mixture was stirred at 120° C. for 1.5 h under microwave. The mixture was basified with ammonium hydroxide solution until pH 8 and then concentrated in vacuo. The residue was purified by preparative HPLC (HCl condition) to give 2-[4-(2-amino-1,6-dimethyl-benzimidazol-4-yl)-2-methyl-pyrazol-3-yl]benzonitrile hydrochloride, Example 6-2 (27.7 mg, 72.5 μmol, 25% yield) as an off-white solid. LCMS[ESI,M+1] +:343.2. 1 H NMR(400MHz,MeOD-d4) δ=7.89-7.82(m,2H),7.82-7.72(m,2H),7.70-7.63(m,1H),7.17(s,1H),6.54(s,1H),3.86(s,3H),3.65(s,3H),2.23(s,3H).

[0280] Example 6-3 [ka] Step 1: To a solution of intermediate M (100 mg, 226 μmol, 1.00 equiv.) and triethylborane (1.00 M, 1.13 mL, 5.00 equiv.) in dioxane (2.00 mL) and water (0.40 mL), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (18.4 mg, 22.6 μmol, 0.10 equiv.) and potassium carbonate (94.0 mg, 680 μmol, 3.00 equiv.) were added at 25° C. The mixture was stirred at 90° C. for 16 h. The resulting solution was diluted with water (50.0 mL), extracted with ethyl acetate (50.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (0-70% ethyl acetate in acetic acid-petroleum ether) to give 2-[4-[2-(2,5-dimethylpyrrol-1-yl)-6-ethyl-1-methyl-benzimidazol-4-yl]-2-methyl-pyrazol-3-yl]benzonitrile (70.0 mg, 146 μmol, 65% yield) as a colorless gum. LCMS [ESI, M+1]+=435.3.

[0281] Step 2: To a solution of 2-[4-[2-(2,5-dimethylpyrrol-1-yl)-6-ethyl-1-methyl-benzimidazol-4-yl]-2-methyl-pyrazol-3-yl]benzonitrile (65.0 mg, 149 μmol, 1.00 equiv.) in ethyl alcohol (2.00 mL), hydrochloric acid (12 M, 0.20 mL, 1.96 mmol, 13.0 equiv.) was added. The mixture was stirred in a microwave reactor at 120° C. for 1.5 h. The mixture was concentrated. The residue was purified by preparative HPLC (HCl condition) to give 2-[4-(2-amino-6-ethyl-1-methyl-benzimidazol-4-yl)-2-methyl-pyrazol-3-yl]benzonitrile hydrochloride, Example 6-3 (17.6 mg, 42.1 μmol, 28% yield) as a white solid. LCMS[ESI,M+1]+=357.2.1H NMR(400MHz,MeOD) δ=7.89(s,1H),7.86(dt,J=1.2,7.6Hz,1H),7.81-7.73(m,2H),7.70-7.63(m,1H),7.19(s,1H) ,6.54(d,J=1.2Hz,1H),3.87(s,3H),3.67(s,3H),2.53(q,J=7.6Hz,2H),1.00(t,J=7.6Hz,3H).

[0282] Example 7-1 [ka] Step 1: A mixture of 5-bromo-1,2-difluoro-3-nitro-benzene (5.00 g, 21.0 mmol, 1.00 equiv) and methanamine ethyl alcohol (33%, 50.0 mL, 21.0 mmol, 1.00 equiv) was stirred at 20° C. for 0.5 h. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give 4-bromo-2-fluoro-N-methyl-6-nitro-aniline (5.00 g, 19.9 mmol, 95% yield) as a yellow solid. LCMS [M+1] + =250.9. 1H NMR(400MHz,DMSO-d6) δ=7.98(t,J=2.0Hz,1H),7.84(br s,1H),7.74(d,J=2.4,13.6Hz,1H),3.33(br s,3H).

[0283] Step 2: To a solution of 4-bromo-2-fluoro-N-methyl-6-nitro-aniline (2.30 g, 9.24 mmol, 1.00 equiv) in ethyl acetate (15.0 mL) and water (1.00 mL) was added iron powder (3.09 g, 55.4 mmol, 6.00 equiv) and acetic acid (5.00 mL). The reaction was stirred at 50° C. for 1 h. The reaction mixture was filtered, the filtrate was neutralized to pH 7 with aqueous sodium bicarbonate, and the aqueous phase was extracted with ethyl acetate (30.0 mL×3). The combined organic layers were washed with brine (40.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give 5-bromo-3-fluoro-N2-methyl-benzene-1,2-diamine (1.38 g, crude) as a yellow oil. 1 H NMR(400MHz,DMSO-d6) δ=6.57(dd,J=1.6,2.0Hz,1H),6.51(dd,J=2.4,11.2Hz,1H),5.24(s,2H),4.06(d,J=2.0Hz,1H),3.31(s,3H).

[0284] Step 3: To a solution of 5-bromo-3-fluoro-N2-methyl-benzene-1,2-diamine (1.38 g, 6.30 mmol, 1.00 equiv) in ethanol (20.0 mL) was added cyanogen bromide (1.33 g, 12.6 mmol, 2.00 equiv). The reaction was stirred at 20° C. for 2 h. The mixture was filtered and the filtrate was concentrated under reduced pressure to give 5-bromo-7-fluoro-1-methyl-benzimidazol-2-amine (916 mg, 3.57 mmol, 56% yield) as a white solid. LCMS [M+1] + =244.2. 1 H NMR(400MHz,DMSO-d6) δ=8.74(s,2H),7.48(dd,J=1.2,10.8Hz,1H),7.40(d,J=1.2Hz,1H),3.69(s,3H).

[0285] Step 4: To a mixture of 5-bromo-7-fluoro-1-methyl-benzimidazol-2-amine (500 mg, 2.05 mmol, 1.00 equiv.), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (624 mg, 2.46 mmol, 1.20 equiv.) in dioxane (10.0 mL), Pd(dppf)Cl2 (150 mg, 205 μmol, 0.10 equiv.) and potassium acetate (603 mg, 6.15 mmol, 3.00 equiv.) were added. The mixture was degassed and stirred at 90° C. for 14 h. The mixture was concentrated under vacuum. The residue was diluted with water (20.0 mL) and extracted with ethyl acetate (20.0×3 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (50-100% ethyl acetate in petroleum ether) to give 7-fluoro-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzimidazol-2-amine (400 mg, 1.37 mmol, 67% yield) as a dark brown gum. 1 H NMR(400MHz,DMSO-d6) δ=7.26(s,1H),6.92(d,J=11.6Hz,1H),6.70(s br,2H),3.66(s,3H),1.28(s,12H).

[0286] Step 5: A mixture of 3-(chloromethyl)pyridine (92.0 mg, 721 μmol, 1.05 equiv.), 7-fluoro-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzimidazol-2-amine (200 mg, 687 μmol, 1.00 equiv.), Pd(dppf)Cl2 (50.3 mg, 68.7 μmol, 0.10 equiv.), potassium carbonate (285 mg, 2.06 mmol, 3.00 equiv.), dioxane (5.00 mL), and water (1.00 mL) was degassed and stirred at 100° C. for 4 h. The mixture was cooled to room temperature and partitioned between ethyl acetate (30.0 mL) and water (30.0 mL). The organic layer was dried over sodium sulfate and then concentrated in vacuo. The residue was purified by silica gel column chromatography (10-20% methanol in dichloromethane) and then further purified by preparative HPLC (HCl conditions) to give 7-fluoro-1-methyl-5-(3-pyridylmethyl)benzimidazol-2-amine hydrochloride, Example 7-1 (25.6 mg, 85.6 μmol, 15% yield) as a white solid. LCMS [M+1] + =257.0. 1 H NMR(400MHz,CD3OD) δ=8.83(s,1H),8.76(d,J=5.6Hz,1H),8.53(d,J=8.0Hz,1H),8.05(dd,J=6.0,8 .4Hz,1H),7.23(s,1H),7.11(dd,J=0.8,12.0Hz,1H),4.35(s,2H),3.81(s,3H).

[0287] Example A This example demonstrates that the compounds of formula (I) of the present invention can bind to PRMT5 in the presence of MTA.

[0288] The PRMT5 binding activity of the compounds of the present invention was determined using an HTRF binding assay or an SPR assay.

[0289] HTRF binding assay Recombinant human dual-expressed Avi PRMT5 / His-MEP50 protein (corresponding to amino acids 2-637 of PRMT5 and 2-342 of MEP50 expressed in baculovirus) was incubated with the target fragment overnight at 2-8 °C in final buffer (25 mM ADA at pH 7.2, 30 μM MTA, 1 mM TCEP, 50 mM NaCl, 0.002% Tween, 5 nM of proprietary tracer binding compound prepared in-house). After overnight incubation, binding is monitored after 1 h incubation at room temperature (total binding time approximately 20-24 h) and addition of 0.5 nM anti-His-Tb (Cisbio). HTRF signals were measured using the manufacturer's instructions for Clariostar reader (BMG) excitation filters (Ex Tr), dichroic filters (LP TP), and emission filters (F665-10 and F620-10). HTRF ratios were calculated using the formula: [emission 665 / emission 620] x 10000. IC50s were fitted using Xlfit software (IDBS) with the Hill equation set to 1 (fit background + Bmax / (1 + ((x / IC50)^Hill))) and results for representative compounds of formula (I) are shown in Table A1. [Table 3-1] [Table 3-2] [Table 3-3]

[0290] SPR binding assay In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 at pH 7.6 and injected at a flow rate of 5 μl / min onto flow cell 2 (FC2) of a Series S Sensor Chip SA (Cytiva) in a Biacore T200 or Biacore 8K plus (Cytiva). SPR screening was performed in MTA running buffer (25 mM Bicine, 100 mM NaCl, 1 mM TCEP, 20 μM MTA, 0.05% Tween-20, and 2% DMSO at pH 7.6). Before starting, the biotinylated PRMT5-MEP50 surface was equilibrated with MTA running buffer for 12 hours. The affinity of the test compounds was determined using multiple cycle injections of 0.001–500 μM of each fragment across PRMT5·MTA at a flow rate of 30 μl / min and association and dissociation times of 20 and 60 s, respectively. PRMT5·MTA surface activity was measured at the start and at 100 ng / mL for EPZ015666 (K D The end of the run was checked by titration of EPZ015666 (K = 11 and 13 mM). Compound titration was then repeated in SAM running buffer (25 mM Bicine at pH 7.6, 100 mM NaCl, 1 mM TCEP, 20 μM SAM, 0.05% Tween-20, and 2% DMSO). PRMT5·SAM surfaces were equilibrated for at least 5 h prior to compound titration and EPZ015666 (K D PRMT5 SAM surface activity was confirmed at the end of the fragment titration, which was performed by titration of 100 nM (<1 nM). After double referencing, steady-state responses were extracted for each fragment concentration and fitted to a Langmuir isotherm to determine the equilibrium dissociation constant (K D ) was decided.

[0291] The data in Table A2 was generated using a surface plasmon resonance ("SPR") binding assay. [Table 4-1] [Table 4-2]

[0292] Example B This example demonstrates that compounds of formula (I) of the present invention synergistically inhibit PRMT5 enzyme activity in the presence of MTA.

[0293] The PRMT5 inhibitory activity of the compounds of the present invention was determined using the PRMT5:MEP50 FlashPlate assay and the PRMT5:MEP50 HotSpot assay (Reaction Biology Corporation).

[0294] PRMT5:MEP50 FlashPlate assay The assay uses purified human PRMT5 enzyme to measure S-adenosyl-L-[methyl- 3 H] methionine + histone H4 L-arginine to S-adenosyl-L-homocysteine ​​+ histone H4 [methyl- 3 The tritiated methyl group is converted to S-adenosyl-L-[methyl-H]-L-arginine. The assay was performed using a streptavidin-coated FlashPlate (Perkin Elmer) containing scintillant embedded in the plastic of the plate. A histone H4 peptide substrate was conjugated with biotin that binds to the streptavidin-coated wells of the plate, with the H4 peptide positioned on the side of the well and adjacent to the scintillant. The tritiated methyl group is converted to S-adenosyl-L-[methyl- 3 Radiolabeled histone H4 was generated by the transfer of [H] methionine to the bound histone H4 peptide, which was quantified by scintillation counting to determine PRMT5 enzyme activity in the presence and absence of compounds. Assay reactions were also performed in the presence and absence of MTA to determine whether compounds exhibit MTA synergistic activity. Briefly, compounds of the present invention were solubilized in 100% DMSO at a maximum concentration of 10 mM. IC 50For the measurement of PRMT5 inhibitory activity, the initial starting concentration of serial dilutions of each compound was 50 μM. Control samples lacking compound, PRMT5 / MEP50 complex, or various reaction components were also prepared and processed in parallel with the compound test samples. SAH was used as a positive control for assay validation. To measure PRMT5 inhibitory activity, 3 nM PRMT5 / MEP50 complex (Reaction Biology Corporation) was preincubated for 20 min at room temperature with test compound in assay buffer containing 40 nM histone H4 peptide (amino acids 1-15)-biotin conjugate. The enzymatic reaction was initiated by adding 1 μM tritiated S-adenosylmethionine (final concentration) and the reaction was allowed to proceed for 20 min. The reaction was stopped and the amount of bound and tritiated H4 peptide in each sample was determined using a scintillation counter. The IC of each compound was calculated using GraphPad Prism software. 50 Values ​​were calculated from 10-point dose-response curves for samples with and without MTA, respectively, and results for a representative compound of formula (I) are shown in Table B1. [Table 5-1] [Table 5-2]

[0295] PRMT5:MEP50 HotSpot Assay The assay uses recombinant full-length histone H2A as a PRMT5 substrate. The tritiated methyl group is enzymatically transferred from S-adenosyl-L-[methyl-3H]methionine to histone H2A protein to generate radiolabeled histone H2A4, which is measured in a scintillation counter to determine PRMT5 enzyme activity in the presence and absence of compounds. The assay reaction was also performed in the presence of MTA to determine whether the compounds exhibit MTA synergistic activity. Briefly, the compounds of the present invention were solubilized in 100% DMSO at a maximum concentration of 10 mM. IC 50For the measurement of , the initial starting concentration of serial dilutions of each compound was 50 μM. Control samples lacking compound, PRMT5 / MEP50 complex, or various reaction components were also prepared and processed in parallel with the compound test samples. SAH was used as a positive control for assay validation. To measure PRMT5 inhibitory activity, 1 nM PRMT5 / MEP50 complex (Reaction Biology Corporation) was pre-incubated with test compound in assay buffer containing 5 μM full-length histone H2A for 20 min at room temperature. The enzymatic reaction was initiated by adding 1 μM tritiated S-adenosylmethionine (final concentration) and the reaction was allowed to proceed for 60 min. The reaction was stopped and transferred to filter paper for detection. The amount of tritiated H2A in each sample was determined using a scintillation counter. The IC of each compound was calculated using GraphPad Prism software. 50 Values ​​were calculated from each 10-point dose-response curve and results for a representative compound of formula (I) are shown in Table B2. [Table 6]

[0296] While the invention has been described in relation to particular embodiments thereof, it will be understood that the embodiments are capable of further modification, and that this application is generally intended to cover any variation, use, or alteration of the invention in accordance with the principles of the invention, and includes such departures from the present disclosure as come within known or customary practice in the art to which the invention pertains and may be adapted to the essential features set forth above, and as fall within the scope of the appended claims.

Claims

1. A compound of formula I, [Formula 1] or a pharma- ceutically acceptable salt thereof, wherein: X is CR 2 or N, Y is CR 3 or N, R 1 But, -C 1 -C 2 Alkyl or -CH 2 -phenyl, R 2 is hydrogen, cyano, -C 1 -C 2 haloalkyl or halogen; R 3 is hydrogen, halogen, or -L-R 30 and -L is absent or -(CH 2 ) 0-2 -NH-(CH 2 ) 0-2 -, -N(CH 3 )-(CH 2 ) 0-2 -, -N(C(O)CH 3 )-(CH 2 ) 0-2 -, (-CH 2 -) 1-2 , -C (halo) 2 -, -C(CH 3 )H-, -O-, -S-, -C(O)-, -NH-(CH 2 ) 0-1 -CH(CH 3 )-(CH 2 ) 0-1 -, -NH-C(O)-(CH 2 ) 0-1 -, and -NH-CH(phenyl)-(CH 2 ) 0-1 - selected from the group consisting of R 30 Phenyl, isoxazole, oxazole, pyrrolidinone, morpholine, imidazopyridine, piperidinone, pyridinone, naphthalene, pyrazine, pyrazolidinone, -N(C 1 -C 2 Alkyl) 2 , thiazole, thiadiazole, pyrimidine, imidazole optionally substituted with naphthyl, wherein the naphthyl is cyano, halogen, or -C(O)NH 2 (further optionally substituted with one or more substituents selected from), pyrrolidine optionally fused to a cyclopropane, —CH 2 -CH 2 - a pyrazole optionally substituted with pyrrolidinone or naphthalene, a pyridine optionally fused to a cyclohexane, a triazole optionally fused to a ring forming a pyrrolidine or morpholine, or a tetrahydrofuran optionally spiro-bonded to a cyclobutane, Each R 30 But, -C 1 -C 3 Alkyl, -C 1 -C 2 Haloalkyl, halogen, hydroxy, -C(O)NH 2 , -C 1 -C 2 optionally substituted or optionally further substituted with one or more substituents independently selected from alkoxy, phenyl, cyano-phenyl, and cyano; R 4 is hydrogen, -C 1 -C 2 Alkyl, -CH 2 -O-CH 3 or halogen, R 5 but, hydrogen, -L-R 50 where L is as defined above and R 50 but, CH(OH)-CH 3, pyridine, pyrazine, isoxazole, pyridazine, pyrimidine, pyrazole, pyrrolidine or morpholine optionally fused to a ring forming triazole, tetrahydro-thiopyran-dioxide, thiazole, furan, isoquinoline, naphthalene, pyrrolidine, phenyl where L is not absent, imidazole optionally fused to piperidine, tetrahydrofuran optionally substituted with imidazole, tetrahydropyran optionally spiro-bonded to cyclobutane, or cyclobutane fused to tetrahydropyran; Each R 50 is halogen, hydroxy, -C 1 -C 4 Alkyl, -C 1 -C 4 Alkoxy, -C 1 -C 4 -L-R optionally substituted or optionally further substituted with one or more substituents independently selected from haloalkyl, cyano, and phenyl; 50 , - (C 0 -C 3 ) alkyl-(CO)N(R 10 ) (R 11 ) in which R 10 However, pyridyl (C 1 -C 6 alkyl), wherein pyridyl is optionally substituted with halogen or trifluoromethyl; R 11 However, pyridyl (C 1 -C 6 alkyl), pyrimidinyl (C 1 -C 6 alkyl), independently cyano, C 1 -C 3 Alkyl, cyclopropylmethyl, cyclopropyl, halogen, or C 1 -C 2 naphthyl optionally substituted at the 1, 3, or 4 position (the 2 position being the point of attachment to the N) with one, two, or three of alkoxy, or 5,6,7,8-tetrahydroquinoxalinyl; 0 -C 3 ) alkyl-(CO)N(R 10 ) (R 11 ),or - (C 0 -C 3 ) alkyl-NH-C(O)(C 1 -C 2 alkyl) (R 12 ) in which R 12 is hydrogen, C 1 -C 2 Alkyl, or cyano, chloro, fluoro, cyclopropyloxy, cyclopropylmethyl, or C 1 -C 2 naphthyl optionally substituted with alkyl; 0 -C 3 ) alkyl-NH-C(O)(C 1 -C 2 alkyl) (R 12 ) and R 3 , R 4 , and R 5 (i) hydrogen, (ii) C alkyl, (iii) R 2 is not cyano; (iv) halogen; (v) cyano; or (vi) R 5 and Y is nitrogen or R 2 is cyano, and R 1 is C alkyl and Y is nitrogen, then R 1 is not C1 alkyl, or a pharma- ceutically acceptable salt thereof.

2. Ring A is [Case 2] 2. The compound or salt of claim 1, selected from:

3. A, [C3] 3. The compound or salt of claim 2,

4. Ring A is [C4] 3. The compound or salt of claim 2,

5. Ring A is [C5] 3. The compound or salt of claim 2,

6. A compound of formula IA, [C6] During the ceremony, R 1 But, -C 1 -C 2 Alkyl or -CH 2 -phenyl, R 2 is hydrogen, cyano, -C 1 -C 2 haloalkyl or halogen; R 3 is hydrogen, halogen, or -L-R 30 and -L is absent or -(CH 2 ) 0-2 -NH-(CH 2 ) 0-2 -, -N(CH 3 )-(CH 2 ) 0-2 -, -N(C(O)CH 3 )-(CH 2 ) 0-2 -, (-CH 2 -) 1-2 , -C (halo) 2 -, -C(CH 3 )H-, -O-, -S-, -C(O)-, -NH-(CH 2 ) 0-1 -CH(CH 3 )-(CH 2 ) 0-1 -, -NH-C(O)-(CH 2 ) 0-1 -, and -NH-CH(phenyl)-(CH 2 ) 0-1 - selected from the group consisting of R 30Phenyl, isoxazole, oxazole, pyrrolidinone, morpholine, imidazopyridine, piperidinone, pyridinone, naphthalene, pyrazine, pyrazolidinone, -N(C 1 -C 2 Alkyl) 2 , thiazole, thiadiazole, pyrimidine, imidazole optionally substituted with naphthyl, wherein the naphthyl is cyano, halogen, or -C(O)NH 2 (further optionally substituted with one or more substituents selected from), pyrrolidine optionally fused to a cyclopropane, —CH 2 -CH 2 - a pyrazole optionally substituted with pyrrolidinone or naphthalene, a pyridine optionally fused to a cyclohexane, a triazole optionally fused to a ring forming a pyrrolidine or morpholine, or a tetrahydrofuran optionally spiro-bonded to a cyclobutane, Each R 30 But, -C 1 -C 3 Alkyl, -C 1 -C 2 Haloalkyl, halogen, hydroxy, -C(O)NH 2 , -C 1 -C 2 optionally substituted or optionally further substituted with one or more substituents independently selected from alkoxy, phenyl, cyano-phenyl, and cyano; R 4 is hydrogen, -C 1 -C 2 Alkyl, -CH 2 -O-CH 3 or halogen, R 5 but, hydrogen, -L-R 50 where L is as defined above and R 50 but, -CH(OH)-CH 3, pyridine, pyrazine, isoxazole, pyridazine, pyrimidine, pyrazole, pyrrolidine or morpholine optionally fused to a ring forming triazole, tetrahydro-thiopyran-dioxide, thiazole, furan, isoquinoline, naphthalene, pyrrolidine, phenyl where L is not absent, imidazole optionally fused to piperidine, tetrahydrofuran optionally substituted with imidazole, tetrahydropyran optionally spiro-bonded to cyclobutane, or cyclobutane fused to tetrahydropyran; Each R 50 is halogen, hydroxy, -C 1 -C 4 Alkyl, -C 1 -C 4 Alkoxy, -C 1 -C 4 -L-R optionally substituted or optionally further substituted with one or more substituents independently selected from haloalkyl, cyano, and phenyl; 50 , - (C 0 -C 3 ) alkyl-(CO)N(R 10 ) (R 11 ) in which R 10 However, pyridyl (C 1 -C 6 alkyl), wherein pyridyl is optionally substituted with halogen or trifluoromethyl; R 11 However, pyridyl (C 1 -C 6 alkyl), pyrimidinyl (C 1 -C 6 alkyl), independently cyano, C 1 -C 3 Alkyl, cyclopropylmethyl, cyclopropyl, halogen, or C 1 -C 2 naphthyl optionally substituted at the 1, 3, or 4 position (the 2 position being the point of attachment to the N) with one, two, or three of alkoxy, or 5,6,7,8-tetrahydroquinoxalinyl; 0 -C 3 ) alkyl-(CO)N(R 10 ) (R 11 ),or - (C 0 -C 3 ) alkyl-NH-C(O)(C 1 -C 2 alkyl) (R 12 ) in which R 12 is hydrogen, C 1 -C 2 naphthyl optionally substituted with alkyl, or cyano; 0 -C 3 ) alkyl-NH-C(O)(C 1 -C 2 alkyl) (R 12 ) and R 3 , R 4 , and R 5 (i) hydrogen, (ii) C alkyl, (iii) R 2 is not cyano; (iv) halogen; (v) cyano; or (vi) R 5 or R 2 is cyano, and R 1 is C1 alkyl; or a pharma- ceutically acceptable salt thereof.

7. The compound or salt of any one of claims 1 to 6, wherein L is absent.

8. The compound or salt according to any one of claims 1 to 6, wherein L is -NH-.

9. L is -(CH 2 ) 0-2 -NH-(CH 2 ) 0-2 The compound or salt according to any one of claims 1 to 6,

10. R 3is -L-isoxazole, -L-oxazole, -L-imidazopyridine, -L-pyrazine, -L-pyrazolidinone, -L-thiazole, -L-thiadiazole, -L-pyrimidine, -L-imidazole optionally substituted with naphthyl, said naphthyl being cyano, halogen, and -C(O)NH 2 and optionally further substituted with one or more substituents selected from: 2 -CH 2 -L-pyrazole optionally substituted with pyrrolidinone or naphthalene, -L-pyridine optionally fused to cyclohexane, or -L-triazole optionally fused to a ring forming pyrrolidine or morpholine, R 3 10. The compound or salt of any one of claims 1 to 9, wherein: is optionally substituted or optionally further substituted.

11. R 3 is -L-pyrrolidinone, -L-morpholine, -L-piperidinone, -L-pyridinone, -L-pyrrolidine optionally fused to cyclopropane, or -L-tetrahydrofuran optionally spiro-linked to cyclobutane; R 3 10. The compound or salt of any one of claims 1 to 9, wherein: is optionally substituted or optionally further substituted.

12. R 5 is -L-pyridine, -L-pyrazine, -L-isoxazole, -L-pyridazine, -L-pyrimidine, -L-pyrazole, -L-triazole optionally fused to a ring forming a pyrrolidine or morpholine, -L-thiazole, -L-furan, -L-isoquinoline, or -L-imidazole optionally fused to piperidine; R 5 12. The compound or salt of any one of claims 1 to 11, wherein: is optionally substituted or optionally further substituted.

13. R 5is -L-tetrahydro-thiopyran-dioxide, -L-pyrrolidine, -L-tetrahydrofuran optionally substituted with imidazole, -L-tetrahydropyran optionally spiro-linked to cyclobutane, R 5 12. The compound or salt of any one of claims 1 to 11, wherein: is optionally substituted or optionally further substituted.

14. (a) R 3 is -L-isoxazole, -L-oxazole, -L-imidazopyridine, -L-pyrazine, -L-pyrazolidinone, -L-thiazole, -L-thiadiazole, -L-pyrimidine, -L-imidazole optionally substituted with naphthyl, said naphthyl being cyano, halogen, and -C(O)NH 2 and optionally further substituted with one or more substituents selected from: 2 -CH 2 -L-pyrazole optionally substituted with pyrrolidinone or naphthalene, -L-pyridine optionally fused to cyclohexane, or -L-triazole optionally fused to a ring forming pyrrolidine or morpholine, R 3 is optionally substituted or optionally further substituted; R 5 is hydrogen, -L-CH(OH)-CH 3 , -L-tetrahydro-thiopyran-dioxide, -L-naphthalene, -L-pyrrolidine, -L-phenyl (L is not absent), -L-tetrahydrofuran optionally substituted with imidazole, -L-tetrahydropyran optionally spiro-linked to cyclobutane, or -L-cyclobutane fused to tetrahydropyran, with R 5 is optionally substituted or optionally further substituted, or (b) R 3 is hydrogen, halogen, -L-phenyl, -L-pyrrolidinone, -L-morpholine, -L-piperidinone, -L-pyridinone, -L-naphthalene, -L-N(C 1 -C 2 Alkyl) 2 , -L-pyrrolidine optionally fused to a cyclopropane, or -L-tetrahydrofuran optionally spiro-linked to a cyclobutane; R 3 is optionally substituted or optionally further substituted with one or more substituents; R 5 is -L-pyridine, -L-pyrazine, -L-isoxazole, -L-pyridazine, -L-pyrimidine, -L-pyrazole, -L-triazole optionally fused to a ring forming a pyrrolidine or morpholine, -L-thiazole, -L-furan, -L-isoquinoline, or -L-imidazole optionally fused to piperidine; R 5 10. The compound or salt of any one of claims 1 to 9, wherein: is optionally substituted or optionally further substituted.

15. (a) R 3 is -L-pyrrolidinone, -L-morpholine, -L-piperidinone, -L-pyridinone, -L-pyrrolidine optionally fused to cyclopropane, or -L-tetrahydrofuran optionally spiro-linked to cyclobutane; R 3 is optionally substituted or optionally further substituted; R 5 is hydrogen, -L-CH(OH)-CH 3 , -L-pyridine, -L-pyrazine, -L-isoxazole, -L-pyridazine, -L-pyrimidine, -L-pyrazole, -L-triazole optionally fused to a ring forming a pyrrolidine or morpholine, -L-thiazole, -L-furan, -L-isoquinoline, -L-naphthalene, -L-phenyl (L is not absent), -L-imidazole optionally fused to piperidine, or -L-cyclobutane fused to tetrahydropyran; 5 is halogen, hydroxy, --C 1 -C 4 Alkyl, --C 1 -C 4 Alkoxy, --C 1 -C 4optionally substituted or optionally further substituted with one or more substituents independently selected from haloalkyl, cyano, and phenyl; or (b) R 3 is hydrogen, halogen, -L-phenyl, -L-isoxazole, -L-oxazole, -L-imidazopyridine, -L-naphthalene, -L-pyrazine, -L-pyrazolidinone, -L-N(C 1 -C 2 Alkyl) 2 , -L-thiazole, -L-thiadiazole, -L-pyrimidine, -L-imidazole optionally substituted with naphthyl, said naphthyl being cyano, halogen, and -C(O)NH 2 and optionally further substituted with one or more substituents selected from: 2 -CH 2 -L-pyrazole optionally substituted with pyrrolidinone or naphthalene, -L-pyridine optionally fused to cyclohexane, or -L-triazole optionally fused to a ring forming pyrrolidine or morpholine, R 3 is optionally substituted or optionally further substituted; R 5 is -L-tetrahydro-thiopyran-dioxide, -L-pyrrolidine, -L-tetrahydrofuran optionally substituted with imidazole, -L-tetrahydropyran optionally spiro-linked to cyclobutane, R 5 10. The compound or salt of any one of claims 1 to 9, wherein: is optionally substituted or optionally further substituted.

16. R 5 but, -(CO)N(R 10 ) (R 11 ) in which R 10 However, pyridyl (C 1 -C 6 alkyl), wherein pyridyl is optionally substituted with halogen or trifluoromethyl; R 11 However, pyridyl (C 1 -C 6 alkyl), pyrimidinyl (C 1 -C 6 alkyl), independently cyano, C 1 -C 3 Alkyl, cyclopropylmethyl, cyclopropyl, halogen, or C 1 -C 2 naphthyl optionally substituted at the 1, 3, or 4 position (the 2 position being the point of attachment to the N) with one, two, or three of alkoxy, or 5,6,7,8-tetrahydroquinoxalinyl; 10 ) (R 11 ),or - (C 1 -C 2 alkyl)-NH-C(O)(C 1 -C 2 alkyl) (R 12 ) in which R 12 is hydrogen, C 1 -C 2 Alkyl, or cyano, chloro, fluoro, cyclopropyloxy, cyclopropylmethyl, or C 1 -C 2 naphthyl optionally substituted with alkyl; 1 -C 2 alkyl)-NH-C(O)(C 1 -C 2 alkyl) (R 12 8. The compound or salt according to claim 1, wherein

17. [Claim 7-1] [C7-2] [Case 7-3] [Case 7-4] [C7-5] [C7-6] [Case 7-7] [C7-8] [Case 7-9] [C7-10] [Case 7-11] [C7-12] A compound, Or a pharma- ceutically acceptable salt of the above compound.

18. rac-N5-(1-(1H-1,2,4-triazol-1-yl)propan-2-yl)-1-methyl-1H-benzo[d]imidazole-2,5-diamine, 1-methyl-5-(1-methyl-1H-pyrazol-3-yl)-1H-benzo[d]imidazol-2-amine, rac-1-methyl-N5-(1-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl)ethyl)-1H-benzo[d]imidazole-2,5-diamine, rac-4-((2-amino-1-methyl-1H-benzo[d]imidazol-5-yl)amino)-2,2-dimethyltetrahydro-2H-thiopyran 1,1-dioxide, 1-methyl-N5-((4-methyltetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-2,5-diamine, N4-((4-(tert-butyl)oxazol-2-yl)methyl)-1-methyl-1H-benzo[d]imidazole-2,4-diamine, rac-(R)-1-methyl-N5-(1-phenyl-2-(1H-1,2,4-triazol-1-yl)ethyl)-1H-benzo[d]imidazole-2,5-diamine, 1-methyl-N4-((2-methyl-1-phenyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-2,4-diamine, 1-methyl-N4-((5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-benzo[d]imidazole-2,4-diamine, 2-(((2-amino-1-methyl-1H-benzo[d]imidazol-4-yl)amino)methyl)phenol, 2-((2-amino-1-methyl-1H-benzo[d]imidazol-4-yl)amino)-4-(dimethylamino)benzonitrile, rac-1-methyl-N5-(5-oxaspiro[3.5]nonan-8-yl)-1H-benzo[d]imidazole-2,5-diamine, N4-((5-methoxypyridin-3-yl)methyl)-1-methyl-1H-benzo[d]imidazole-2,4-diamine, 1-methyl-N4-(5,6,7,8-tetrahydroquinolin-3-yl)-1H-benzo[d]imidazole-2,4-diamine, N4-(5-(1,1-difluoroethyl)pyridin-3-yl)-1-methyl-1H-benzo[d]imidazole-2,4-diamine, 1-methyl-N5-(pyridin-2-yl)-1H-benzo[d]imidazole-2,5-diamine, 1-methyl-N5-(pyrimidin-2-yl)-1H-benzo[d]imidazole-2,5-diamine, rac-(1-methyl-N5-(2-methyl-3-(1H-pyrazol-1-yl)propyl)-1H-benzo[d]imidazole-2,5-diamine, N5-((4-ethyl-4H-1,2,4-triazol-3-yl)methyl)-1-methyl-1H-benzo[d]imidazole-2,5-diamine, rac-1-((2-amino-1-methyl-1H-benzo[d]imidazol-5-yl)amino)propan-2-ol, rac-1-methyl-N5-(1-(2-methylthiazol-5-yl)ethyl)-1H-benzo[d]imidazole-2,5-diamine, 1-methyl-N5-(4-methyltetrahydrofuran-3-yl)-1H-benzo[d]imidazole-2,5-diamine, N5-(2-oxabicyclo[4.2.0]octan-7-yl)-1-methyl-1H-benzo[d]imidazole-2,5-diamine, N4-(5-methoxypyridin-3-yl)-1-methyl-1H-benzo[d]imidazole-2,4-diamine, N4-(5,6-dimethylpyridin-3-yl)-1-methyl-1H-benzo[d]imidazole-2,4-diamine, N4-(5-chloro-6-methylpyridin-3-yl)-1-methyl-1H-benzo[d]imidazole-2,4-diamine, N4-((4,5-dimethylthiazol-2-yl)methyl)-1-methyl-1H-benzo[d]imidazole-2,4-diamine, 4-((2-amino-1-methyl-1H-benzo[d]imidazol-4-yl)amino)-1-methyl-1H-imidazole-5-carbonitrile, N4-(5-isopropyl-1,2,4-thiadiazol-3-yl)-1-methyl-1H-benzo[d]imidazole-2,4-diamine, N4-(1-isopropyl-1H-1,2,4-triazol-3-yl)-1-methyl-1H-benzo[d]imidazole-2,4-diamine, N4-(1-isopropyl-1H-imidazol-4-yl)-1-methyl-1H-benzo[d]imidazole-2,4-diamine, rac-(1-methyl-N4-(5-oxaspiro[3.4]octan-7-yl)-1H-benzo[d]imidazole-2,4-diamine, N5-(3-methoxybenzyl)-N5,1-dimethyl-1H-benzo[d]imidazole-2,5-diamine, 1-methyl-5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-2-amine, 1-methyl-5-(1-methyl-1H-pyrazol-5-yl)-1H-benzo[d]imidazol-2-amine, 1-methyl-5-(4-methylpyridin-3-yl)-1H-benzo[d]imidazol-2-amine, 3-(2-amino-1-methyl-1H-benzo[d]imidazol-5-yl)-2-fluorophenol, 2-(2-amino-1-methyl-1H-benzo[d]imidazol-5-yl)furan-3-carbonitrile, 1-methyl-4-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-2-amine, 1-methyl-4-(1H-pyrazol-4-yl)-1H-benzo[d]imidazol-2-amine, N5-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-benzo[d]imidazole-2,5-diamine, 1-methyl-N4-(pyrimidin-2-yl)-1H-benzo[d]imidazole-2,4-diamine, N4-(imidazo[1,2-a]pyridin-2-ylmethyl)-1-methyl-1H-benzo[d]imidazole-2,4-diamine, 1-methyl-N5-(1-methyl-1H-pyrazol-5-yl)-1H-benzo[d]imidazole-2,5-diamine, N5-((5,6-dihydro-8H-[1,2,4]triazolo[3,4-c][1,4]oxazin-3-yl)methyl)-N5,1-dimethyl-1H-benzo[d]imidazole-2,5-diamine, N-[(2-amino-1-methyl-benzimidazol-5-yl)methyl]-N-(1-cyano-2-naphthyl)acetamide, 7-chloro-1-methyl-4-(1-methylpyrazol-4-yl)benzimidazol-2-amine, 2-[4-(2-amino-7-chloro-1-methyl-benzimidazol-4-yl)-2-methyl-pyrazol-3-yl]-3-fluoro-naphthalene-1-carbonitrile, 7-chloro-1-methyl-4-(5,6,7,8-tetrahydroquinolin-3-ylmethyl)benzimidazol-2-amine, 7-Chloro-1-methyl-N 4-(5,6,7,8-tetrahydroquinolin-3-yl)-1H-benzo[d]imidazole-2,4-diamine, 7-chloro-1-methyl-4-tetrahydrofuran-3-yl-benzimidazol-2-amine, 7-chloro-N5-1-dimethyl-N5-(3-pyridyl)benzimidazole-2,5-diamine, 7-chloro-1-methyl-5-(3-pyridylmethyl)benzimidazol-2-amine, 7-Chloro-1-methyl-5-(3-pyridyloxy)benzimidazol-2-amine 7-chloro-6-(methoxymethyl)-1-methyl-benzimidazol-2-amine, 2-amino-3-methyl-1,2-dihydrobenzimidazole-4-carbonitrile, 2-amino-3-methyl-6-(3-pyridylmethyl)benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-(2-pyridylmethyl)benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-(4-pyridylmethyl)benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-(1-methylpyrazolo[4,3-c]pyridin-3-yl)benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-[(1-methylpyrazol-4-yl)methyl]benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-[(1-methylpyrazol-3-yl)methyl]benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-[(2-methylpyrazol-3-yl)methyl]benzimidazole-4-carbonitrile, 2-amino-6-(7-isoquinolylmethyl)-3-methyl-benzimidazole-4-carbonitrile, 2-amino-6-[(2-cyanophenyl)methyl]-3-methyl-benzimidazole-4-carbonitrile, 2-amino-5-benzyl-1-methyl-1H-benzo[d]imidazole-7-carbonitrile, 2-(2-amino-7-cyano-1-methyl-benzimidazol-5-yl)-N-phenyl-acetamide, 2-amino-3-methyl-6-(3-pyridyloxy)benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-(3-pyridylsulfanyl)benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-[1-(3-pyridyl)ethyl]benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-(pyridine-3-carbonyl)benzimidazole-4-carbonitrile, 2-amino-6-[difluoro(3-pyridyl)methyl]-3-methyl-benzimidazole-4-carbonitrile, 2-amino-7-fluoro-3-methyl-benzimidazole-4-carbonitrile, 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-7-(3-oxopyrazolidin-1-yl)benzimidazole-4-carbonitrile, 2-amino-4-methoxy-1-methyl-1H-benzo[d]imidazole-7-carbonitrile, 2-amino-7-methoxy-3-methyl-6-(3-pyridylmethyl)benzimidazole-4-carbonitrile, 2-amino-5-(((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methyl)amino)-1-methyl-1H-benzo[d]imidazole-7-carbonitrile, 2-amino-5-(((4-ethyl-4H-1,2,4-triazol-3-yl)methyl)amino)-1-methyl-1H-benzo[d]imidazole-7-carbonitrile, N-[(2-amino-7-cyano-1-methyl-benzimidazol-5-yl)methyl]-N-(1-cyano-2-naphthyl)acetamide, 2-amino-1-methyl-4-((5,6,7,8-tetrahydroquinolin-3-yl)amino)-1H-benzo[d]imidazole-7-carbonitrile, 7-(difluoromethyl)-1-methyl-5-(3-pyridylmethyl)benzimidazol-2-amine, 7-(difluoromethyl)-1-methyl-5-(2-pyridylmethyl)benzimidazol-2-amine, 1-ethyl-1H-imidazo[4,5-b]pyridin-2-amine, 1-benzylimidazo[4,5-b]pyridin-2-amine, 3-methyl-6-(3-pyridyloxy)imidazo[4,5-b]pyridin-2-amine, 2-[4-(2-amino-6-chloro-1-methyl-benzimidazol-4-yl)-2-methyl-pyrazol-3-yl]benzonitrile, 2-[4-(2-amino-1,6-dimethyl-benzimidazol-4-yl)-2-methyl-pyrazol-3-yl]benzonitrile, 2-[4-(2-amino-6-ethyl-1-methyl-benzimidazol-4-yl)-2-methyl-pyrazol-3-yl]benzonitrile, A compound which is 7-fluoro-1-methyl-5-(3-pyridylmethyl)benzimidazol-2-amine, or A pharma- ceutically acceptable salt thereof.

19. 1-methyl-5-(1-methyl-1H-pyrazol-3-yl)-1H-benzo[d]imidazol-2-amine, 1-methyl-N4-((2-methyl-1-phenyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-2,4-diamine, 1-methyl-N4-((5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-benzo[d]imidazole-2,4-diamine, 2-((2-amino-1-methyl-1H-benzo[d]imidazol-4-yl)amino)-4-(dimethylamino)benzonitrile, 1-methyl-N4-(5,6,7,8-tetrahydroquinolin-3-yl)-1H-benzo[d]imidazole-2,4-diamine, N4-(5-(1,1-difluoroethyl)pyridin-3-yl)-1-methyl-1H-benzo[d]imidazole-2,4-diamine, 1-methyl-N5-(pyrimidin-2-yl)-1H-benzo[d]imidazole-2,5-diamine, rac-1-((2-amino-1-methyl-1H-benzo[d]imidazol-5-yl)amino)propan-2-ol, N4-(5,6-dimethylpyridin-3-yl)-1-methyl-1H-benzo[d]imidazole-2,4-diamine, N4-(5-chloro-6-methylpyridin-3-yl)-1-methyl-1H-benzo[d]imidazole-2,4-diamine, N4-((4,5-dimethylthiazol-2-yl)methyl)-1-methyl-1H-benzo[d]imidazole-2,4-diamine, N4-(5-isopropyl-1,2,4-thiadiazol-3-yl)-1-methyl-1H-benzo[d]imidazole-2,4-diamine, N5-(3-methoxybenzyl)-N5,1-dimethyl-1H-benzo[d]imidazole-2,5-diamine, 1-methyl-5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-2-amine, 1-methyl-5-(1-methyl-1H-pyrazol-5-yl)-1H-benzo[d]imidazol-2-amine, 1-methyl-5-(4-methylpyridin-3-yl)-1H-benzo[d]imidazol-2-amine, 3-(2-amino-1-methyl-1H-benzo[d]imidazol-5-yl)-2-fluorophenol, 1-methyl-4-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-2-amine, 1-methyl-4-(1H-pyrazol-4-yl)-1H-benzo[d]imidazol-2-amine, N5-((5,6-dihydro-8H-[1,2,4]triazolo[3,4-c][1,4]oxazin-3-yl)methyl)-N5,1-dimethyl-1H-benzo[d]imidazole-2,5-diamine, 2-(4-(2-amino-1-methyl-1H-benzo[d]imidazol-4-yl)-1-methyl-1H-pyrazol-5-yl)benzonitrile, 4-methoxy-1-methyl-5-(3-pyridylmethyl)benzimidazol-2-amine, 2-[4-(2-amino-7-chloro-1-methyl-benzimidazol-4-yl)-2-methyl-pyrazol-3-yl]-3-fluoro-naphthalene-1-carbonitrile, 7-chloro-1-methyl-4-(5,6,7,8-tetrahydroquinolin-3-ylmethyl)benzimidazol-2-amine, 7-Chloro-1-methyl-N 4 -(5,6,7,8-tetrahydroquinolin-3-yl)-1H-benzo[d]imidazole-2,4-diamine, 7-chloro-1-methyl-4-tetrahydrofuran-3-yl-benzimidazol-2-amine, 7-chloro-N5-1-dimethyl-N5-(3-pyridyl)benzimidazole-2,5-diamine, 7-chloro-1-methyl-5-(3-pyridylmethyl)benzimidazol-2-amine, 7-Chloro-1-methyl-5-(3-pyridyloxy)benzimidazol-2-amine 7-chloro-6-(methoxymethyl)-1-methyl-benzimidazol-2-amine, 2-amino-3-methyl-1,2-dihydrobenzimidazole-4-carbonitrile, 2-amino-3-methyl-6-(3-pyridylmethyl)benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-(2-pyridylmethyl)benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-(1-methylpyrazolo[4,3-c]pyridin-3-yl)benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-[(1-methylpyrazol-4-yl)methyl]benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-[(1-methylpyrazol-3-yl)methyl]benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-[(2-methylpyrazol-3-yl)methyl]benzimidazole-4-carbonitrile, 2-amino-6-(7-isoquinolylmethyl)-3-methyl-benzimidazole-4-carbonitrile, 2-amino-6-[(2-cyanophenyl)methyl]-3-methyl-benzimidazole-4-carbonitrile, 2-amino-5-benzyl-1-methyl-1H-benzo[d]imidazole-7-carbonitrile, 2-(2-amino-7-cyano-1-methyl-benzimidazol-5-yl)-N-phenyl-acetamide, 2-amino-3-methyl-6-(3-pyridyloxy)benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-(3-pyridylsulfanyl)benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-[1-(3-pyridyl)ethyl]benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-(pyridine-3-carbonyl)benzimidazole-4-carbonitrile, 2-amino-7-fluoro-3-methyl-benzimidazole-4-carbonitrile, 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-7-(3-oxopyrazolidin-1-yl)benzimidazole-4-carbonitrile, 2-amino-4-methoxy-1-methyl-1H-benzo[d]imidazole-7-carbonitrile, 2-amino-7-methoxy-3-methyl-6-(3-pyridylmethyl)benzimidazole-4-carbonitrile, 2-amino-5-(((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methyl)amino)-1-methyl-1H-benzo[d]imidazole-7-carbonitrile, N-[(2-amino-7-cyano-1-methyl-benzimidazol-5-yl)methyl]-N-(1-cyano-2-naphthyl)acetamide, 2-amino-1-methyl-4-((5,6,7,8-tetrahydroquinolin-3-yl)amino)-1H-benzo[d]imidazole-7-carbonitrile, 1-benzylimidazo[4,5-b]pyridin-2-amine, 2-[4-(2-amino-6-chloro-1-methyl-benzimidazol-4-yl)-2-methyl-pyrazol-3-yl]benzonitrile, 2-[4-(2-amino-1,6-dimethyl-benzimidazol-4-yl)-2-methyl-pyrazol-3-yl]benzonitrile, 2-[4-(2-amino-6-ethyl-1-methyl-benzimidazol-4-yl)-2-methyl-pyrazol-3-yl]benzonitrile, A compound which is 7-fluoro-1-methyl-5-(3-pyridylmethyl)benzimidazol-2-amine, or A pharma- ceutically acceptable salt thereof.

20. 2-(4-(2-amino-1-methyl-1H-benzo[d]imidazol-4-yl)-1-methyl-1H-pyrazol-5-yl)benzonitrile, 7-chloro-1-methyl-5-(3-pyridylmethyl)benzimidazol-2-amine, 2-[4-(2-amino-7-chloro-1-methyl-benzimidazol-4-yl)-2-methyl-pyrazol-3-yl]-3-fluoro-naphthalene-1-carbonitrile, 2-amino-3-methyl-1,2-dihydrobenzimidazole-4-carbonitrile, 2-amino-6-[(2-cyanophenyl)methyl]-3-methyl-benzimidazole-4-carbonitrile, 2-(2-amino-7-cyano-1-methyl-benzimidazol-5-yl)-N-phenyl-acetamide, 2-amino-3-methyl-6-(3-pyridyloxy)benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-[1-(3-pyridyl)ethyl]benzimidazole-4-carbonitrile, rac-1-((2-amino-1-methyl-1H-benzo[d]imidazol-5-yl)amino)propan-2-ol, N4-((8-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1-methyl-1H-benzo[d]imidazole-2,4-diamine, 1-methyl-N5-(pyrazin-2-yl)-1H-benzo[d]imidazole-2,5-diamine, 2-amino-7-fluoro-3-methyl-benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-(3-pyridylmethyl)benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-(2-pyridylmethyl)benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-[(1-methylpyrazol-4-yl)methyl]benzimidazole-4-carbonitrile, 2-amino-3-methyl-6-[(1-methylpyrazol-3-yl)methyl]benzimidazole-4-carbonitrile, 2-amino-6-(7-isoquinolylmethyl)-3-methyl-benzimidazole-4-carbonitrile, 2-amino-5-(((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methyl)amino)-1-methyl-1H-benzo[d]imidazole-7-carbonitrile, 2-amino-5-(((4-ethyl-4H-1,2,4-triazol-3-yl)methyl)amino)-1-methyl-1H-benzo[d]imidazole-7-carbonitrile, N-[(2-amino-7-cyano-1-methyl-benzimidazol-5-yl)methyl]-N-(1-cyano-2-naphthyl)acetamide, 7-(difluoromethyl)-1-methyl-5-(2-pyridylmethyl)benzimidazol-2-amine, 1-benzylimidazo[4,5-b]pyridin-2-amine, 2-[4-(2-amino-6-chloro-1-methyl-benzimidazol-4-yl)-2-methyl-pyrazol-3-yl]benzonitrile, 2-[4-(2-amino-1,6-dimethyl-benzimidazol-4-yl)-2-methyl-pyrazol-3-yl]benzonitrile, 2-[4-(2-amino-6-ethyl-1-methyl-benzimidazol-4-yl)-2-methyl-pyrazol-3-yl]benzonitrile, 7-fluoro-1-methyl-5-(3-pyridylmethyl)benzimidazol-2-amine, 3-(2-amino-1-methyl-1H-benzo[d]imidazol-5-yl)-2-fluorophenol, A compound which is 2-(2-amino-1-methyl-1H-benzo[d]imidazol-5-yl)furan-3-carbonitrile, or A pharma- ceutically acceptable salt thereof.

21. (S)-2-amino-1-methyl-N-(5,6,7,8-tetrahydroquinoxalin-5-yl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1H-benzo[d]imidazole-5-carboxamide, (R)-2-amino-1-methyl-N-(5,6,7,8-tetrahydroquinoxalin-5-yl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1H-benzo[d]imidazole-5-carboxamide, (S)-2-amino-N-((5-bromopyridin-2-yl)methyl)-1-methyl-N-(1-(pyrimidin-2-yl)ethyl)-1H-benzo[d]imidazole-5-carboxamide, (R)-2-amino-N-((5-bromopyridin-2-yl)methyl)-1-methyl-N-(1-(pyrimidin-2-yl)ethyl)-1H-benzo[d]imidazole-5-carboxamide 2-amino-6-[(2-cyanophenyl)methyl]-3-methyl-benzimidazole-4-carbonitrile, 2-amino-5-(((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methyl)amino)-1-methyl-1H-benzo[d]imidazole-7-carbonitrile, N-[(2-amino-7-cyano-1-methyl-benzimidazol-5-yl)methyl]-N-(1-cyano-2-naphthyl)acetamide, or A pharma- ceutically acceptable salt thereof.

22. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 21 or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

23. A method for inhibiting PRMT5 activity in a cell, comprising contacting the cell in which inhibition of PRMT5 activity is desired with an effective amount of a compound according to any one of claims 1 to 21 or a pharma- ceutical composition according to claim 22.

24. 22. A method for treating cancer, comprising administering to a patient having cancer a therapeutically effective amount of a compound according to any one of claims 1 to 21, or a pharma- ceutically acceptable salt thereof, alone or in combination with a pharma- ceutically acceptable carrier, excipient, or diluent.

25. 25. The method of claim 24, wherein said therapeutically effective amount of said compound is about 0.01 to 300 mg / kg per day.

26. 25. The method of claim 24, wherein said therapeutically effective amount of said compound is about 0.1 to 100 g / kg per day.

27. The cancers are: Heart: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma, and teratoma; Lung: primary bronchial carcinoma (squamous cell, small undifferentiated cell, large undifferentiated cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondroitin hamartoma, mesothelioma; Gastrointestinal: Esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor, vipoma), small intestine (adenocarcinoma, lymphoma, carcinoid tumor, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large intestine (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); genitourinary tract: kidney (adenocarcinoma) , Wilms' tumor (nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, malignant teratoma, choriocarcinoma, sarcoma, interstitial cell tumor, fibroma, fibroadenoma, adenomatoid tumor, lipoma); liver: hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; biliary tract: gallbladder cancer, duodenal papilla cancer, bile duct cancer; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor of bone chordoma, osteochondroma (osteochondroma exostosis), benign chondroma, chondroblastoma, chondromyxoid fibroma, osteoid osteoma, and giant cell tumor; nervous system: skull (osteoma, hemangioma, granuloma, xanthomas, osteitis deformans), marrow Membranes (meningiomas, malignant meningiomas, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal neurofibroma, meningioma, glioma, sarcoma); gynecology: uterus (endometrial carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa theca cell 27. The method according to any one of claims 24 to 26, wherein the tumor is selected from the group consisting of: tumor, Sertoli-Leydig cell tumor, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, carcinoma in situ, adenocarcinoma, fibrosarcoma, malignant melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tube (carcinoma); hematology: blood (myeloid leukemia (acute and chronic), acute lymphocytic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, myelodysplastic syndromes), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma); skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, lenticular dysplastic nevus, lipoma, hemangioma, dermatofibroma, keloid, psoriasis; and adrenal gland: neuroblastoma.

28. The method of any one of claims 24 to 26, wherein the cancer is an MTAP-associated cancer.

29. The method of any one of claims 24 to 26, wherein the cancer is hepatocellular carcinoma, breast cancer, skin cancer, bladder cancer, liver cancer, pancreatic cancer, or head and neck cancer.

Citation Information

Patent Citations

  • Pyridine compounds and their pharmaceutical uses

    JP2002537298A

  • Diaminopyrimidines and their use as angiogenesis inhibitors

    JP2005524668A

  • 2-imino-benzimidazoles

    JP2009523816A

  • 2-Amino-6-(pyridinyl)-3H-imidazo[4,5-b]pyridines and their cardiotonic use

    US4391811A

  • Compounds that expand hematopoietic stem cells

    WO2012102937A2